PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
303241-5	1977	Its amino acid composition and apparent molecular weight estimated by Sephadex G-25 chromatography, indicate that FTS is a nonapeptide of composition lysine, aspartic acid (or asparagine), serine 2, glutamic acid (or glutamine) 2, glycine 2, and alanine.	cholecystokinin C-terminal flanking peptide	189-212	AKT interacting protein	Homo sapiens	114-117
32078087-8	2020	HSP27 was phosphorylated at serine 78 and 82 after exposure to LPS.	cholecystokinin C-terminal flanking peptide	28-34	heat shock protein family B (small) member 1	Homo sapiens	0-5
32067263-2	2021	Akt regulates a wide variety of cell processes including cell proliferation, survival, and angiogenesis through serine/threonine phosphorylation of downstream targets including mTOR and glycogen-synthase-kinase-3-beta (GSK3beta).	cholecystokinin C-terminal flanking peptide	112-118	AKT serine/threonine kinase 1	Homo sapiens	0-3
32067263-2	2021	Akt regulates a wide variety of cell processes including cell proliferation, survival, and angiogenesis through serine/threonine phosphorylation of downstream targets including mTOR and glycogen-synthase-kinase-3-beta (GSK3beta).	cholecystokinin C-terminal flanking peptide	112-118	mechanistic target of rapamycin kinase	Homo sapiens	177-181
31820681-0	2020	Discovery of Novel Serine/Threonine Protein phosphatase 1 Inhibitors from Traditional Chinese Medicine through Virtual Screening and Biological Assays.	cholecystokinin C-terminal flanking peptide	19-25	inorganic pyrophosphatase 1	Homo sapiens	36-57
31762365-2	2020	We therefore developed an S-nitrosylated L-serine-modified polyamidoamine dendrimer (SNO-Ser-PAMAM), in which multiple S-nitrosothiols (NO donors) were covalently bound to L-serine-modified dendrimer, as a kidney-targeting NO donor.	cholecystokinin C-terminal flanking peptide	41-49	strawberry notch homolog 1	Homo sapiens	85-88
31659695-7	2020	These PTTGs participate in the biological process of the JAK-STAT cascade and are located in the nucleus, exert a molecular function in protein serine/threonine kinase activity, and regulate the erbB signaling pathway.	cholecystokinin C-terminal flanking peptide	144-150	epidermal growth factor receptor	Homo sapiens	195-199
31696776-7	2020	We also demonstrated that STYK1 elevated the serine phosphorylation of BECN1, thereby decreasing the interaction between BECN1 and BCL2.	cholecystokinin C-terminal flanking peptide	45-51	serine/threonine/tyrosine kinase 1	Homo sapiens	26-31
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	555-561	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	38-43
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	555-561	protein kinase AMP-activated non-catalytic subunit gamma 1	Homo sapiens	72-78
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	555-561	serine/threonine kinase 11	Homo sapiens	130-135
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	2060-2066	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	38-43
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	2060-2066	protein kinase AMP-activated non-catalytic subunit gamma 1	Homo sapiens	72-78
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	cholecystokinin C-terminal flanking peptide	2060-2066	serine/threonine kinase 11	Homo sapiens	130-135
31863650-2	2020	The Raf serine/threonine (Ser/Thr) protein kinase isoforms including B-Raf and RAF1, are the upstream in the MAPK cascade that play essential functions in regulating cellular proliferation and survival.	cholecystokinin C-terminal flanking peptide	8-14	zinc fingers and homeoboxes 2	Homo sapiens	4-7
31863650-2	2020	The Raf serine/threonine (Ser/Thr) protein kinase isoforms including B-Raf and RAF1, are the upstream in the MAPK cascade that play essential functions in regulating cellular proliferation and survival.	cholecystokinin C-terminal flanking peptide	8-14	zinc fingers and homeoboxes 2	Homo sapiens	71-74
31863650-2	2020	The Raf serine/threonine (Ser/Thr) protein kinase isoforms including B-Raf and RAF1, are the upstream in the MAPK cascade that play essential functions in regulating cellular proliferation and survival.	cholecystokinin C-terminal flanking peptide	8-14	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	79-83
31696776-7	2020	We also demonstrated that STYK1 elevated the serine phosphorylation of BECN1, thereby decreasing the interaction between BECN1 and BCL2.	cholecystokinin C-terminal flanking peptide	45-51	beclin 1	Homo sapiens	71-76
31696776-7	2020	We also demonstrated that STYK1 elevated the serine phosphorylation of BECN1, thereby decreasing the interaction between BECN1 and BCL2.	cholecystokinin C-terminal flanking peptide	45-51	beclin 1	Homo sapiens	121-126
31696776-7	2020	We also demonstrated that STYK1 elevated the serine phosphorylation of BECN1, thereby decreasing the interaction between BECN1 and BCL2.	cholecystokinin C-terminal flanking peptide	45-51	BCL2 apoptosis regulator	Homo sapiens	131-135
32017060-1	2020	High temperature requirement A1 (HTRA1) is a serine protease playing a modulatory role in various cell processes, particularly in the regulation of transforming growth factor-beta (TGF-beta) signaling.	cholecystokinin C-terminal flanking peptide	45-51	HtrA serine peptidase 1	Homo sapiens	0-31
32017060-1	2020	High temperature requirement A1 (HTRA1) is a serine protease playing a modulatory role in various cell processes, particularly in the regulation of transforming growth factor-beta (TGF-beta) signaling.	cholecystokinin C-terminal flanking peptide	45-51	HtrA serine peptidase 1	Homo sapiens	33-38
32017087-1	2020	T-complex 11 like 2 (TCP11L2) is a protein containing a serine-rich region in its N-terminal region.	cholecystokinin C-terminal flanking peptide	56-62	t-complex 11 like 2	Bos taurus	0-19
32060996-0	2020	Phosphorylation of GATA4 at serine-105 is required for left ventricular remodelling process in angiotensin-II - induced hypertension in rats.	cholecystokinin C-terminal flanking peptide	28-34	angiotensinogen	Rattus norvegicus	95-109
32017087-1	2020	T-complex 11 like 2 (TCP11L2) is a protein containing a serine-rich region in its N-terminal region.	cholecystokinin C-terminal flanking peptide	56-62	t-complex 11 like 2	Bos taurus	21-28
31828582-2	2020	Nemo-like kinase (NLK) encoding a serine/threonine kinase, Yin Yang 1 (YY1) encoding a zinc-finger transcription factor and PA2G4 encoding an ErbB3 binding protein have both of these two opposing functions.	cholecystokinin C-terminal flanking peptide	34-40	nemo like kinase	Homo sapiens	0-16
31828582-2	2020	Nemo-like kinase (NLK) encoding a serine/threonine kinase, Yin Yang 1 (YY1) encoding a zinc-finger transcription factor and PA2G4 encoding an ErbB3 binding protein have both of these two opposing functions.	cholecystokinin C-terminal flanking peptide	34-40	nemo like kinase	Homo sapiens	18-21
32060996-0	2020	Phosphorylation of GATA4 at serine-105 is required for left ventricular remodelling process in angiotensin-II - induced hypertension in rats.	cholecystokinin C-terminal flanking peptide	28-34	GATA binding protein 4	Rattus norvegicus	19-24
31902083-8	2020	More specifically, APNp increased AMP-activated protein kinase (AMPK) activation-dependent Drp1 serine 637 (S637) phosphorylation, which inhibited the translocation of Drp1 to the mitochondrial membrane and reduced mitochondrial fragmentation and the production of mitochondrial superoxide, ultimately attenuating inflammatory brain injury induced by hemorrhage.	cholecystokinin C-terminal flanking peptide	96-102	adiponectin, C1Q and collagen domain containing	Mus musculus	19-23
31902083-8	2020	More specifically, APNp increased AMP-activated protein kinase (AMPK) activation-dependent Drp1 serine 637 (S637) phosphorylation, which inhibited the translocation of Drp1 to the mitochondrial membrane and reduced mitochondrial fragmentation and the production of mitochondrial superoxide, ultimately attenuating inflammatory brain injury induced by hemorrhage.	cholecystokinin C-terminal flanking peptide	96-102	collapsin response mediator protein 1	Mus musculus	91-95
31970928-1	2020	PURPOSE: We investigated associations between neovascular age-related macular degeneration (AMD) and rs10490924 polymorphism of ARMS2 gene (age-related maculopathy susceptibility 2), rs1061170 polymorphism of gene for complement factor H (CFH), rs2230199 polymorphism of gene for complement component C3 and rs11200638 polymorphism of gene for serine protease high-temperature requirement A1 (HTRA1) in the Czech population.	cholecystokinin C-terminal flanking peptide	344-350	age-related maculopathy susceptibility 2	Homo sapiens	128-133
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	elastase, neutrophil expressed	Homo sapiens	73-75
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	cathepsin G	Homo sapiens	111-115
31900456-0	2020	A serine protease inhibitor induces type 1 regulatory T cells through IFN-gamma/STAT1 signaling.	cholecystokinin C-terminal flanking peptide	2-8	interferon gamma	Homo sapiens	70-79
31900456-0	2020	A serine protease inhibitor induces type 1 regulatory T cells through IFN-gamma/STAT1 signaling.	cholecystokinin C-terminal flanking peptide	2-8	signal transducer and activator of transcription 1	Homo sapiens	80-85
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	cathepsin G	Homo sapiens	98-109
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	proteinase 3	Homo sapiens	78-90
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	serine protease 57	Homo sapiens	121-125
31995266-1	2020	Neutrophils contain at least four serine endopeptidases namely elastase (NE), proteinase 3 (PR3), cathepsin G (CatG) and NSP4, which contribute to the regulation of infection and of inflammatory processes.	cholecystokinin C-terminal flanking peptide	34-40	proteinase 3	Homo sapiens	92-95
32020604-3	2020	In the present study, we demonstrate that the previously uncharacterized testis-specific serine protease TRYX5 (1700074P13Rik) is required for male fertility in mice.	cholecystokinin C-terminal flanking peptide	89-95	protease, serine 59	Mus musculus	105-110
31556340-1	2020	P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase, which is associated with many cancer diseases, and thus being considered as a potential drug target.	cholecystokinin C-terminal flanking peptide	35-41	p21 (RAC1) activated kinase 4	Homo sapiens	0-22
31556340-1	2020	P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase, which is associated with many cancer diseases, and thus being considered as a potential drug target.	cholecystokinin C-terminal flanking peptide	35-41	p21 (RAC1) activated kinase 4	Homo sapiens	24-28
31590614-0	2020	Computationally guided identification of Akt-3, a serine/threonine kinase inhibitors: Insights from homology modelling, structure-based screening, molecular dynamics and quantum mechanical calculations.	cholecystokinin C-terminal flanking peptide	50-56	AKT serine/threonine kinase 3	Homo sapiens	41-46
32074489-7	2020	Glucose stress led to intense TG2 phosphorylation in serine/threonine CDK-target.	cholecystokinin C-terminal flanking peptide	53-59	transglutaminase 2	Rattus norvegicus	30-33
31782787-1	2020	OBJECTIVES: Adipsin, or complement factor D, is a serine proteinase catalysing complement factor C3 breakdown, leading to the production of opsonin (C3b), membrane attack complex (C5b-C9) and anaphylatoxins (C3a and C5a).	cholecystokinin C-terminal flanking peptide	50-56	complement factor D	Homo sapiens	12-19
31836685-2	2020	The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target.	cholecystokinin C-terminal flanking peptide	4-10	fibroblast activation protein alpha	Homo sapiens	20-49
31836685-2	2020	The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target.	cholecystokinin C-terminal flanking peptide	4-10	fibroblast activation protein alpha	Homo sapiens	51-54
31836685-2	2020	The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target.	cholecystokinin C-terminal flanking peptide	4-10	fibroblast activation protein alpha	Homo sapiens	114-117
31626788-7	2020	Leptin can activate ROCK in a pathological way, increasing MAPK activity and decreasing insulin signaling via insulin receptor substrate 1 (IRS1) serine 307 residue phosphorylation, phosphatase and tensin homolog, and protein kinase Cbeta2.	cholecystokinin C-terminal flanking peptide	146-152	insulin receptor substrate 1	Homo sapiens	140-144
31902050-11	2020	miR-4766-5p further suppressed serine/threonine kinase PAK2.	cholecystokinin C-terminal flanking peptide	31-37	p21 (RAC1) activated kinase 2	Homo sapiens	55-59
32016419-5	2020	Treatment of A549 cells with IL-1beta induced the activation of p38 mitogen-activated protein kinase (MAP kinase) and MAP kinase-activated protein kinase-2 (MAPKAPK-2), as well as EGFR phosphorylation at serine 1047.	cholecystokinin C-terminal flanking peptide	204-210	interleukin 1 alpha	Homo sapiens	29-37
31782787-1	2020	OBJECTIVES: Adipsin, or complement factor D, is a serine proteinase catalysing complement factor C3 breakdown, leading to the production of opsonin (C3b), membrane attack complex (C5b-C9) and anaphylatoxins (C3a and C5a).	cholecystokinin C-terminal flanking peptide	50-56	complement factor D	Homo sapiens	24-43
31782787-1	2020	OBJECTIVES: Adipsin, or complement factor D, is a serine proteinase catalysing complement factor C3 breakdown, leading to the production of opsonin (C3b), membrane attack complex (C5b-C9) and anaphylatoxins (C3a and C5a).	cholecystokinin C-terminal flanking peptide	50-56	complement C3	Homo sapiens	149-152
31943058-2	2020	Here, we focused on PAK3, a serine/threonine kinase whose gene mutations cause X-linked ID.	cholecystokinin C-terminal flanking peptide	28-34	p21 (RAC1) activated kinase 3	Mus musculus	20-24
32035161-5	2020	Radiation-induced MPO activation was determined by EPR spectroscopy and computational analysis identified tyrosine, serine, and threonine residues near MPO"s active site.	cholecystokinin C-terminal flanking peptide	116-122	myeloperoxidase	Mus musculus	18-21
32035161-5	2020	Radiation-induced MPO activation was determined by EPR spectroscopy and computational analysis identified tyrosine, serine, and threonine residues near MPO"s active site.	cholecystokinin C-terminal flanking peptide	116-122	myeloperoxidase	Mus musculus	152-155
31975425-3	2020	In other organ systems, cAMP can increase neuronal NO production by stimulating PKA to phosphorylate neuronal NO synthase (nNOS) Serine-1412 (S1412).	cholecystokinin C-terminal flanking peptide	129-140	nitric oxide synthase 1, neuronal	Mus musculus	123-127
32077093-1	2020	BACKGROUND AND PURPOSE: Fatty acid amide hydrolase (FAAH) is an intracellular serine amidase that terminates the signaling activity of various lipid messengers involved in pain regulation, including agonists at cannabinoid receptors (e.g., anandamide) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [e.g., palmitoylethanolamide (PEA)].	cholecystokinin C-terminal flanking peptide	78-84	fatty acid amide hydrolase	Mus musculus	24-50
32077093-1	2020	BACKGROUND AND PURPOSE: Fatty acid amide hydrolase (FAAH) is an intracellular serine amidase that terminates the signaling activity of various lipid messengers involved in pain regulation, including agonists at cannabinoid receptors (e.g., anandamide) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [e.g., palmitoylethanolamide (PEA)].	cholecystokinin C-terminal flanking peptide	78-84	fatty acid amide hydrolase	Mus musculus	52-56
32077093-1	2020	BACKGROUND AND PURPOSE: Fatty acid amide hydrolase (FAAH) is an intracellular serine amidase that terminates the signaling activity of various lipid messengers involved in pain regulation, including agonists at cannabinoid receptors (e.g., anandamide) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [e.g., palmitoylethanolamide (PEA)].	cholecystokinin C-terminal flanking peptide	78-84	peroxisome proliferator activated receptor alpha	Mus musculus	256-304
32077093-1	2020	BACKGROUND AND PURPOSE: Fatty acid amide hydrolase (FAAH) is an intracellular serine amidase that terminates the signaling activity of various lipid messengers involved in pain regulation, including agonists at cannabinoid receptors (e.g., anandamide) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [e.g., palmitoylethanolamide (PEA)].	cholecystokinin C-terminal flanking peptide	78-84	peroxisome proliferator activated receptor alpha	Mus musculus	306-316
32073747-6	2020	In addition, the levels of total IRS1 and p-IRS1 at serine sites showed decreasing and increasing trends,respectively, and the hematoxylin and eosin staining showed that liver tissues of mice in the maximum-dose group exhibited obvious hepatocyte degeneration and hemorrhage.	cholecystokinin C-terminal flanking peptide	52-58	insulin receptor substrate 1	Mus musculus	33-37
31728832-1	2020	BACKGROUND: PIN1, a peptidyl-prolyl cis-trans isomerase, specifically can regulate phosphorylation of proteins on serine/threonine residues that precede proline and has critical roles in cell proliferation and transformation.	cholecystokinin C-terminal flanking peptide	114-120	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	12-16
32077105-1	2020	BACKGROUND: Defects in serine biosynthesis caused by loss of function mutations in PHGDH, PSAT1, and PSPH cause a set of rare, autosomal recessive diseases known as Neu-Laxova syndrome (NLS) or serine-deficiency disorders.	cholecystokinin C-terminal flanking peptide	23-29	phosphoserine aminotransferase 1	Homo sapiens	90-95
32077105-4	2020	METHODS: Here, we describe a functional assay that leverages the evolutionary conservation of an enzyme in the serine biosynthesis pathway, phosphoserine aminotransferase, and the ability of the human protein coding sequence (PSAT1) to functionally replace its yeast ortholog (SER1).	cholecystokinin C-terminal flanking peptide	111-117	phosphoserine aminotransferase 1	Homo sapiens	226-231
32077105-4	2020	METHODS: Here, we describe a functional assay that leverages the evolutionary conservation of an enzyme in the serine biosynthesis pathway, phosphoserine aminotransferase, and the ability of the human protein coding sequence (PSAT1) to functionally replace its yeast ortholog (SER1).	cholecystokinin C-terminal flanking peptide	111-117	O-phospho-L-serine:2-oxoglutarate transaminase	Saccharomyces cerevisiae S288C	277-281
31841636-4	2020	The results, including a crystal structure of the clinically relevant VIM-2 metallo beta-lactamase in complex with the inhibitor, reveal the potential of boronate inhibitors without the canonical acylamino side chain for inhibition of a broader range of serine- and metallo- beta-lactamases compared to previous bicyclic boronates, including the metallo-beta-lactamase L1.	cholecystokinin C-terminal flanking peptide	254-260	vimentin 2, pseudogene	Homo sapiens	70-75
31975425-3	2020	In other organ systems, cAMP can increase neuronal NO production by stimulating PKA to phosphorylate neuronal NO synthase (nNOS) Serine-1412 (S1412).	cholecystokinin C-terminal flanking peptide	142-147	nitric oxide synthase 1, neuronal	Mus musculus	123-127
31975425-4	2020	We hypothesized that cAMP also increases nNOS S1412 phosphorylation by PKA in enteric neurons to augment nitrergic relaxation of mouse ileum.	cholecystokinin C-terminal flanking peptide	46-51	nitric oxide synthase 1, neuronal	Mus musculus	41-45
31975425-5	2020	EXPERIMENTAL APPROACH: We measured contractile force and nNOS S1412 phosphorylation in ileal rings suspended in physiologic organ bath.	cholecystokinin C-terminal flanking peptide	62-67	nitric oxide synthase 1, neuronal	Mus musculus	57-61
31975425-7	2020	KEY RESULTS: Forskolin stimulated phosphorylation of nNOS S1412 in mouse ileum.	cholecystokinin C-terminal flanking peptide	58-63	nitric oxide synthase 1, neuronal	Mus musculus	53-57
31975425-12	2020	CONCLUSION AND IMPLICATIONS: PKA phosphorylation of nNOS S1412 augments forskolin-induced nitrergic ileal relaxation.	cholecystokinin C-terminal flanking peptide	57-62	nitric oxide synthase 1, neuronal	Mus musculus	52-56
31653643-1	2020	Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a highly conserved serine/threonine kinase that is ubiquitously expressed throughout the human body.	cholecystokinin C-terminal flanking peptide	75-81	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	0-43
31653643-1	2020	Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a highly conserved serine/threonine kinase that is ubiquitously expressed throughout the human body.	cholecystokinin C-terminal flanking peptide	75-81	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	45-51
31863285-4	2020	In certain cell types, IL-18 also activates mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase/ AKT serine/threonine kinase (PI3K/AKT) signaling modules leading to the production and release of proinflammatory cytokines.	cholecystokinin C-terminal flanking peptide	121-127	interleukin 18	Homo sapiens	23-28
32002713-5	2020	Mechanisms that activate IL-1beta include the classical NLRP3 inflammasome-caspase-1 and the neutrophil serine proteases, neutrophil elastase, and proteinase-3.	cholecystokinin C-terminal flanking peptide	104-110	interleukin 1 alpha	Mus musculus	25-33
31863285-4	2020	In certain cell types, IL-18 also activates mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase/ AKT serine/threonine kinase (PI3K/AKT) signaling modules leading to the production and release of proinflammatory cytokines.	cholecystokinin C-terminal flanking peptide	121-127	AKT serine/threonine kinase 1	Homo sapiens	117-120
31990410-4	2020	Expression of the iron regulatory peptide hepcidin is negatively regulated by the serine protease TMPRSS6.	cholecystokinin C-terminal flanking peptide	82-88	hepcidin antimicrobial peptide	Mus musculus	42-50
32022307-0	2020	Phosphoproteomic analysis of STRIPAK mutants identifies a conserved serine phosphorylation site in PAK kinase CLA4 to be important in fungal sexual development and polarized growth.	cholecystokinin C-terminal flanking peptide	68-74	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	110-114
32022307-8	2020	This analysis identified (de)phosphorylation of a highly conserved serine (S685) residue in the catalytic domain of CLA4 as being important for fungal cellular development.	cholecystokinin C-terminal flanking peptide	67-73	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	116-120
32004752-11	2020	We also show that ionising radiation at 5 Gy results in phosphorylation of p53 at serine 15, a key phosphorylation site for p53-mediated apoptosis, and that hypoxia attenuates this phosphorylation.	cholecystokinin C-terminal flanking peptide	82-88	tumor protein p53	Homo sapiens	75-78
32004752-11	2020	We also show that ionising radiation at 5 Gy results in phosphorylation of p53 at serine 15, a key phosphorylation site for p53-mediated apoptosis, and that hypoxia attenuates this phosphorylation.	cholecystokinin C-terminal flanking peptide	82-88	tumor protein p53	Homo sapiens	124-127
32044416-1	2020	Serpin B1 regulates the innate immune system by inhibiting serine and cysteine proteases that control programmed cell death and proliferation pathways.	cholecystokinin C-terminal flanking peptide	59-65	serpin family B member 1	Homo sapiens	0-9
31962201-1	2020	The serine/arginine protein kinases respond to the EGFR-PI3K-AKT signaling module in the context of pre-mRNA alternative splicing regulation.	cholecystokinin C-terminal flanking peptide	4-10	AKT serine/threonine kinase 1	Homo sapiens	61-64
31802381-6	2020	Ang II acts through different signal transduction pathways via various tyrosine kinases (receptor/non-receptor) and protein serine/threonine kinases, initiating a downstream cascade of molecular events.	cholecystokinin C-terminal flanking peptide	124-130	angiotensinogen	Homo sapiens	0-6
31990410-4	2020	Expression of the iron regulatory peptide hepcidin is negatively regulated by the serine protease TMPRSS6.	cholecystokinin C-terminal flanking peptide	82-88	transmembrane serine protease 6	Homo sapiens	98-105
31978503-1	2020	Glycogen synthase kinase-3beta (GSK-3beta) is an evolutionarily conserved serine/threonine kinase, functioning in numerous cellular processes including cell proliferation, DNA repair, cell cycle, signaling and metabolic pathways.	cholecystokinin C-terminal flanking peptide	74-80	glycogen synthase kinase 3 beta	Homo sapiens	0-30
31978503-1	2020	Glycogen synthase kinase-3beta (GSK-3beta) is an evolutionarily conserved serine/threonine kinase, functioning in numerous cellular processes including cell proliferation, DNA repair, cell cycle, signaling and metabolic pathways.	cholecystokinin C-terminal flanking peptide	74-80	glycogen synthase kinase 3 alpha	Homo sapiens	32-41
31625162-1	2020	Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase) is a serine/threonine kinase pertinent to normal mitosis progression and mitotic phosphorylation of histone H3 at threonine 3 in mammalian cells.	cholecystokinin C-terminal flanking peptide	64-70	histone H3 associated protein kinase	Homo sapiens	0-6
32006900-2	2020	Among them, the serine/threonine phosphatase PPM1D, also referred to as wild-type p53-induced phosphatase 1 (Wip1) or protein phosphatase 2C delta (PP2Cdelta), is emerging as an important oncoprotein due to its negative regulation on a number of crucial cancer suppressor pathways.	cholecystokinin C-terminal flanking peptide	16-22	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	45-50
32006900-2	2020	Among them, the serine/threonine phosphatase PPM1D, also referred to as wild-type p53-induced phosphatase 1 (Wip1) or protein phosphatase 2C delta (PP2Cdelta), is emerging as an important oncoprotein due to its negative regulation on a number of crucial cancer suppressor pathways.	cholecystokinin C-terminal flanking peptide	16-22	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	72-107
32006900-2	2020	Among them, the serine/threonine phosphatase PPM1D, also referred to as wild-type p53-induced phosphatase 1 (Wip1) or protein phosphatase 2C delta (PP2Cdelta), is emerging as an important oncoprotein due to its negative regulation on a number of crucial cancer suppressor pathways.	cholecystokinin C-terminal flanking peptide	16-22	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	109-113
32006900-2	2020	Among them, the serine/threonine phosphatase PPM1D, also referred to as wild-type p53-induced phosphatase 1 (Wip1) or protein phosphatase 2C delta (PP2Cdelta), is emerging as an important oncoprotein due to its negative regulation on a number of crucial cancer suppressor pathways.	cholecystokinin C-terminal flanking peptide	16-22	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	148-157
32008052-7	2020	Subsequently, mTORC2 specifically promoted phosphorylation of AKT at the serine 473 residue.	cholecystokinin C-terminal flanking peptide	73-79	CREB regulated transcription coactivator 2	Mus musculus	14-20
32008052-7	2020	Subsequently, mTORC2 specifically promoted phosphorylation of AKT at the serine 473 residue.	cholecystokinin C-terminal flanking peptide	73-79	thymoma viral proto-oncogene 1	Mus musculus	62-65
32014551-1	2020	The post-translational modification of serine and threonine residues of nuclear, cytosolic, and mitochondrial proteins by O-linked beta-N-acetyl glucosamine (O-GlcNAc) has long been seen as an important regulatory mechanism in the cardiovascular system.	cholecystokinin C-terminal flanking peptide	39-45	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	158-166
31919642-14	2020	Differentially expressed genes enriched in the signaling pathways including Ras signaling pathway; cytokine receptor interaction; tight junction; MAPK signaling pathway, Glycine, serine and threonine metabolism.	cholecystokinin C-terminal flanking peptide	179-185	interleukin 18 receptor 1	Homo sapiens	99-116
31800122-1	2020	Human neutrophil elastase (HNE) is a proteolytic enzyme belonging to the serine protease family and is involved in a variety of pathologies.	cholecystokinin C-terminal flanking peptide	73-79	elastase, neutrophil expressed	Homo sapiens	6-25
31800122-1	2020	Human neutrophil elastase (HNE) is a proteolytic enzyme belonging to the serine protease family and is involved in a variety of pathologies.	cholecystokinin C-terminal flanking peptide	73-79	elastase, neutrophil expressed	Homo sapiens	27-30
31625162-1	2020	Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase) is a serine/threonine kinase pertinent to normal mitosis progression and mitotic phosphorylation of histone H3 at threonine 3 in mammalian cells.	cholecystokinin C-terminal flanking peptide	64-70	histone H3 associated protein kinase	Homo sapiens	8-57
31965176-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) is a highly evolutionarily conserved serine/threonine kinase that regulates cell growth and metabolism in response to multiple environmental cues, such as nutrients, hormones, energy, and stress.	cholecystokinin C-terminal flanking peptide	88-94	CREB regulated transcription coactivator 1	Mus musculus	43-49
32005903-1	2020	p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC.	cholecystokinin C-terminal flanking peptide	41-47	H3 histone pseudogene 16	Homo sapiens	0-3
32005903-1	2020	p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC.	cholecystokinin C-terminal flanking peptide	41-47	H3 histone pseudogene 16	Homo sapiens	91-94
32005903-1	2020	p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC.	cholecystokinin C-terminal flanking peptide	41-47	cell division cycle 42	Homo sapiens	111-116
32005903-1	2020	p21-activated kinases (PAKs) are protein serine/threonine kinases stimulated by Rho-family p21 GTPases such as CDC42 and RAC.	cholecystokinin C-terminal flanking peptide	41-47	AKT serine/threonine kinase 1	Homo sapiens	121-124
31912134-8	2020	Serine hydroxymethyltransferase 2 (Shmt2), methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), and glycine decarboxylase protein of the glycine cleavage system (Gldc) mRNA expression was significantly lower in PP compared with other groups.	cholecystokinin C-terminal flanking peptide	0-6	serine hydroxymethyltransferase 2	Rattus norvegicus	35-40
32029440-2	2020	Following activation of RTK, ERK enters the nucleus and serine-phosphorylates CIC, releasing it from its targets to permit gene expression.	cholecystokinin C-terminal flanking peptide	56-62	capicua transcriptional repressor	Homo sapiens	78-81
31912134-8	2020	Serine hydroxymethyltransferase 2 (Shmt2), methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), and glycine decarboxylase protein of the glycine cleavage system (Gldc) mRNA expression was significantly lower in PP compared with other groups.	cholecystokinin C-terminal flanking peptide	0-6	glycine decarboxylase	Rattus norvegicus	161-165
32002787-1	2020	Mutations in the CDKL5 gene, which encodes a serine/threonine kinase, causes a rare encephalopathy, characterized by early-onset epilepsy and severe intellectual disability, named CDKL5 deficiency disorder (CDD).	cholecystokinin C-terminal flanking peptide	45-51	cyclin dependent kinase like 5	Homo sapiens	17-22
31952070-4	2020	AKT and mTOR are serine/threonine kinases which play important roles in cell growth, proliferation, survival, and differentiation.	cholecystokinin C-terminal flanking peptide	17-23	AKT serine/threonine kinase 1	Homo sapiens	0-3
31952070-4	2020	AKT and mTOR are serine/threonine kinases which play important roles in cell growth, proliferation, survival, and differentiation.	cholecystokinin C-terminal flanking peptide	17-23	mechanistic target of rapamycin kinase	Homo sapiens	8-12
32035284-4	2020	This work hypothesizes about the synergistic relationship between alpha-syn aggregation and neuroinflammation to up-regulate expression of the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1).	cholecystokinin C-terminal flanking peptide	143-149	synuclein alpha	Homo sapiens	66-75
32035284-4	2020	This work hypothesizes about the synergistic relationship between alpha-syn aggregation and neuroinflammation to up-regulate expression of the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1).	cholecystokinin C-terminal flanking peptide	143-149	serpin family E member 1	Homo sapiens	213-218
32032735-2	2020	CDD is caused by mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene that encodes a serine/threonine kinase with a predominant expression in the brain.	cholecystokinin C-terminal flanking peptide	93-99	cyclin-dependent kinase-like 5	Mus musculus	34-64
32032735-2	2020	CDD is caused by mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene that encodes a serine/threonine kinase with a predominant expression in the brain.	cholecystokinin C-terminal flanking peptide	93-99	cyclin-dependent kinase-like 5	Mus musculus	66-71
31958486-0	2020	Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.	cholecystokinin C-terminal flanking peptide	59-65	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	45-48
32060059-4	2020	The signalling mechanism underlying increased degranulation involved Rac2 activation, subsequently resulting in proteinase-activated receptor 2 activation by serine proteinases and enhanced reactive oxygen species production.	cholecystokinin C-terminal flanking peptide	158-164	Rac family small GTPase 2	Homo sapiens	69-73
32060059-4	2020	The signalling mechanism underlying increased degranulation involved Rac2 activation, subsequently resulting in proteinase-activated receptor 2 activation by serine proteinases and enhanced reactive oxygen species production.	cholecystokinin C-terminal flanking peptide	158-164	F2R like trypsin receptor 1	Homo sapiens	112-143
32045603-5	2020	The results showed that SIT attenuated the insulin receptor substrate-1 serine phosphorylation (p-IRS-1Ser636) (P = 0.0003).	cholecystokinin C-terminal flanking peptide	72-78	insulin receptor substrate 1	Rattus norvegicus	43-71
31997382-2	2020	PKD is a serine/threonine kinase activated by the lipid second messenger diacylglycerol (DAG).	cholecystokinin C-terminal flanking peptide	9-15	protein kinase D1	Homo sapiens	0-3
32035620-0	2020	Crotonylation at serine 46 impairs p53 activity.	cholecystokinin C-terminal flanking peptide	17-23	tumor protein p53	Homo sapiens	35-38
32035620-4	2020	Surprisingly this crotonylation targets serine 46, instead of any predicted lysine residues, of p53, as detected in TCEP-probe labeled crotonylation and anti-crotonylated peptide antibody reaction assays.	cholecystokinin C-terminal flanking peptide	40-46	tumor protein p53	Homo sapiens	96-99
32035620-7	2020	Since serine 46 is only found in human p53, our studies unveil an unconventional PTM unique for human p53, impairing its activity in response to CA.	cholecystokinin C-terminal flanking peptide	6-12	tumor protein p53	Homo sapiens	39-42
32035620-7	2020	Since serine 46 is only found in human p53, our studies unveil an unconventional PTM unique for human p53, impairing its activity in response to CA.	cholecystokinin C-terminal flanking peptide	6-12	tumor protein p53	Homo sapiens	102-105
32017888-2	2020	Rab8a is one of several Rab GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to Parkinson"s disease.	cholecystokinin C-terminal flanking peptide	99-105	RAB8A, member RAS oncogene family	Homo sapiens	0-5
32017888-2	2020	Rab8a is one of several Rab GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to Parkinson"s disease.	cholecystokinin C-terminal flanking peptide	99-105	leucine rich repeat kinase 2	Homo sapiens	59-87
32017888-2	2020	Rab8a is one of several Rab GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to Parkinson"s disease.	cholecystokinin C-terminal flanking peptide	99-105	leucine rich repeat kinase 2	Homo sapiens	89-94
32045362-7	2020	RNA and protein analysis of Tsc2-null myometrial tumors and xenografts demonstrate high expression and activity of the serine protease neutrophil elastase (NE), with selective qPCR studies indicating a stromal origin of the NE.	cholecystokinin C-terminal flanking peptide	119-125	TSC complex subunit 2	Mus musculus	28-32
31899361-2	2020	Circulating alpha1-antitrypsin (AAT), a serine-protease inhibitor predominantly produced by hepatocytes, which rises during acute phase responses, is lost in patient"s stool due to gastrointestinal GVHD, and its augmentation was found to attenuate GVHD.	cholecystokinin C-terminal flanking peptide	40-46	serpin family A member 1	Homo sapiens	12-30
31899361-2	2020	Circulating alpha1-antitrypsin (AAT), a serine-protease inhibitor predominantly produced by hepatocytes, which rises during acute phase responses, is lost in patient"s stool due to gastrointestinal GVHD, and its augmentation was found to attenuate GVHD.	cholecystokinin C-terminal flanking peptide	40-46	serpin family A member 1	Homo sapiens	32-35
32045782-1	2020	Neutrophil elastase (NE) is a serine protease stored in the azurophilic granules of neutrophils and released into the extracellular milieu during inflammatory response or formation of neutrophil extracellular traps (NETs).	cholecystokinin C-terminal flanking peptide	30-36	elastase, neutrophil expressed	Mus musculus	0-19
32045782-1	2020	Neutrophil elastase (NE) is a serine protease stored in the azurophilic granules of neutrophils and released into the extracellular milieu during inflammatory response or formation of neutrophil extracellular traps (NETs).	cholecystokinin C-terminal flanking peptide	30-36	elastase, neutrophil expressed	Mus musculus	21-23
31997435-2	2020	HAI-1 regulates type II transmembrane serine proteases that activate protease-activated receptor-2 (PAR-2).	cholecystokinin C-terminal flanking peptide	38-44	serine protease inhibitor, Kunitz type 1	Mus musculus	0-5
31997435-2	2020	HAI-1 regulates type II transmembrane serine proteases that activate protease-activated receptor-2 (PAR-2).	cholecystokinin C-terminal flanking peptide	38-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	69-98
31997435-2	2020	HAI-1 regulates type II transmembrane serine proteases that activate protease-activated receptor-2 (PAR-2).	cholecystokinin C-terminal flanking peptide	38-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	100-105
31997435-8	2020	These results suggest that serine proteases promote intestinal carcinogenesis through activation of PAR-2, and that HAI-1 plays a critical tumor suppressor role as an inhibitor of matriptase, kallikreins, and other PAR-2 activating proteases.	cholecystokinin C-terminal flanking peptide	27-33	coagulation factor II (thrombin) receptor-like 1	Mus musculus	100-105
31972359-1	2020	OBJECTIVE: Our study is to examine the citron rho-interacting, serine/threonine kinase 21 (CIT) in bladder cancer.	cholecystokinin C-terminal flanking peptide	63-69	citron rho-interacting serine/threonine kinase	Homo sapiens	91-94
31902112-13	2020	The Bumphunter method for DNA methylation analysis showed statistically significant regions related to the genes involved in nerve regeneration ninjurin 2 (NINJ2) and functionality (BR serine/threonine kinase 2 BRSK2, claudin 4 CLDN4).	cholecystokinin C-terminal flanking peptide	185-191	ninjurin 2	Homo sapiens	144-154
31902112-13	2020	The Bumphunter method for DNA methylation analysis showed statistically significant regions related to the genes involved in nerve regeneration ninjurin 2 (NINJ2) and functionality (BR serine/threonine kinase 2 BRSK2, claudin 4 CLDN4).	cholecystokinin C-terminal flanking peptide	185-191	ninjurin 2	Homo sapiens	156-161
32045362-7	2020	RNA and protein analysis of Tsc2-null myometrial tumors and xenografts demonstrate high expression and activity of the serine protease neutrophil elastase (NE), with selective qPCR studies indicating a stromal origin of the NE.	cholecystokinin C-terminal flanking peptide	119-125	elastase, neutrophil expressed	Homo sapiens	135-154
31790278-1	2020	Serpina3n is a secretory serine protease inhibitor belonging to clade "a" exhibiting unique structural and physiological characteristics, playing significant roles ranging from complement cascade, apoptosis, wound healing to Alzheimer by inhibiting a wide range of proteases.	cholecystokinin C-terminal flanking peptide	25-31	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Mus musculus	0-9
31823667-6	2020	Among them, the upregulated Bcl-associated X protein was related to "apoptosis," while the downregulated 5"-aminolevulinate synthase 2 (ALAS2) was related to both "glycine, serine, and threonine metabolism" and "porphyrin and chlorophyll metabolism" in pathway enrichment analysis.	cholecystokinin C-terminal flanking peptide	173-179	5'-aminolevulinate synthase 2	Homo sapiens	105-134
31823667-6	2020	Among them, the upregulated Bcl-associated X protein was related to "apoptosis," while the downregulated 5"-aminolevulinate synthase 2 (ALAS2) was related to both "glycine, serine, and threonine metabolism" and "porphyrin and chlorophyll metabolism" in pathway enrichment analysis.	cholecystokinin C-terminal flanking peptide	173-179	5'-aminolevulinate synthase 2	Homo sapiens	136-141
31973581-1	2020	Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds and promotes the lysosomal degradation of the low-density lipoprotein receptors (LDLR).	cholecystokinin C-terminal flanking peptide	73-79	proprotein convertase subtilisin/kexin type 9	Homo sapiens	14-59
31973581-1	2020	Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds and promotes the lysosomal degradation of the low-density lipoprotein receptors (LDLR).	cholecystokinin C-terminal flanking peptide	73-79	proprotein convertase subtilisin/kexin type 9	Homo sapiens	61-66
31973581-1	2020	Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds and promotes the lysosomal degradation of the low-density lipoprotein receptors (LDLR).	cholecystokinin C-terminal flanking peptide	73-79	low density lipoprotein receptor	Homo sapiens	146-179
31973581-1	2020	Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds and promotes the lysosomal degradation of the low-density lipoprotein receptors (LDLR).	cholecystokinin C-terminal flanking peptide	73-79	low density lipoprotein receptor	Homo sapiens	181-185
31919718-3	2020	P21-activated kinase 1 (PAK1), a member of serine/threonine kinases, is associated with the progression of multiple types of human cancers.	cholecystokinin C-terminal flanking peptide	43-49	p21 (RAC1) activated kinase 1	Homo sapiens	0-22
31919718-3	2020	P21-activated kinase 1 (PAK1), a member of serine/threonine kinases, is associated with the progression of multiple types of human cancers.	cholecystokinin C-terminal flanking peptide	43-49	p21 (RAC1) activated kinase 1	Homo sapiens	24-28
31793068-5	2020	These unbiased approaches in conjunction with site-directed mutagenesis studies revealed that PARP1 inhibited NFATc1 expression and OC formation by ADP-ribosylating histone H2B at serine 7 and decreasing the occupancy of this histone variant at the NFATc1 promoter.	cholecystokinin C-terminal flanking peptide	180-186	poly (ADP-ribose) polymerase family, member 1	Mus musculus	94-99
31793068-5	2020	These unbiased approaches in conjunction with site-directed mutagenesis studies revealed that PARP1 inhibited NFATc1 expression and OC formation by ADP-ribosylating histone H2B at serine 7 and decreasing the occupancy of this histone variant at the NFATc1 promoter.	cholecystokinin C-terminal flanking peptide	180-186	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	110-116
31990656-3	2020	In this study, PGRN mediated the chemotaxis of RAW264.7, impaired insulin action and stimulated production of inflammatory factors in adipocytes, which was accompanied by increased c-Jun N-terminal kinase (JNK) activation and serine phosphorylation of insulin receptor substrate-1.	cholecystokinin C-terminal flanking peptide	226-232	granulin precursor	Homo sapiens	15-19
32017993-4	2020	Analogue 2c (l-serine derivative of TGG), the best representative of the series showed IC50 of 1.5 microM (MCF-7), and induced apoptosis in MCF-7 by activating caspase-3/7.	cholecystokinin C-terminal flanking peptide	13-21	caspase 3	Homo sapiens	160-169
31785377-3	2020	SerpinB1 is a serine protease inhibitor in neutrophils and can directly promote the proliferation of beta cells.	cholecystokinin C-terminal flanking peptide	14-20	serpin family B member 1	Homo sapiens	0-8
31967407-6	2020	In particular two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)-NOT (Negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1) were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC).	cholecystokinin C-terminal flanking peptide	156-162	CCR4-NOT transcription complex subunit 2	Homo sapiens	139-147
32061436-5	2020	Mechanistically cadmium-mediated OCT2 translocation was found to involve protein-protein interaction between serine/threonine-protein kinase AKT2, calcium/calmodulin and the AKT substrate AS160 in in vitro cellular studies.	cholecystokinin C-terminal flanking peptide	109-115	solute carrier family 22 member 2	Homo sapiens	33-37
32061436-5	2020	Mechanistically cadmium-mediated OCT2 translocation was found to involve protein-protein interaction between serine/threonine-protein kinase AKT2, calcium/calmodulin and the AKT substrate AS160 in in vitro cellular studies.	cholecystokinin C-terminal flanking peptide	109-115	AKT serine/threonine kinase 2	Homo sapiens	141-145
32061436-5	2020	Mechanistically cadmium-mediated OCT2 translocation was found to involve protein-protein interaction between serine/threonine-protein kinase AKT2, calcium/calmodulin and the AKT substrate AS160 in in vitro cellular studies.	cholecystokinin C-terminal flanking peptide	109-115	AKT serine/threonine kinase 1	Homo sapiens	141-144
32044430-3	2020	These include a disulphide bond, involved in protein oxidative folding and protein structure stabilization, and a free cysteine residue, substituted by serine only in the pheromonal protein Darcin (MUP20).	cholecystokinin C-terminal flanking peptide	152-158	major urinary protein 20	Mus musculus	190-196
32044430-3	2020	These include a disulphide bond, involved in protein oxidative folding and protein structure stabilization, and a free cysteine residue, substituted by serine only in the pheromonal protein Darcin (MUP20).	cholecystokinin C-terminal flanking peptide	152-158	major urinary protein 20	Mus musculus	198-203
32054790-5	2020	XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells.	cholecystokinin C-terminal flanking peptide	65-71	AKT serine/threonine kinase 1	Homo sapiens	61-64
32054790-5	2020	XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells.	cholecystokinin C-terminal flanking peptide	65-71	AKT serine/threonine kinase 1	Homo sapiens	90-93
32054790-5	2020	XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells.	cholecystokinin C-terminal flanking peptide	65-71	AKT serine/threonine kinase 1	Homo sapiens	90-93
31967407-6	2020	In particular two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)-NOT (Negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1) were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC).	cholecystokinin C-terminal flanking peptide	156-162	serine hydroxymethyltransferase 1	Homo sapiens	258-263
31967407-6	2020	In particular two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)-NOT (Negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1) were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC).	cholecystokinin C-terminal flanking peptide	238-244	CCR4-NOT transcription complex subunit 2	Homo sapiens	139-147
31967407-6	2020	In particular two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)-NOT (Negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1) were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC).	cholecystokinin C-terminal flanking peptide	238-244	serine hydroxymethyltransferase 1	Homo sapiens	258-263
32034309-3	2020	Here, we reported that serine/threonine homeodomain-interacting protein kinase 2 (HIPK2) was frequently downregulated in HCC tissues compared with the adjacent normal tissues, and patients with lower HIPK2 protein expression were associated with worse overall survival.	cholecystokinin C-terminal flanking peptide	23-29	homeodomain interacting protein kinase 2	Homo sapiens	40-80
31638083-9	2020	Urokinase-type plasminogen activator (uPA) is a serine proteinase and one of the plasminogen activators, that upon binding to its receptor (uPAR) not only catalyzes the conversion of plasminogen into plasmin on the cell surface, but also activates cell signaling pathways that promote cell migration, proliferation and survival.	cholecystokinin C-terminal flanking peptide	48-54	plasminogen activator, urokinase	Homo sapiens	0-36
31638083-9	2020	Urokinase-type plasminogen activator (uPA) is a serine proteinase and one of the plasminogen activators, that upon binding to its receptor (uPAR) not only catalyzes the conversion of plasminogen into plasmin on the cell surface, but also activates cell signaling pathways that promote cell migration, proliferation and survival.	cholecystokinin C-terminal flanking peptide	48-54	plasminogen activator, urokinase	Homo sapiens	38-41
31638083-9	2020	Urokinase-type plasminogen activator (uPA) is a serine proteinase and one of the plasminogen activators, that upon binding to its receptor (uPAR) not only catalyzes the conversion of plasminogen into plasmin on the cell surface, but also activates cell signaling pathways that promote cell migration, proliferation and survival.	cholecystokinin C-terminal flanking peptide	48-54	plasminogen activator, urokinase receptor	Homo sapiens	140-144
31638083-9	2020	Urokinase-type plasminogen activator (uPA) is a serine proteinase and one of the plasminogen activators, that upon binding to its receptor (uPAR) not only catalyzes the conversion of plasminogen into plasmin on the cell surface, but also activates cell signaling pathways that promote cell migration, proliferation and survival.	cholecystokinin C-terminal flanking peptide	48-54	plasminogen	Homo sapiens	15-22
31981057-5	2020	Protein phosphatase 2A (PP2A) is a conserved serine/threonine protein phosphatase that has been linked to many neurological diseases; however, there are few reports about PP2A in the context of drug addiction.	cholecystokinin C-terminal flanking peptide	45-51	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	24-28
31981057-6	2020	In this study, we measured the level of phosphorylated (p-) GluN2B (Serine; Ser 1303), PP2A/B (a regulatory subunit of PP2A), and PP2A/C (a catalytic subunit of PP2A) in different brain regions such as the prefrontal cortex (PFc), nucleus accumbens (NAc), dorsal striatum (DS), and hippocampus (Hip).	cholecystokinin C-terminal flanking peptide	68-74	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	60-66
32034309-3	2020	Here, we reported that serine/threonine homeodomain-interacting protein kinase 2 (HIPK2) was frequently downregulated in HCC tissues compared with the adjacent normal tissues, and patients with lower HIPK2 protein expression were associated with worse overall survival.	cholecystokinin C-terminal flanking peptide	23-29	homeodomain interacting protein kinase 2	Homo sapiens	82-87
32034309-3	2020	Here, we reported that serine/threonine homeodomain-interacting protein kinase 2 (HIPK2) was frequently downregulated in HCC tissues compared with the adjacent normal tissues, and patients with lower HIPK2 protein expression were associated with worse overall survival.	cholecystokinin C-terminal flanking peptide	23-29	homeodomain interacting protein kinase 2	Homo sapiens	200-205
31969433-16	2020	Thus, we identified pUL69 as the first HCMV-encoded protein that is phosphorylated by cellular and viral serine/threonine kinases in order to serve as a substrate for Pin1.	cholecystokinin C-terminal flanking peptide	105-111	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	167-171
31595658-4	2020	RESULTS: In lepidopteran species, ovarian serine protease (Osp), which encodes a member of the serine protease family, is essential for oogenesis.	cholecystokinin C-terminal flanking peptide	42-48	ovarian serine protease	Bombyx mori	59-62
31945382-6	2020	The results showed that: (1) SIRT1 levels were downregulated in NMDA model; (2) NMDA induced an increase in serine phosphorylation of HuR, while inhibition of serine phosphorylation of HuR increased SIRT1 levels, promoting cell survival; (3) PKC inhibitor (Go 6976) reversed NMDA insults and also suppressed serine phosphorylation of HuR; (4) 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA-AM), an intracellular calcium chelator, fully reversed NMDA insults and also inhibited PKC activity evoked by NMDA.	cholecystokinin C-terminal flanking peptide	159-165	sirtuin 1	Homo sapiens	29-34
31945382-6	2020	The results showed that: (1) SIRT1 levels were downregulated in NMDA model; (2) NMDA induced an increase in serine phosphorylation of HuR, while inhibition of serine phosphorylation of HuR increased SIRT1 levels, promoting cell survival; (3) PKC inhibitor (Go 6976) reversed NMDA insults and also suppressed serine phosphorylation of HuR; (4) 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA-AM), an intracellular calcium chelator, fully reversed NMDA insults and also inhibited PKC activity evoked by NMDA.	cholecystokinin C-terminal flanking peptide	159-165	sirtuin 1	Homo sapiens	29-34
31945382-6	2020	The results showed that: (1) SIRT1 levels were downregulated in NMDA model; (2) NMDA induced an increase in serine phosphorylation of HuR, while inhibition of serine phosphorylation of HuR increased SIRT1 levels, promoting cell survival; (3) PKC inhibitor (Go 6976) reversed NMDA insults and also suppressed serine phosphorylation of HuR; (4) 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid (BAPTA-AM), an intracellular calcium chelator, fully reversed NMDA insults and also inhibited PKC activity evoked by NMDA.	cholecystokinin C-terminal flanking peptide	108-114	ELAV like RNA binding protein 1	Homo sapiens	134-137
32050753-10	2020	Our data also showed that TRIP-Br1 increased XIAP phosphorylation at serine87, an active form of XIAP.	cholecystokinin C-terminal flanking peptide	69-75	SERTA domain containing 1	Homo sapiens	26-34
32050753-10	2020	Our data also showed that TRIP-Br1 increased XIAP phosphorylation at serine87, an active form of XIAP.	cholecystokinin C-terminal flanking peptide	69-75	X-linked inhibitor of apoptosis	Homo sapiens	45-49
32050753-10	2020	Our data also showed that TRIP-Br1 increased XIAP phosphorylation at serine87, an active form of XIAP.	cholecystokinin C-terminal flanking peptide	69-75	X-linked inhibitor of apoptosis	Homo sapiens	97-101
32065217-1	2020	The transforming growth factor type-beta (TGF-beta) has been demonstrated to play an important role in the development of atherosclerosis through binding to the serine/threonine kinase transmembrane type I and type II receptors.	cholecystokinin C-terminal flanking peptide	161-167	transforming growth factor alpha	Homo sapiens	42-50
31983427-6	2020	Consistent with this, the mutation of serine into alanine (S1947A) prevented the regulation of Cdk5 on CaV1.3 channel activity.	cholecystokinin C-terminal flanking peptide	38-44	cyclin dependent kinase 5	Homo sapiens	95-99
31983427-6	2020	Consistent with this, the mutation of serine into alanine (S1947A) prevented the regulation of Cdk5 on CaV1.3 channel activity.	cholecystokinin C-terminal flanking peptide	38-44	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	103-109
32041905-4	2020	TAOK1 and TAOK2 can phosphorylate serine residues 210, 218 and 240 near the C-terminus of Rnd3 and induce Rnd3 translocation from the plasma membrane to the cytosol.	cholecystokinin C-terminal flanking peptide	34-40	TAO kinase 1	Homo sapiens	0-5
32032748-1	2020	Protein phosphatase 2A (PP2A) is an evolutionarily conserved serine/threonine phosphatase abundant in mammalian brains.	cholecystokinin C-terminal flanking peptide	61-67	protein phosphatase 2 phosphatase activator	Homo sapiens	24-28
32041905-4	2020	TAOK1 and TAOK2 can phosphorylate serine residues 210, 218 and 240 near the C-terminus of Rnd3 and induce Rnd3 translocation from the plasma membrane to the cytosol.	cholecystokinin C-terminal flanking peptide	34-40	TAO kinase 2	Homo sapiens	10-15
32041905-4	2020	TAOK1 and TAOK2 can phosphorylate serine residues 210, 218 and 240 near the C-terminus of Rnd3 and induce Rnd3 translocation from the plasma membrane to the cytosol.	cholecystokinin C-terminal flanking peptide	34-40	Rho family GTPase 3	Homo sapiens	90-94
32041905-4	2020	TAOK1 and TAOK2 can phosphorylate serine residues 210, 218 and 240 near the C-terminus of Rnd3 and induce Rnd3 translocation from the plasma membrane to the cytosol.	cholecystokinin C-terminal flanking peptide	34-40	Rho family GTPase 3	Homo sapiens	106-110
32041905-5	2020	TAOKs are activated catalytically during mitosis and Rnd3 phosphorylation on serine 210 increases in dividing cells.	cholecystokinin C-terminal flanking peptide	77-83	Rho family GTPase 3	Homo sapiens	53-57
32032548-3	2020	Two serine residues in Yorkie, S74 and S97, are Atg1/ULK1 consensus target sites and are phosphorylated by ULK1 in vitro, thereby preventing its binding to Scalloped.	cholecystokinin C-terminal flanking peptide	4-10	unc-51 like autophagy activating kinase 1	Homo sapiens	48-52
31941600-3	2020	Here, we found that human CREB3 is phosphorylated within its transcription activation domain on serine 46 by protein kinase CK2.	cholecystokinin C-terminal flanking peptide	96-102	cAMP responsive element binding protein 3	Homo sapiens	26-31
31941600-5	2020	However, phosphorylation at serine 46 reduced the stability of CREB3.	cholecystokinin C-terminal flanking peptide	28-34	cAMP responsive element binding protein 3	Homo sapiens	63-68
31964709-0	2020	Identification of serine residues in the Connexin43 carboxyl tail important for BCR-mediated spreading of B-lymphocytes.	cholecystokinin C-terminal flanking peptide	18-24	gap junction protein alpha 1	Homo sapiens	41-51
31964709-0	2020	Identification of serine residues in the Connexin43 carboxyl tail important for BCR-mediated spreading of B-lymphocytes.	cholecystokinin C-terminal flanking peptide	18-24	BCR activator of RhoGEF and GTPase	Homo sapiens	80-83
31964709-8	2020	Site-specific serine to alanine mutations, S255A, S262A, S279A and S282A, resulted in differential effects on both BCR signaling, and BCR-mediated spreading.	cholecystokinin C-terminal flanking peptide	14-20	BCR activator of RhoGEF and GTPase	Homo sapiens	115-118
31964709-8	2020	Site-specific serine to alanine mutations, S255A, S262A, S279A and S282A, resulted in differential effects on both BCR signaling, and BCR-mediated spreading.	cholecystokinin C-terminal flanking peptide	14-20	BCR activator of RhoGEF and GTPase	Homo sapiens	134-137
32032548-3	2020	Two serine residues in Yorkie, S74 and S97, are Atg1/ULK1 consensus target sites and are phosphorylated by ULK1 in vitro, thereby preventing its binding to Scalloped.	cholecystokinin C-terminal flanking peptide	4-10	unc-51 like autophagy activating kinase 1	Homo sapiens	53-57
32032548-3	2020	Two serine residues in Yorkie, S74 and S97, are Atg1/ULK1 consensus target sites and are phosphorylated by ULK1 in vitro, thereby preventing its binding to Scalloped.	cholecystokinin C-terminal flanking peptide	4-10	unc-51 like autophagy activating kinase 1	Homo sapiens	107-111
31912833-2	2020	The aberrant phosphorylation of alpha-synuclein at serine 129 is the key process on its early onset, which alters the cellular conformation to oligomers and insoluble aggregates, underpinning cellular oxidative stress and mitochondrial dysfunction, leading to devastating PD synucleinopathy.	cholecystokinin C-terminal flanking peptide	51-57	synuclein alpha	Homo sapiens	32-47
31950832-7	2020	Interestingly, TNF-alpha treatment not only enhances the interaction between CSN and IKK, but also induces an IKK-dependent phosphorylation of CSN5 at serine 201, linking CSN to TNF-alpha signaling through IKK.	cholecystokinin C-terminal flanking peptide	151-157	tumor necrosis factor	Homo sapiens	15-24
31950832-7	2020	Interestingly, TNF-alpha treatment not only enhances the interaction between CSN and IKK, but also induces an IKK-dependent phosphorylation of CSN5 at serine 201, linking CSN to TNF-alpha signaling through IKK.	cholecystokinin C-terminal flanking peptide	151-157	COP9 signalosome subunit 5	Homo sapiens	143-147
31950832-7	2020	Interestingly, TNF-alpha treatment not only enhances the interaction between CSN and IKK, but also induces an IKK-dependent phosphorylation of CSN5 at serine 201, linking CSN to TNF-alpha signaling through IKK.	cholecystokinin C-terminal flanking peptide	151-157	tumor necrosis factor	Homo sapiens	178-187
31919867-6	2020	Furthermore, molecular analysis of osteoclast- and osteoblast-derived WNT5A identified a serine-phosphorylated WNT5A that is unique to RANKL-treated macrophages mimicking osteoclasts.	cholecystokinin C-terminal flanking peptide	89-95	wingless-type MMTV integration site family, member 5A	Mus musculus	70-75
31614064-3	2020	Additionally, WNK kinases phosphorylate SPAK and OSR1 at a highly conserved serine residue on their S-motif, the function of which remains elusive.	cholecystokinin C-terminal flanking peptide	76-82	serine/threonine kinase 39	Homo sapiens	40-44
31614064-3	2020	Additionally, WNK kinases phosphorylate SPAK and OSR1 at a highly conserved serine residue on their S-motif, the function of which remains elusive.	cholecystokinin C-terminal flanking peptide	76-82	odd-skipped related transcription factor 1	Homo sapiens	49-53
32035750-1	2020	Serine/threonine protein kinases Aurora A, B, and C play essential roles in cell mitosis and cytokinesis, and a number of Aurora kinase inhibitors have been evaluated in the clinic.	cholecystokinin C-terminal flanking peptide	0-6	aurora kinase A	Homo sapiens	33-41
31994358-6	2020	RESULTS: A systemic injection of the A1 antagonist DPCPX induced an increase in phosphorylation of AMPA receptor GluA1 subunits at a PKA-dependent site, serine 845 (S845), in the two subdivisions of the striatum, the caudate putamen, and nucleus accumbens.	cholecystokinin C-terminal flanking peptide	153-159	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	113-118
31994358-6	2020	RESULTS: A systemic injection of the A1 antagonist DPCPX induced an increase in phosphorylation of AMPA receptor GluA1 subunits at a PKA-dependent site, serine 845 (S845), in the two subdivisions of the striatum, the caudate putamen, and nucleus accumbens.	cholecystokinin C-terminal flanking peptide	153-159	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	133-136
31994402-1	2020	The proto-oncogene serine/threonine-protein kinase PIM3 plays critical roles in cancer, and it has been extensively exploited as a drug target.	cholecystokinin C-terminal flanking peptide	19-25	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	51-55
31975428-1	2020	UHMK1 is a nuclear serine/threonine kinase recently implicated in carcinogenesis.	cholecystokinin C-terminal flanking peptide	19-25	U2AF homology motif kinase 1	Homo sapiens	0-5
31823335-1	2020	It is known that the activities of estrogen receptor alpha (ERalpha) can be modulated by epidermal growth factor (EGF) through the phosphatidylinostitol 3-kinase-alpha serine/threonine protein kinase (PI3K-AKT) pathway by phosphorylation.	cholecystokinin C-terminal flanking peptide	168-174	estrogen receptor 1	Homo sapiens	35-58
31823335-1	2020	It is known that the activities of estrogen receptor alpha (ERalpha) can be modulated by epidermal growth factor (EGF) through the phosphatidylinostitol 3-kinase-alpha serine/threonine protein kinase (PI3K-AKT) pathway by phosphorylation.	cholecystokinin C-terminal flanking peptide	168-174	estrogen receptor 1	Homo sapiens	60-67
31919867-6	2020	Furthermore, molecular analysis of osteoclast- and osteoblast-derived WNT5A identified a serine-phosphorylated WNT5A that is unique to RANKL-treated macrophages mimicking osteoclasts.	cholecystokinin C-terminal flanking peptide	89-95	wingless-type MMTV integration site family, member 5A	Mus musculus	111-116
31919867-6	2020	Furthermore, molecular analysis of osteoclast- and osteoblast-derived WNT5A identified a serine-phosphorylated WNT5A that is unique to RANKL-treated macrophages mimicking osteoclasts.	cholecystokinin C-terminal flanking peptide	89-95	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	135-140
31866331-2	2020	Tissue kallikrein (TK), a subgroup of serine proteinases, is an important component of the kallikrein-kinin system.	cholecystokinin C-terminal flanking peptide	38-44	kallikrein 1	Homo sapiens	0-17
31562563-1	2020	AURKA is a serine/threonine kinase overexpressed in several cancers.	cholecystokinin C-terminal flanking peptide	11-17	aurora kinase A	Homo sapiens	0-5
31866331-2	2020	Tissue kallikrein (TK), a subgroup of serine proteinases, is an important component of the kallikrein-kinin system.	cholecystokinin C-terminal flanking peptide	38-44	kallikrein 1	Homo sapiens	19-21
31904348-1	2020	OBJECTIVES: Kallikrein-related peptidases (KLKs) are a subgroup of 15 secreted chymotrypsin- and trypsin-like serine proteases that have been reported to possess novel functions in innate immunity and inflammation.	cholecystokinin C-terminal flanking peptide	110-116	kallikrein related peptidase 10	Homo sapiens	43-47
31786094-7	2020	Serine protease inhibitor-9 is a natural known intracellular inhibitor of Granzyme B, however there is less data available about the potential inhibitors that can regulate its activity in an extracellular environment.	cholecystokinin C-terminal flanking peptide	0-6	granzyme B	Homo sapiens	74-84
31960530-10	2020	Importantly, FSH promoted the expression of serine/threonine kinase PTEN induced putative kinase 1 (PINK1) and the E3 ligase Parkin during hypoxia stress through a HIF-1alpha dependent manner.	cholecystokinin C-terminal flanking peptide	44-50	PTEN induced kinase 1	Homo sapiens	68-98
31960530-10	2020	Importantly, FSH promoted the expression of serine/threonine kinase PTEN induced putative kinase 1 (PINK1) and the E3 ligase Parkin during hypoxia stress through a HIF-1alpha dependent manner.	cholecystokinin C-terminal flanking peptide	44-50	PTEN induced kinase 1	Homo sapiens	100-105
31960530-10	2020	Importantly, FSH promoted the expression of serine/threonine kinase PTEN induced putative kinase 1 (PINK1) and the E3 ligase Parkin during hypoxia stress through a HIF-1alpha dependent manner.	cholecystokinin C-terminal flanking peptide	44-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	164-174
31960210-6	2020	The results demonstrated that hyperglycemia resulted in a significant increase in the levels of insulin receptor substrate-1 (IRS-1) serine phosphorylation and decrease in Akt phosphorylation.	cholecystokinin C-terminal flanking peptide	133-139	insulin receptor substrate 1	Homo sapiens	96-124
31751628-4	2020	Expression of IkappaB kinases (IKKs) induces proteasome-dependent C-terminal processing of Aq-NF-kappaB in human cells, and processing requires C-terminal serines in Aq-NF-kappaB.	cholecystokinin C-terminal flanking peptide	155-162	nuclear factor kappa B subunit 1	Homo sapiens	169-178
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin	Homo sapiens	49-56
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin receptor substrate 1	Homo sapiens	87-91
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin	Homo sapiens	110-117
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin	Homo sapiens	110-117
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin receptor substrate 1	Homo sapiens	322-326
31866237-7	2020	RESULTS: NDE levels of phosopho-serine312-type 1 insulin receptor substrate ([P-Ser312-IRS1], an inhibitor of insulin signalling) increased sevenfold in the immediate post-operative period (from 7.90 +- 0.89 to 58.54 +- 6.77 pg/mL; p < .001), whereas those of pan-tyrosine-phospho insulin receptor substrate ([P-panTyr-IRS1], which facilitates insulin signalling), rose only 50% (from 0.41 +- 0.07 to 0.63 +- 0.10 pg/mL; p = .03).	cholecystokinin C-terminal flanking peptide	23-38	insulin	Homo sapiens	110-117
31712129-1	2020	Complement factor I (CFI) is a serine protease which plays a key role in the modulation of complement system and the induced-fit factor responsible for controlling the complement-mediated processes.	cholecystokinin C-terminal flanking peptide	31-37	complement factor I	Homo sapiens	21-24
31751559-1	2020	BACKGROUND & AIMS: Mutations in the human serine protease 1 gene (PRSS1), which encodes cationic trypsinogen, can accelerate its autoactivation and cause hereditary or sporadic chronic pancreatitis.	cholecystokinin C-terminal flanking peptide	46-52	serine protease 1	Homo sapiens	70-75
31751559-1	2020	BACKGROUND & AIMS: Mutations in the human serine protease 1 gene (PRSS1), which encodes cationic trypsinogen, can accelerate its autoactivation and cause hereditary or sporadic chronic pancreatitis.	cholecystokinin C-terminal flanking peptide	46-52	serine protease 1	Homo sapiens	92-112
32065498-0	2020	Sanguinarine disrupts the colocalization and interaction of HIF-1alpha with tyrosine and serine phosphorylated-STAT3 in breast cancer.	cholecystokinin C-terminal flanking peptide	89-95	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
31974640-5	2020	The effects of BIRB-796 on TNFalpha stimulated phosphorylation of p38 MAPK and GR at serine (S) 226 by Western blot.	cholecystokinin C-terminal flanking peptide	85-91	tumor necrosis factor	Homo sapiens	27-35
31960210-6	2020	The results demonstrated that hyperglycemia resulted in a significant increase in the levels of insulin receptor substrate-1 (IRS-1) serine phosphorylation and decrease in Akt phosphorylation.	cholecystokinin C-terminal flanking peptide	133-139	insulin receptor substrate 1	Homo sapiens	126-131
32035020-1	2020	BACKGROUND: Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT.	cholecystokinin C-terminal flanking peptide	101-107	AKT serine/threonine kinase 1	Homo sapiens	125-128
31932471-4	2020	Mechanistically, we find that SMAD4 interacts with and inhibits RICTOR, a component of the mTORC2 complex, resulting in suppression of downstream effector phosphorylation of AKT at Serine 473.	cholecystokinin C-terminal flanking peptide	181-187	SMAD family member 4	Homo sapiens	30-35
31932471-4	2020	Mechanistically, we find that SMAD4 interacts with and inhibits RICTOR, a component of the mTORC2 complex, resulting in suppression of downstream effector phosphorylation of AKT at Serine 473.	cholecystokinin C-terminal flanking peptide	181-187	RPTOR independent companion of MTOR complex 2	Homo sapiens	64-70
31932471-4	2020	Mechanistically, we find that SMAD4 interacts with and inhibits RICTOR, a component of the mTORC2 complex, resulting in suppression of downstream effector phosphorylation of AKT at Serine 473.	cholecystokinin C-terminal flanking peptide	181-187	CREB regulated transcription coactivator 2	Mus musculus	91-97
31932471-4	2020	Mechanistically, we find that SMAD4 interacts with and inhibits RICTOR, a component of the mTORC2 complex, resulting in suppression of downstream effector phosphorylation of AKT at Serine 473.	cholecystokinin C-terminal flanking peptide	181-187	AKT serine/threonine kinase 1	Homo sapiens	174-177
32028527-3	2020	These post-translational modification events are predominantly serine-linked and require HPF1, an accessory factor that is specific for the DNA damage response and switches the amino-acid specificity of PARP1/2 from aspartate/glutamate to serine residues5-10.	cholecystokinin C-terminal flanking peptide	63-69	histone PARylation factor 1	Homo sapiens	89-93
31899196-4	2020	Treatment with 200 muM glutamate showed increased GluA1 phosphorylation at serine 831 and activation of CaMKIIalpha by phosphorylation at threonine 286 like LTP, whereas 100 muM glutamate treatment showed decrease in GluA1 phosphorylation level at both pGluA1(S831) and pGluA1(S845), and activation of GSK3beta by de-phosphorylating pGSK3beta at serine 9 like LTD.	cholecystokinin C-terminal flanking peptide	75-81	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	50-55
32028527-3	2020	These post-translational modification events are predominantly serine-linked and require HPF1, an accessory factor that is specific for the DNA damage response and switches the amino-acid specificity of PARP1/2 from aspartate/glutamate to serine residues5-10.	cholecystokinin C-terminal flanking peptide	63-69	poly(ADP-ribose) polymerase 1	Homo sapiens	203-208
32028527-3	2020	These post-translational modification events are predominantly serine-linked and require HPF1, an accessory factor that is specific for the DNA damage response and switches the amino-acid specificity of PARP1/2 from aspartate/glutamate to serine residues5-10.	cholecystokinin C-terminal flanking peptide	239-245	histone PARylation factor 1	Homo sapiens	89-93
32028527-3	2020	These post-translational modification events are predominantly serine-linked and require HPF1, an accessory factor that is specific for the DNA damage response and switches the amino-acid specificity of PARP1/2 from aspartate/glutamate to serine residues5-10.	cholecystokinin C-terminal flanking peptide	239-245	poly(ADP-ribose) polymerase 1	Homo sapiens	203-208
31836451-1	2020	PIM kinases are a class of serine/threonine kinases that play a role in several of the hallmarks of cancer including cell cycle progression, metabolism, inflammation and immune evasion.	cholecystokinin C-terminal flanking peptide	27-33	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-3
31980741-5	2020	Mechanistically, MEK5 downregulation impairs phosphorylation of the catalytic subunit of DNA-PK at serine 2056 in response to IR or etoposide treatment.	cholecystokinin C-terminal flanking peptide	99-105	mitogen-activated protein kinase kinase 5	Homo sapiens	17-21
32063193-2	2020	AAT inhibits not only serine proteases but also cysteine and aspartic proteases.	cholecystokinin C-terminal flanking peptide	22-28	serpin family A member 1	Homo sapiens	0-3
32004989-8	2020	Moreover, convallatoxin reduced the P-STAT3 (T705) via the JAK1, JAK2, and Src pathways and inhibited serine-727 phosphorylation of STAT3 via the PI3K-AKT-mTOR-STAT3 pathways in colorectal cancer cells.	cholecystokinin C-terminal flanking peptide	102-108	signal transducer and activator of transcription 3	Mus musculus	132-137
31959328-1	2020	The serine/threonine kinase RIPK1 has emerged as a crucial component of the inflammatory response activated downstream of several immune receptors, where it paradoxically functions as a scaffold to protect the cell from death or instead as an active kinase to promote the killing of the cell.	cholecystokinin C-terminal flanking peptide	4-10	receptor interacting serine/threonine kinase 1	Homo sapiens	28-33
31852782-8	2020	DYRK1A is a proline directed kinase that phosphorylates cyclin L2 at serine residues.	cholecystokinin C-terminal flanking peptide	69-75	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-6
31902278-8	2020	There was a significantly enhanced late INa but reduced peak INa due to enhanced steady-state inactivation in atrial myocytes of patients with SDB consistent with significantly increased CaMKII-dependent cardiac Na channel phosphorylation (NaV1.5, at serine 571, Western blotting).	cholecystokinin C-terminal flanking peptide	251-257	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	187-193
31852782-8	2020	DYRK1A is a proline directed kinase that phosphorylates cyclin L2 at serine residues.	cholecystokinin C-terminal flanking peptide	69-75	cyclin L2	Homo sapiens	56-65
31852782-9	2020	Mutants of cyclin L2 at serine residues preceding proline significantly stabilized cyclin L2 and increased HIV-1 replication in macrophages.	cholecystokinin C-terminal flanking peptide	24-30	cyclin L2	Homo sapiens	11-20
31852782-9	2020	Mutants of cyclin L2 at serine residues preceding proline significantly stabilized cyclin L2 and increased HIV-1 replication in macrophages.	cholecystokinin C-terminal flanking peptide	24-30	cyclin L2	Homo sapiens	83-92
32071282-6	2020	Accordingly, depletion of DDX11 causes reduced levels of single-stranded DNA, a reduction of chromatin-bound replication protein A, and impaired CHK1 phosphorylation at serine-345.	cholecystokinin C-terminal flanking peptide	169-175	DEAD/H-box helicase 11	Homo sapiens	26-31
32071282-6	2020	Accordingly, depletion of DDX11 causes reduced levels of single-stranded DNA, a reduction of chromatin-bound replication protein A, and impaired CHK1 phosphorylation at serine-345.	cholecystokinin C-terminal flanking peptide	169-175	checkpoint kinase 1	Homo sapiens	145-149
31901745-7	2020	Among new functionalized amino acid derivatives of serine and GABA analogs, compounds with preferential mGAT3/4 inhibitory activity were discovered.	cholecystokinin C-terminal flanking peptide	51-57	solute carrier family 6 (neurotransmitter transporter, GABA), member 11	Mus musculus	104-109
32066292-1	2021	Background: Serine protease inhibitor Kazal type I (SPINK1) is highly expressed and promotes tumor progress in different cancers.	cholecystokinin C-terminal flanking peptide	12-18	serine peptidase inhibitor Kazal type 1	Homo sapiens	52-58
32066292-8	2021	GSEA revealed that glycine, serine, threonine and bile acid metabolism may be the underlying mechanism of SPINK1 in HCC.Conclusions: In conclusion, high SPINK1 expression is associated with poor prognosis of HCC.	cholecystokinin C-terminal flanking peptide	28-34	serine peptidase inhibitor Kazal type 1	Homo sapiens	153-159
31901745-10	2020	The novel compounds (4-hydroxybutanoic, 4-hydroxypentanoic, and 4-aminobutanoic acid derivatives and serine analogs) provide new insights into the structure-activity relationship of mGAT3/mGAT4 inhibitors and indicate a new direction in the search for potential treatment of neuropathic pain of various origin.	cholecystokinin C-terminal flanking peptide	101-107	solute carrier family 6 (neurotransmitter transporter, GABA), member 11	Mus musculus	182-187
31901745-10	2020	The novel compounds (4-hydroxybutanoic, 4-hydroxypentanoic, and 4-aminobutanoic acid derivatives and serine analogs) provide new insights into the structure-activity relationship of mGAT3/mGAT4 inhibitors and indicate a new direction in the search for potential treatment of neuropathic pain of various origin.	cholecystokinin C-terminal flanking peptide	101-107	solute carrier family 6 (neurotransmitter transporter, GABA), member 11	Mus musculus	188-193
31876149-10	2020	Rictor is a component of mTORC2, one of the complexes formed by the serine/threonine kinase mTOR [4].	cholecystokinin C-terminal flanking peptide	68-74	RPTOR independent companion of MTOR complex 2	Homo sapiens	0-6
31876149-10	2020	Rictor is a component of mTORC2, one of the complexes formed by the serine/threonine kinase mTOR [4].	cholecystokinin C-terminal flanking peptide	68-74	CREB regulated transcription coactivator 2	Mus musculus	25-31
31876149-10	2020	Rictor is a component of mTORC2, one of the complexes formed by the serine/threonine kinase mTOR [4].	cholecystokinin C-terminal flanking peptide	68-74	mechanistic target of rapamycin kinase	Homo sapiens	25-29
32075106-1	2020	The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4), and both proteins play a central role in the modulation of diverse cellular processes, including proliferation and cell survival.	cholecystokinin C-terminal flanking peptide	4-10	AKT serine/threonine kinase 1	Homo sapiens	36-40
32075106-1	2020	The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4), and both proteins play a central role in the modulation of diverse cellular processes, including proliferation and cell survival.	cholecystokinin C-terminal flanking peptide	4-10	C-X-C motif chemokine receptor 4	Homo sapiens	93-98
32074998-2	2020	This gene encodes the protein PPP2R5D (also known as the B56 delta subunit), which is an isoform of the subunit family B56 of the enzyme serine/threonine-protein phosphatase 2A (PP2A).	cholecystokinin C-terminal flanking peptide	137-143	protein phosphatase 2 regulatory subunit B'delta	Homo sapiens	30-37
32074998-2	2020	This gene encodes the protein PPP2R5D (also known as the B56 delta subunit), which is an isoform of the subunit family B56 of the enzyme serine/threonine-protein phosphatase 2A (PP2A).	cholecystokinin C-terminal flanking peptide	137-143	protein phosphatase 2 phosphatase activator	Homo sapiens	178-182
32053876-2	2020	The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes.	cholecystokinin C-terminal flanking peptide	46-52	mechanistic target of rapamycin kinase	Homo sapiens	4-33
32050972-12	2020	This translocation could be stimulated by MARK"s phosphorylation of the serine 47 residue flanking the NLS due to aberrant expression of glial cell line-derived neurotrophic factor (GDNF).	cholecystokinin C-terminal flanking peptide	72-78	glial cell line derived neurotrophic factor	Mus musculus	137-180
32050972-12	2020	This translocation could be stimulated by MARK"s phosphorylation of the serine 47 residue flanking the NLS due to aberrant expression of glial cell line-derived neurotrophic factor (GDNF).	cholecystokinin C-terminal flanking peptide	72-78	glial cell line derived neurotrophic factor	Mus musculus	182-186
32045478-1	2020	Mst1 is a serine/threonine kinase involved in cell survival, proliferation, apoptosis, and tumorigenesis.	cholecystokinin C-terminal flanking peptide	10-16	macrophage stimulating 1 (hepatocyte growth factor-like)	Mus musculus	0-4
32053876-2	2020	The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities, including the control of metabolic processes.	cholecystokinin C-terminal flanking peptide	46-52	mechanistic target of rapamycin kinase	Homo sapiens	35-39
32041943-4	2020	STAT3 aberrantly transactivates the epigenetic kinase mitogen- and stress-activated protein kinase 1 (MSK1), thereby phosphorylating histone H3 serine10 (H3S10) and STAT3 itself during carcinogen-induced gastric tumorigenesis.	cholecystokinin C-terminal flanking peptide	144-152	signal transducer and activator of transcription 3	Homo sapiens	0-5
32054064-3	2020	In PD, E3 ubiquitin ligase Parkin and the serine/threonine-protein kinase PTEN-induced kinase 1 (PINK1) mediate the mitophagy pathway for mitochondrial quality control via phosphorylation and ubiquitination of their substrates.	cholecystokinin C-terminal flanking peptide	42-48	PTEN induced putative kinase 1	Mus musculus	74-95
32054064-3	2020	In PD, E3 ubiquitin ligase Parkin and the serine/threonine-protein kinase PTEN-induced kinase 1 (PINK1) mediate the mitophagy pathway for mitochondrial quality control via phosphorylation and ubiquitination of their substrates.	cholecystokinin C-terminal flanking peptide	42-48	PTEN induced putative kinase 1	Mus musculus	97-102
31896304-6	2020	Furthermore, HFD increased the protein level, phosphorylation (at the activating serine 616 site), oligomerization, mitochondrial translocation, and GTPase activity of Drp1 in mouse hearts, indicating that Drp1 was activated.	cholecystokinin C-terminal flanking peptide	81-87	dynamin 1-like	Mus musculus	206-210
31910958-3	2020	Human carboxylesterase 1 (hCE1) is an important member of the serine hydrolase superfamily and is closely related to the occurrence of HCC.	cholecystokinin C-terminal flanking peptide	62-68	carboxylesterase 1	Homo sapiens	6-24
31910958-3	2020	Human carboxylesterase 1 (hCE1) is an important member of the serine hydrolase superfamily and is closely related to the occurrence of HCC.	cholecystokinin C-terminal flanking peptide	62-68	carboxylesterase 1	Homo sapiens	26-30
32045997-7	2020	Our results also revealed that MCT4-regulated GBM cell motility and monocyte adhesion are mediated by activation of the serine/threonine-specific protein kinase (AKT), focal adhesion kinase (FAK), and epidermal growth factor receptor (EGFR) signaling pathways.	cholecystokinin C-terminal flanking peptide	120-126	solute carrier family 16 member 3	Homo sapiens	31-35
32041943-4	2020	STAT3 aberrantly transactivates the epigenetic kinase mitogen- and stress-activated protein kinase 1 (MSK1), thereby phosphorylating histone H3 serine10 (H3S10) and STAT3 itself during carcinogen-induced gastric tumorigenesis.	cholecystokinin C-terminal flanking peptide	144-152	ribosomal protein S6 kinase A5	Homo sapiens	102-106
32049046-3	2020	AURKB directly phosphorylates MYC at serine 67, counteracting GSK3beta-directed threonine 58 phosphorylation and subsequent FBXW7-mediated proteasomal degradation.	cholecystokinin C-terminal flanking peptide	37-43	aurora kinase B	Homo sapiens	0-5
32049046-3	2020	AURKB directly phosphorylates MYC at serine 67, counteracting GSK3beta-directed threonine 58 phosphorylation and subsequent FBXW7-mediated proteasomal degradation.	cholecystokinin C-terminal flanking peptide	37-43	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	30-33
32049046-3	2020	AURKB directly phosphorylates MYC at serine 67, counteracting GSK3beta-directed threonine 58 phosphorylation and subsequent FBXW7-mediated proteasomal degradation.	cholecystokinin C-terminal flanking peptide	37-43	glycogen synthase kinase 3 alpha	Homo sapiens	62-70
32076367-11	2020	We also show that removing the 1673 codon sites with both AGN and UCN codons (encoding serine) in our alignment can partially reconcile discrepancies between nucleotide-based and AA-based tree, partly because two sequences, one with AGN and the other with UCN, would be identical at the amino acid level but quite different at the nucleotide level.	cholecystokinin C-terminal flanking peptide	87-93	urocortin	Homo sapiens	66-69
32049046-3	2020	AURKB directly phosphorylates MYC at serine 67, counteracting GSK3beta-directed threonine 58 phosphorylation and subsequent FBXW7-mediated proteasomal degradation.	cholecystokinin C-terminal flanking peptide	37-43	F-box and WD repeat domain containing 7	Homo sapiens	124-129
32076367-11	2020	We also show that removing the 1673 codon sites with both AGN and UCN codons (encoding serine) in our alignment can partially reconcile discrepancies between nucleotide-based and AA-based tree, partly because two sequences, one with AGN and the other with UCN, would be identical at the amino acid level but quite different at the nucleotide level.	cholecystokinin C-terminal flanking peptide	87-93	urocortin	Homo sapiens	256-259
32033440-3	2020	The roles of Protein Kinase D (PKD) family of serine/threonine kinases in osteoclasts have not been well characterized.	cholecystokinin C-terminal flanking peptide	46-52	protein kinase D1	Homo sapiens	13-29
32033440-3	2020	The roles of Protein Kinase D (PKD) family of serine/threonine kinases in osteoclasts have not been well characterized.	cholecystokinin C-terminal flanking peptide	46-52	protein kinase D1	Homo sapiens	31-34
32033142-3	2020	Unc-51-like kinase 1 (ULK1) is a serine/threonine kinase that participates in the initiation of autophagy.	cholecystokinin C-terminal flanking peptide	33-39	unc-51 like autophagy activating kinase 1	Homo sapiens	0-20
32028882-1	2020	BACKGROUND: The serine protease KLK12 belongs to the human fifteen-member family of kallikrein-related peptidases.	cholecystokinin C-terminal flanking peptide	16-22	kallikrein related peptidase 12	Homo sapiens	32-37
32033142-3	2020	Unc-51-like kinase 1 (ULK1) is a serine/threonine kinase that participates in the initiation of autophagy.	cholecystokinin C-terminal flanking peptide	33-39	unc-51 like autophagy activating kinase 1	Homo sapiens	22-26
32033228-8	2020	We further investigated phosphopeptide signature across five cancer types which led to the prediction of aurora kinase A (AURKA) and kinases-serine/threonine-protein kinase Nek2 (NEK2) as the most activated kinases targets.	cholecystokinin C-terminal flanking peptide	141-147	NIMA related kinase 2	Homo sapiens	173-177
31845908-3	2020	We performed multistep biochemical, structural, and computational experiments to define a spherical 24-monomer complex composed of 12 HSP27 dimers with a phosphorylation pocket flanked by serine residues between their N-terminal domains.	cholecystokinin C-terminal flanking peptide	188-194	heat shock protein family B (small) member 1	Homo sapiens	134-139
32033228-8	2020	We further investigated phosphopeptide signature across five cancer types which led to the prediction of aurora kinase A (AURKA) and kinases-serine/threonine-protein kinase Nek2 (NEK2) as the most activated kinases targets.	cholecystokinin C-terminal flanking peptide	141-147	NIMA related kinase 2	Homo sapiens	179-183
31932503-4	2020	Here, we report that Arl4A acts with the serine/threonine protein kinase Pak1 to modulate cell migration through their cooperative recruitment to the plasma membrane.	cholecystokinin C-terminal flanking peptide	41-47	ADP ribosylation factor like GTPase 4A	Homo sapiens	21-26
31932503-4	2020	Here, we report that Arl4A acts with the serine/threonine protein kinase Pak1 to modulate cell migration through their cooperative recruitment to the plasma membrane.	cholecystokinin C-terminal flanking peptide	41-47	p21 (RAC1) activated kinase 1	Homo sapiens	73-77
31902729-2	2020	MSCI is directed by a DNA damage response (DDR) pathway centered on the phosphorylation of histone variant H2AX at serine 139 (termed gammaH2AX).	cholecystokinin C-terminal flanking peptide	115-121	H2A.X variant histone	Mus musculus	107-111
31902729-2	2020	MSCI is directed by a DNA damage response (DDR) pathway centered on the phosphorylation of histone variant H2AX at serine 139 (termed gammaH2AX).	cholecystokinin C-terminal flanking peptide	115-121	H2A.X variant histone	Mus musculus	134-143
31701492-3	2020	SPINT2, also known as HAI-2, is an important serine protease inhibitor that can affect MET signaling.	cholecystokinin C-terminal flanking peptide	45-51	serine peptidase inhibitor, Kunitz type 2	Homo sapiens	0-6
32044881-3	2020	FAK molecule has several tyrosine, serine, and threonine phosphorylation sites which have an important regulatory role.	cholecystokinin C-terminal flanking peptide	35-41	protein tyrosine kinase 2	Homo sapiens	0-3
32044881-5	2020	We sought to examine the frequency and extent of serine-910 phosphorylated FAK (P-FAKSer910) expression in a spectrum of melanocytic proliferations as well as it"s correlation with other histopathologic predictors and its effect on patient"s survival.	cholecystokinin C-terminal flanking peptide	49-55	protein tyrosine kinase 2	Homo sapiens	75-78
32044881-5	2020	We sought to examine the frequency and extent of serine-910 phosphorylated FAK (P-FAKSer910) expression in a spectrum of melanocytic proliferations as well as it"s correlation with other histopathologic predictors and its effect on patient"s survival.	cholecystokinin C-terminal flanking peptide	49-55	protein tyrosine kinase 2	Homo sapiens	80-91
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	cholecystokinin C-terminal flanking peptide	45-51	polo like kinase 4	Homo sapiens	0-18
31926341-1	2020	Polo-like kinase 4 (PLK4) is a member of the serine/threonine protein kinase family involved in cell-cycle regulation and cellular response to stresses.	cholecystokinin C-terminal flanking peptide	45-51	polo like kinase 4	Homo sapiens	20-24
31831854-0	2020	The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.	cholecystokinin C-terminal flanking peptide	39-45	myeloid leukemia factor 2	Homo sapiens	31-35
31831854-0	2020	The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.	cholecystokinin C-terminal flanking peptide	39-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	52-59
31831854-5	2020	Moreover, phosphorylation at serine 24, detected through Phos-tag sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was required to maintain the activity of MLF2 in CML.	cholecystokinin C-terminal flanking peptide	29-35	myeloid leukemia factor 2	Homo sapiens	166-170
31831854-6	2020	The effects of MLF2 overexpression on the colony-formation ability in vitro and mouse survival in vivo could be alleviated by point mutation of MLF2 at serine 24.	cholecystokinin C-terminal flanking peptide	152-158	myeloid leukemia factor 2	Mus musculus	15-19
31831854-6	2020	The effects of MLF2 overexpression on the colony-formation ability in vitro and mouse survival in vivo could be alleviated by point mutation of MLF2 at serine 24.	cholecystokinin C-terminal flanking peptide	152-158	myeloid leukemia factor 2	Mus musculus	144-148
31831854-7	2020	These findings uncover the oncogenic role of MLF2 through phosphorylation at serine 24 and provide a novel therapeutic target in CML.	cholecystokinin C-terminal flanking peptide	77-83	myeloid leukemia factor 2	Homo sapiens	45-49
31760171-6	2020	A cytosolic serine/threonine protein kinase (Tpl2) modulates ATF-2-regulated effects on the endothelial cell cycle.	cholecystokinin C-terminal flanking peptide	12-18	mitogen-activated protein kinase kinase kinase 8	Homo sapiens	45-49
31701492-3	2020	SPINT2, also known as HAI-2, is an important serine protease inhibitor that can affect MET signaling.	cholecystokinin C-terminal flanking peptide	45-51	serine peptidase inhibitor, Kunitz type 2	Homo sapiens	22-27
31760171-6	2020	A cytosolic serine/threonine protein kinase (Tpl2) modulates ATF-2-regulated effects on the endothelial cell cycle.	cholecystokinin C-terminal flanking peptide	12-18	activating transcription factor 2	Homo sapiens	61-66
31630284-4	2020	Metabolic changes are observed in the majority of TNBC and a large proportion upregulate enzymes within the serine synthesis pathway, including phosphoserine aminotransferase 1 (PSAT1).	cholecystokinin C-terminal flanking peptide	108-114	phosphoserine aminotransferase 1	Homo sapiens	144-176
31772275-0	2020	ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer.	cholecystokinin C-terminal flanking peptide	43-49	interleukin enhancer binding factor 3	Homo sapiens	0-4
31772275-0	2020	ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer.	cholecystokinin C-terminal flanking peptide	43-49	speckle type BTB/POZ protein	Homo sapiens	23-27
31772275-8	2020	Taken together, deregulation of ILF3 via the EGF-ERK signaling plays an important role in systemic serine metabolic reprogramming and confers a predilection toward CRC development.	cholecystokinin C-terminal flanking peptide	99-105	interleukin enhancer binding factor 3	Homo sapiens	32-36
31630284-4	2020	Metabolic changes are observed in the majority of TNBC and a large proportion upregulate enzymes within the serine synthesis pathway, including phosphoserine aminotransferase 1 (PSAT1).	cholecystokinin C-terminal flanking peptide	108-114	phosphoserine aminotransferase 1	Homo sapiens	178-183
31916625-3	2020	The immunophilin FK506-binding protein 51 (FKBP51), in conjunction with the serine/threonine protein phosphatase 5C (PPP5C), inhibits ISOC .	cholecystokinin C-terminal flanking peptide	76-82	protein phosphatase 5 catalytic subunit	Homo sapiens	117-122
31908030-0	2020	Phosphorylation at Serine 21 in G protein-coupled receptor kinase 1 (GRK1) is required for normal kinetics of dark adaption in rod but not cone photoreceptors.	cholecystokinin C-terminal flanking peptide	19-25	G protein-coupled receptor kinase 1	Mus musculus	32-67
31908030-0	2020	Phosphorylation at Serine 21 in G protein-coupled receptor kinase 1 (GRK1) is required for normal kinetics of dark adaption in rod but not cone photoreceptors.	cholecystokinin C-terminal flanking peptide	19-25	G protein-coupled receptor kinase 1	Mus musculus	69-73
31943016-3	2020	We applied trio whole exome sequencing to a young woman who experienced extreme developmental regression starting at 2.5 years of age and identified compound heterozygous nonsense mutations in TMPRSS9, which encodes for polyserase-1, a transmembrane serine protease of poorly understood physiological function.	cholecystokinin C-terminal flanking peptide	250-256	transmembrane serine protease 9	Homo sapiens	193-200
31943016-3	2020	We applied trio whole exome sequencing to a young woman who experienced extreme developmental regression starting at 2.5 years of age and identified compound heterozygous nonsense mutations in TMPRSS9, which encodes for polyserase-1, a transmembrane serine protease of poorly understood physiological function.	cholecystokinin C-terminal flanking peptide	250-256	transmembrane serine protease 9	Homo sapiens	220-232
31894307-2	2020	The serine/threonine protein kinase phosphoinositide-dependent kinase 1 (PDK1), a pivotal downstream effector of phosphatidyl inositol-3 kinase (PI3K) signaling, plays a vital role in cellular signaling.	cholecystokinin C-terminal flanking peptide	4-10	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	73-77
31596952-4	2020	In this study we identified several serine/threonine residues on the N-terminal extension (NTE) of Arabidopsis thaliana phyB that are differentially phosphorylated in response to light and temperature and examined transgenic plants expressing non-phosphorylatable and phosphomimic phyB mutants.	cholecystokinin C-terminal flanking peptide	36-42	phytochrome B	Arabidopsis thaliana	120-124
31894299-5	2020	This study identified a positive association between FLI1 expression and mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor.	cholecystokinin C-terminal flanking peptide	125-131	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	53-57
31894299-5	2020	This study identified a positive association between FLI1 expression and mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor.	cholecystokinin C-terminal flanking peptide	125-131	MAPK interacting serine/threonine kinase 1	Homo sapiens	151-156
31894299-5	2020	This study identified a positive association between FLI1 expression and mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor.	cholecystokinin C-terminal flanking peptide	125-131	eukaryotic translation initiation factor 4E	Homo sapiens	199-204
31894307-2	2020	The serine/threonine protein kinase phosphoinositide-dependent kinase 1 (PDK1), a pivotal downstream effector of phosphatidyl inositol-3 kinase (PI3K) signaling, plays a vital role in cellular signaling.	cholecystokinin C-terminal flanking peptide	4-10	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	36-71
31899476-0	2020	A distinct concerted mechanism of structural dynamism defines activity of human serine protease HtrA3.	cholecystokinin C-terminal flanking peptide	80-86	HtrA serine peptidase 3	Homo sapiens	96-101
31899476-1	2020	Human HtrA3 (High temperature requirement protease A3) is a trimeric multitasking propapoptotic serine protease associated with critical cellular functions and pathogenicity.	cholecystokinin C-terminal flanking peptide	96-102	HtrA serine peptidase 3	Homo sapiens	6-11
31899476-1	2020	Human HtrA3 (High temperature requirement protease A3) is a trimeric multitasking propapoptotic serine protease associated with critical cellular functions and pathogenicity.	cholecystokinin C-terminal flanking peptide	96-102	HtrA serine peptidase 3	Homo sapiens	13-53
32003438-0	2020	Correction: Structural modeling and role of HAX-1 as a positive allosteric modulator of human serine protease HtrA2.	cholecystokinin C-terminal flanking peptide	94-100	HCLS1 associated protein X-1	Homo sapiens	44-49
32019242-1	2020	The serine proteases kallikrein-related peptidase (KLK) 5 and KLK7 cleave cell adhesion molecules in the epidermis.	cholecystokinin C-terminal flanking peptide	4-10	kallikrein related peptidase 7	Homo sapiens	62-66
32003438-0	2020	Correction: Structural modeling and role of HAX-1 as a positive allosteric modulator of human serine protease HtrA2.	cholecystokinin C-terminal flanking peptide	94-100	HtrA serine peptidase 2	Homo sapiens	110-115
32023940-5	2020	In addition, agonistic antibodies and human leukocyte antigen (HLA)-G, a natural ligand for KIR2DL4, induce the secretion of leukemia inhibitory factor and serine proteases from human mast cells, which have been implicated in pregnancy establishment and cancer metastasis.	cholecystokinin C-terminal flanking peptide	156-162	major histocompatibility complex, class I, G	Homo sapiens	44-69
32023940-5	2020	In addition, agonistic antibodies and human leukocyte antigen (HLA)-G, a natural ligand for KIR2DL4, induce the secretion of leukemia inhibitory factor and serine proteases from human mast cells, which have been implicated in pregnancy establishment and cancer metastasis.	cholecystokinin C-terminal flanking peptide	156-162	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	Homo sapiens	92-99
32013098-8	2020	Atomistic modelling and molecular dynamics simulations show that dephosphorylation of YB1 at serine residues 102, 165 and 176 increases the accessibility of the nuclear localisation signal (NLS).	cholecystokinin C-terminal flanking peptide	93-99	Y-box binding protein 1	Homo sapiens	86-89
32038174-2	2019	During the immunocytochemical analysis of the role of c-Jun in MNs with a monoclonal (clone Y172) antibody against phospho (p)-c-Jun (serine [Ser]63), unexpected labeling was identified in the cell body cytoplasm.	cholecystokinin C-terminal flanking peptide	134-140	jun proto-oncogene	Mus musculus	54-59
31838052-2	2020	Dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) as a serine/threonine kinase has recently been reported to be upregulated in pancreatic ductal adenocarcinoma (PDAC) and show protumorigenic effect.	cholecystokinin C-terminal flanking peptide	76-82	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-61
31838052-2	2020	Dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) as a serine/threonine kinase has recently been reported to be upregulated in pancreatic ductal adenocarcinoma (PDAC) and show protumorigenic effect.	cholecystokinin C-terminal flanking peptide	76-82	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	63-69
31884166-5	2020	Interestingly, we detected parallel amino acid substitutions, from serine (S) to threonine (T), on the DNA-binding domains of both ancestral DMY and DM-W, resulting from positive selection.	cholecystokinin C-terminal flanking peptide	67-73	doublesex- and mab-3-related transcription factor DM-W	Xenopus laevis	149-153
32038174-2	2019	During the immunocytochemical analysis of the role of c-Jun in MNs with a monoclonal (clone Y172) antibody against phospho (p)-c-Jun (serine [Ser]63), unexpected labeling was identified in the cell body cytoplasm.	cholecystokinin C-terminal flanking peptide	134-140	jun proto-oncogene	Mus musculus	127-132
31722791-1	2020	Lemur tyrosine kinase-2 (LMTK2), a newly identified serine/threonine kinase, is a potential regulator of cell survival and apoptosis.	cholecystokinin C-terminal flanking peptide	52-58	lemur tyrosine kinase 2	Homo sapiens	0-23
31722791-1	2020	Lemur tyrosine kinase-2 (LMTK2), a newly identified serine/threonine kinase, is a potential regulator of cell survival and apoptosis.	cholecystokinin C-terminal flanking peptide	52-58	lemur tyrosine kinase 2	Homo sapiens	25-30
31969605-6	2020	Accordingly, the level of PKC-dependent phosphorylation of KCC2, at the serine 940 site, was significantly increased after learning.	cholecystokinin C-terminal flanking peptide	72-78	solute carrier family 12 member 5	Rattus norvegicus	59-63
32042960-6	2020	Interestingly, we also observed an attenuated cell cycle response to gamma ionizing radiation (gamma-IR) via diminished phosphorylation of checkpoint kinase 1 (Chk1) on serine 345 in these cell lines.	cholecystokinin C-terminal flanking peptide	169-175	checkpoint kinase 1	Homo sapiens	139-158
31961913-0	2020	G protein alpha subunit suppresses sporangium formation through a serine/threonine protein kinase in Phytophthora sojae.	cholecystokinin C-terminal flanking peptide	66-72	PHYSODRAFT_322123	Phytophthora sojae	0-23
31957875-9	2020	Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1.	cholecystokinin C-terminal flanking peptide	110-116	integrin subunit beta 2	Homo sapiens	10-15
31957875-9	2020	Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1.	cholecystokinin C-terminal flanking peptide	110-116	prostaglandin D2 receptor	Homo sapiens	16-19
31957875-9	2020	Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1.	cholecystokinin C-terminal flanking peptide	110-116	microRNA 4319	Homo sapiens	63-71
31957875-9	2020	Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1.	cholecystokinin C-terminal flanking peptide	110-116	microRNA 4319	Homo sapiens	76-84
31957875-9	2020	Moreover, ITGB2-AS1 could target and inhibit the expression of miR-4319 and miR-4319-targeted and -suppressed serine/threonine kinase RAF1.	cholecystokinin C-terminal flanking peptide	110-116	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	134-138
31968628-1	2020	Thrombin, a key enzyme of the serine protease superfamily, plays an integral role in the blood coagulation cascade and thrombotic diseases.	cholecystokinin C-terminal flanking peptide	30-36	coagulation factor II, thrombin	Homo sapiens	0-8
32042960-6	2020	Interestingly, we also observed an attenuated cell cycle response to gamma ionizing radiation (gamma-IR) via diminished phosphorylation of checkpoint kinase 1 (Chk1) on serine 345 in these cell lines.	cholecystokinin C-terminal flanking peptide	169-175	checkpoint kinase 1	Homo sapiens	160-164
31653597-1	2020	Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation.	cholecystokinin C-terminal flanking peptide	65-71	proprotein convertase subtilisin/kexin type 9	Homo sapiens	0-51
31756331-2	2020	Saccharomyces cerevisiae protein Npl3p has six repeats of sequence SRGG, in a disordered domain, which can carry arginine methylation and serine phosphorylation.	cholecystokinin C-terminal flanking peptide	138-144	mRNA-binding protein NPL3	Saccharomyces cerevisiae S288C	33-38
31653597-1	2020	Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation.	cholecystokinin C-terminal flanking peptide	65-71	proprotein convertase subtilisin/kexin type 9	Homo sapiens	53-58
31653597-1	2020	Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation.	cholecystokinin C-terminal flanking peptide	65-71	low density lipoprotein receptor	Homo sapiens	132-170
31816312-7	2020	By mass spectrometry, we identified serine (S) 704 in TBC1D4 as a WNK1-regulated phosphorylation site, and also S565 in the paralogue TBC1D1.	cholecystokinin C-terminal flanking peptide	36-42	TBC1 domain family, member 4	Mus musculus	54-60
31723002-6	2020	Conversely, GSK3beta phosphorylated serine and threonine sites in the C-terminal domain of NDRG1, and limited the protein stability of NDRG1.	cholecystokinin C-terminal flanking peptide	36-42	glycogen synthase kinase 3 beta	Homo sapiens	12-20
31723002-6	2020	Conversely, GSK3beta phosphorylated serine and threonine sites in the C-terminal domain of NDRG1, and limited the protein stability of NDRG1.	cholecystokinin C-terminal flanking peptide	36-42	N-myc downstream regulated 1	Homo sapiens	91-96
31816312-7	2020	By mass spectrometry, we identified serine (S) 704 in TBC1D4 as a WNK1-regulated phosphorylation site, and also S565 in the paralogue TBC1D1.	cholecystokinin C-terminal flanking peptide	36-42	WNK lysine deficient protein kinase 1	Mus musculus	66-70
31911482-4	2020	Two of PHF10 isoforms lacking C-terminal PHD domains contain a cluster of phosphorylated serine residues, designated as X-cluster.	cholecystokinin C-terminal flanking peptide	89-95	PHD finger protein 10	Homo sapiens	7-12
31627046-5	2020	PKC-1, a serine/threonine protein kinase C, further acted downstream of neuronal DLG-1 and MAGI-1 to regulate the GO toxicity.	cholecystokinin C-terminal flanking peptide	9-15	Protein kinase C;Protein kinase C-like 1B	Caenorhabditis elegans	0-5
31770531-5	2020	Interestingly, the induced CD105 expression and cell motility were subjected to the inhibition by the DLC-1-RhoA-Rock1 signaling through inhibiting the serine phosphorylation at a linker region, but not at the C-terminus, of the Smad3 protein and Smad3 protein nuclear translocation down the canonical TGF-beta1 signaling.	cholecystokinin C-terminal flanking peptide	152-158	DLC1 Rho GTPase activating protein	Homo sapiens	102-107
31770531-5	2020	Interestingly, the induced CD105 expression and cell motility were subjected to the inhibition by the DLC-1-RhoA-Rock1 signaling through inhibiting the serine phosphorylation at a linker region, but not at the C-terminus, of the Smad3 protein and Smad3 protein nuclear translocation down the canonical TGF-beta1 signaling.	cholecystokinin C-terminal flanking peptide	152-158	ras homolog family member A	Homo sapiens	108-112
31770531-5	2020	Interestingly, the induced CD105 expression and cell motility were subjected to the inhibition by the DLC-1-RhoA-Rock1 signaling through inhibiting the serine phosphorylation at a linker region, but not at the C-terminus, of the Smad3 protein and Smad3 protein nuclear translocation down the canonical TGF-beta1 signaling.	cholecystokinin C-terminal flanking peptide	152-158	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	113-118
32010690-1	2019	PIN1 is a peptidyl-prolyl cis/trans isomerase that specifically binds and catalyzes the cis/trans isomerization of the phosphorylated serine or threonine residue preceding a proline (pSer/Thr-Pro) motif of its interacting proteins.	cholecystokinin C-terminal flanking peptide	134-140	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	0-4
31627046-5	2020	PKC-1, a serine/threonine protein kinase C, further acted downstream of neuronal DLG-1 and MAGI-1 to regulate the GO toxicity.	cholecystokinin C-terminal flanking peptide	9-15	Disks large homolog 1	Caenorhabditis elegans	81-86
31627046-5	2020	PKC-1, a serine/threonine protein kinase C, further acted downstream of neuronal DLG-1 and MAGI-1 to regulate the GO toxicity.	cholecystokinin C-terminal flanking peptide	9-15	MAGI (Membrane Associated Guanylate kinase Inverted) homolog	Caenorhabditis elegans	91-97
31947691-6	2020	Moreover, omega-3 abrogated decline in expression of total Cx43 as well as its phosphorylated forms at serine 368 along with PKC-epsilon, while decreased pro-fibrotic PKC-delta levels in hypertensive rat heart regardless the sex.	cholecystokinin C-terminal flanking peptide	103-109	gap junction protein, alpha 1	Rattus norvegicus	59-63
32009953-3	2019	Accumulating evidence suggest that thrombin, the main serine protease of the coagulation cascade, is involved in PTS genesis by mediating inflammation and hyperexcitability following blood brain barrier breakdown.	cholecystokinin C-terminal flanking peptide	54-60	coagulation factor II, thrombin	Homo sapiens	35-43
31923181-2	2020	Pancreatic secretory trypsin inhibitor (PSTI), a serine protease inhibitor expressed in gut mucosa may function as a mucosal protective/repair peptide.	cholecystokinin C-terminal flanking peptide	49-55	serine peptidase inhibitor Kazal type 1	Homo sapiens	40-44
31936902-3	2020	Furin is an intracellular serine endopeptidase of the subtilisin family that is closely associated with the activation of multiple protein precursors.	cholecystokinin C-terminal flanking peptide	26-32	furin, paired basic amino acid cleaving enzyme	Homo sapiens	0-5
31709703-3	2020	Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP-L2 on surface-exposed serine residues (LC3C S93 and S96; GABARAP-L2 S87 and S88).	cholecystokinin C-terminal flanking peptide	129-135	TANK binding kinase 1	Homo sapiens	26-30
31709703-3	2020	Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP-L2 on surface-exposed serine residues (LC3C S93 and S96; GABARAP-L2 S87 and S88).	cholecystokinin C-terminal flanking peptide	129-135	microtubule associated protein 1 light chain 3 gamma	Homo sapiens	90-94
31709703-3	2020	Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP-L2 on surface-exposed serine residues (LC3C S93 and S96; GABARAP-L2 S87 and S88).	cholecystokinin C-terminal flanking peptide	129-135	GABA type A receptor associated protein like 2	Homo sapiens	99-109
31709703-3	2020	Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP-L2 on surface-exposed serine residues (LC3C S93 and S96; GABARAP-L2 S87 and S88).	cholecystokinin C-terminal flanking peptide	129-135	microtubule associated protein 1 light chain 3 gamma	Homo sapiens	146-150
31709703-3	2020	Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP-L2 on surface-exposed serine residues (LC3C S93 and S96; GABARAP-L2 S87 and S88).	cholecystokinin C-terminal flanking peptide	129-135	GABA type A receptor-associated protein	Homo sapiens	99-106
31599158-7	2020	In total, 59 phosphorylation sites on 42 phosphopeptides and 32 proteins showing different enrichment patterns between phosphoproteomics and the corresponding proteomics were identified, which are potential candidate sites to regulate the protein subcellular localization, including serine 706 on CD44 and serine 22 on lamin A/C.	cholecystokinin C-terminal flanking peptide	283-289	CD44 molecule (Indian blood group)	Homo sapiens	297-301
31903552-0	2020	Phosphorylation of histone H4 at serine 1 is associated with GCN5 and mediates autophagy in osteosarcoma bone cell lines.	cholecystokinin C-terminal flanking peptide	33-39	lysine acetyltransferase 2A	Homo sapiens	61-65
31903552-9	2020	Results indicated that GCN5 was implicated in the modulation of H4 phosphorylation at serine 1 (Ser1).	cholecystokinin C-terminal flanking peptide	86-92	lysine acetyltransferase 2A	Homo sapiens	23-27
31599158-7	2020	In total, 59 phosphorylation sites on 42 phosphopeptides and 32 proteins showing different enrichment patterns between phosphoproteomics and the corresponding proteomics were identified, which are potential candidate sites to regulate the protein subcellular localization, including serine 706 on CD44 and serine 22 on lamin A/C.	cholecystokinin C-terminal flanking peptide	283-289	lamin A/C	Homo sapiens	319-328
31599158-7	2020	In total, 59 phosphorylation sites on 42 phosphopeptides and 32 proteins showing different enrichment patterns between phosphoproteomics and the corresponding proteomics were identified, which are potential candidate sites to regulate the protein subcellular localization, including serine 706 on CD44 and serine 22 on lamin A/C.	cholecystokinin C-terminal flanking peptide	306-312	CD44 molecule (Indian blood group)	Homo sapiens	297-301
31599158-7	2020	In total, 59 phosphorylation sites on 42 phosphopeptides and 32 proteins showing different enrichment patterns between phosphoproteomics and the corresponding proteomics were identified, which are potential candidate sites to regulate the protein subcellular localization, including serine 706 on CD44 and serine 22 on lamin A/C.	cholecystokinin C-terminal flanking peptide	306-312	lamin A/C	Homo sapiens	319-328
31735643-1	2020	PGAM5 is a mitochondrial serine/threonine phosphatase that regulates multiple metabolic pathways and contributes to tumorigenesis in a poorly understood manner.	cholecystokinin C-terminal flanking peptide	25-31	phosphoglycerate mutase family member 5	Mus musculus	0-5
31548229-2	2020	Crystal structure analysis of PTEN has revealed a C2 domain that binds to phospholipids in membranes and a phosphatase domain that displays dual-specific activity toward both tyrosine (Y), serine (S)/threonine (T), as well as lipid substrates in vitro.	cholecystokinin C-terminal flanking peptide	189-195	phosphatase and tensin homolog	Homo sapiens	30-34
32064167-0	2020	Hepatitis B virus X protein promotes tumor invasion and poor prognosis in hepatocellular carcinoma via phosphorylation of paxillin at Serine 178 by activation of the c-Jun NH2-terminal kinase.	cholecystokinin C-terminal flanking peptide	134-140	paxillin	Homo sapiens	122-130
32064161-0	2020	PLCepsilon knockdown prevents serine/glycine metabolism and proliferation of prostate cancer by suppressing YAP.	cholecystokinin C-terminal flanking peptide	30-36	phospholipase C like 1 (inactive)	Homo sapiens	0-10
32064167-0	2020	Hepatitis B virus X protein promotes tumor invasion and poor prognosis in hepatocellular carcinoma via phosphorylation of paxillin at Serine 178 by activation of the c-Jun NH2-terminal kinase.	cholecystokinin C-terminal flanking peptide	134-140	mitogen-activated protein kinase 8	Homo sapiens	166-191
32064161-7	2020	Secondly, PLCepsilon knockdown can inhibit serine/glycine producing and proliferation of PCa both in vivo and in vitro.	cholecystokinin C-terminal flanking peptide	43-49	phospholipase C like 1 (inactive)	Homo sapiens	10-20
32064167-3	2020	HBx gene manipulation and Western blotting indicated that phosphorylation of PXN at Serine 178 (pS178-PXN) by HBx may promote invasiveness in HCC cells via HBx-mediated JNK activation.	cholecystokinin C-terminal flanking peptide	84-90	paxillin	Homo sapiens	77-80
32064161-8	2020	Mechanistically, PLCepsilon may affect the serine/glycine metabolism by regulating dephosphorylation and nuclear translocation of YAP.	cholecystokinin C-terminal flanking peptide	43-49	phospholipase C like 1 (inactive)	Homo sapiens	17-27
32064167-3	2020	HBx gene manipulation and Western blotting indicated that phosphorylation of PXN at Serine 178 (pS178-PXN) by HBx may promote invasiveness in HCC cells via HBx-mediated JNK activation.	cholecystokinin C-terminal flanking peptide	84-90	paxillin	Homo sapiens	102-105
32064167-3	2020	HBx gene manipulation and Western blotting indicated that phosphorylation of PXN at Serine 178 (pS178-PXN) by HBx may promote invasiveness in HCC cells via HBx-mediated JNK activation.	cholecystokinin C-terminal flanking peptide	84-90	mitogen-activated protein kinase 8	Homo sapiens	169-172
32064161-8	2020	Mechanistically, PLCepsilon may affect the serine/glycine metabolism by regulating dephosphorylation and nuclear translocation of YAP.	cholecystokinin C-terminal flanking peptide	43-49	Yes1 associated transcriptional regulator	Homo sapiens	130-133
32064167-6	2020	In conclusion, phosphorylation of PXN at Serine 178 by HBx-mediated JNK activation may therefore play a critical role in tumor invasiveness and poor prognosis in patients with HBV-infected hepatocellular tumors.	cholecystokinin C-terminal flanking peptide	41-47	paxillin	Homo sapiens	34-37
32064161-9	2020	More interestingly, verteporfin (VP, a specific inhibitor of YAP) could effectively enhance the PLCepsilon-depletion induced inhibition of serine/glycine secretion and growth.	cholecystokinin C-terminal flanking peptide	139-145	Yes1 associated transcriptional regulator	Homo sapiens	61-64
32064161-9	2020	More interestingly, verteporfin (VP, a specific inhibitor of YAP) could effectively enhance the PLCepsilon-depletion induced inhibition of serine/glycine secretion and growth.	cholecystokinin C-terminal flanking peptide	139-145	phospholipase C like 1 (inactive)	Homo sapiens	96-106
32064161-10	2020	Overall, this research revealed the possibility of anomalous serine/glycine levels in the blood for the diagnosis of PCa, identified the important role of the PLCepsilon/YAP axis in regulating serine/glycine metabolism, cell proliferation and tumor growth, and suggested the combination of VP with PLCepsilon-depletion may provide a new idea for the treatment of PCa.	cholecystokinin C-terminal flanking peptide	193-199	phospholipase C like 1 (inactive)	Homo sapiens	159-169
32064167-6	2020	In conclusion, phosphorylation of PXN at Serine 178 by HBx-mediated JNK activation may therefore play a critical role in tumor invasiveness and poor prognosis in patients with HBV-infected hepatocellular tumors.	cholecystokinin C-terminal flanking peptide	41-47	mitogen-activated protein kinase 8	Homo sapiens	68-71
32064161-10	2020	Overall, this research revealed the possibility of anomalous serine/glycine levels in the blood for the diagnosis of PCa, identified the important role of the PLCepsilon/YAP axis in regulating serine/glycine metabolism, cell proliferation and tumor growth, and suggested the combination of VP with PLCepsilon-depletion may provide a new idea for the treatment of PCa.	cholecystokinin C-terminal flanking peptide	193-199	Yes1 associated transcriptional regulator	Homo sapiens	170-173
31629469-6	2020	RAGE knockdown efficiently attenuated hypoxia-induced IR, including inhibiting serine phosphorylation of insulin receptor substrate-1 (IRS-1), increasing the expression of phosphorylated Akt (Ser473), and improving insulin-stimulated glucose uptake.	cholecystokinin C-terminal flanking peptide	79-85	advanced glycosylation end-product specific receptor	Homo sapiens	0-4
31889497-1	2020	INTRODUCTION: Phosphoinositide-Dependent Kinase-1 (PDK1) is a serine/threonine kinase, which belongs to AGC kinase family required by cancer cells.	cholecystokinin C-terminal flanking peptide	62-68	pyruvate dehydrogenase kinase 1	Homo sapiens	14-49
31889497-1	2020	INTRODUCTION: Phosphoinositide-Dependent Kinase-1 (PDK1) is a serine/threonine kinase, which belongs to AGC kinase family required by cancer cells.	cholecystokinin C-terminal flanking peptide	62-68	pyruvate dehydrogenase kinase 1	Homo sapiens	51-55
31629469-6	2020	RAGE knockdown efficiently attenuated hypoxia-induced IR, including inhibiting serine phosphorylation of insulin receptor substrate-1 (IRS-1), increasing the expression of phosphorylated Akt (Ser473), and improving insulin-stimulated glucose uptake.	cholecystokinin C-terminal flanking peptide	79-85	insulin receptor substrate 1	Homo sapiens	105-133
31629469-6	2020	RAGE knockdown efficiently attenuated hypoxia-induced IR, including inhibiting serine phosphorylation of insulin receptor substrate-1 (IRS-1), increasing the expression of phosphorylated Akt (Ser473), and improving insulin-stimulated glucose uptake.	cholecystokinin C-terminal flanking peptide	79-85	insulin	Homo sapiens	105-112
31902919-3	2020	Treatment of primary cultured rat microglia with thrombin, a serine protease that has been proposed as a mediator of cerebrovascular injuries, caused the expression of inducible NO synthase (iNOS) and the production of NO.	cholecystokinin C-terminal flanking peptide	61-67	coagulation factor II	Rattus norvegicus	49-57
31839944-11	2020	Enrichment analysis indicated that these key miRNAs were mainly involved in nine biological processes, such as regulation of MAP kinase activity, JNK cascade signaling and regulation of protein serine/threonine kinase activity) and in 28 pathways, including the mitogen associated protein kinase, the sphingolipid, ErbB, Ras and the C-type lectin receptor signaling pathways.	cholecystokinin C-terminal flanking peptide	194-200	mitogen-activated protein kinase 8	Homo sapiens	146-149
31839944-11	2020	Enrichment analysis indicated that these key miRNAs were mainly involved in nine biological processes, such as regulation of MAP kinase activity, JNK cascade signaling and regulation of protein serine/threonine kinase activity) and in 28 pathways, including the mitogen associated protein kinase, the sphingolipid, ErbB, Ras and the C-type lectin receptor signaling pathways.	cholecystokinin C-terminal flanking peptide	194-200	epidermal growth factor receptor	Homo sapiens	315-319
31902919-3	2020	Treatment of primary cultured rat microglia with thrombin, a serine protease that has been proposed as a mediator of cerebrovascular injuries, caused the expression of inducible NO synthase (iNOS) and the production of NO.	cholecystokinin C-terminal flanking peptide	61-67	nitric oxide synthase 2	Rattus norvegicus	168-189
31839944-11	2020	Enrichment analysis indicated that these key miRNAs were mainly involved in nine biological processes, such as regulation of MAP kinase activity, JNK cascade signaling and regulation of protein serine/threonine kinase activity) and in 28 pathways, including the mitogen associated protein kinase, the sphingolipid, ErbB, Ras and the C-type lectin receptor signaling pathways.	cholecystokinin C-terminal flanking peptide	194-200	C-type lectin domain family 4 member D	Homo sapiens	333-355
31662325-2	2020	Here we demonstrate that Rab7, a recently identified substrate of PTEN phosphatase activity, is also a substrate of the innate immune signaling kinases TBK1/IKKepsilon on the same serine-72 site.	cholecystokinin C-terminal flanking peptide	180-186	RAB7B, member RAS oncogene family	Homo sapiens	25-29
31662325-2	2020	Here we demonstrate that Rab7, a recently identified substrate of PTEN phosphatase activity, is also a substrate of the innate immune signaling kinases TBK1/IKKepsilon on the same serine-72 site.	cholecystokinin C-terminal flanking peptide	180-186	phosphatase and tensin homolog	Homo sapiens	66-70
31662325-2	2020	Here we demonstrate that Rab7, a recently identified substrate of PTEN phosphatase activity, is also a substrate of the innate immune signaling kinases TBK1/IKKepsilon on the same serine-72 site.	cholecystokinin C-terminal flanking peptide	180-186	TANK binding kinase 1	Homo sapiens	152-156
31662325-2	2020	Here we demonstrate that Rab7, a recently identified substrate of PTEN phosphatase activity, is also a substrate of the innate immune signaling kinases TBK1/IKKepsilon on the same serine-72 site.	cholecystokinin C-terminal flanking peptide	180-186	inhibitor of nuclear factor kappa B kinase subunit epsilon	Homo sapiens	157-167
31676368-8	2020	PLA analysis revealed that in response to muscarine, PKCalpha activates Pyk2 through phosphorylating its serine residues.	cholecystokinin C-terminal flanking peptide	105-111	protein kinase C, alpha	Rattus norvegicus	53-61
31676368-8	2020	PLA analysis revealed that in response to muscarine, PKCalpha activates Pyk2 through phosphorylating its serine residues.	cholecystokinin C-terminal flanking peptide	105-111	protein tyrosine kinase 2 beta	Rattus norvegicus	72-76
31654721-2	2020	Previous studies have reported that PML-RARalpha is cleaved by neutrophil elastase (NE), an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARalpha.	cholecystokinin C-terminal flanking peptide	115-121	PML nuclear body scaffold	Homo sapiens	36-39
31678681-0	2020	TCDD-mediated suppression of naive human B cell IgM secretion involves aryl hydrocarbon receptor-mediated reduction in STAT3 serine 727 phosphorylation and is restored by Interferon-gamma.	cholecystokinin C-terminal flanking peptide	125-131	signal transducer and activator of transcription 3	Homo sapiens	119-124
31654721-2	2020	Previous studies have reported that PML-RARalpha is cleaved by neutrophil elastase (NE), an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARalpha.	cholecystokinin C-terminal flanking peptide	115-121	retinoic acid receptor alpha	Homo sapiens	40-48
31654721-2	2020	Previous studies have reported that PML-RARalpha is cleaved by neutrophil elastase (NE), an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARalpha.	cholecystokinin C-terminal flanking peptide	115-121	elastase, neutrophil expressed	Homo sapiens	63-82
31654721-2	2020	Previous studies have reported that PML-RARalpha is cleaved by neutrophil elastase (NE), an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARalpha.	cholecystokinin C-terminal flanking peptide	115-121	PML nuclear body scaffold	Homo sapiens	205-208
31654721-2	2020	Previous studies have reported that PML-RARalpha is cleaved by neutrophil elastase (NE), an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARalpha.	cholecystokinin C-terminal flanking peptide	115-121	retinoic acid receptor alpha	Homo sapiens	238-246
31743657-0	2020	Tumor Necrosis Factor-alpha-Induced Apoptosis in the Intestinal Epithelium due to Chronic Nuclear Factor Kappa B Signaling Is Mediated by Receptor Interacting Serine/Threonine Kinase 1.	cholecystokinin C-terminal flanking peptide	159-165	tumor necrosis factor	Homo sapiens	0-27
31678681-8	2020	By contrast, TCDD significantly reduced levels of STAT3 serine phosphorylation as early as 12 h post B cell activation.	cholecystokinin C-terminal flanking peptide	56-62	signal transducer and activator of transcription 3	Homo sapiens	50-55
31678681-9	2020	These results corresponded with decreased inhibitory phosphorylation of the serine specific phosphatase PP2a, which is regulated by SHP-1.	cholecystokinin C-terminal flanking peptide	76-82	protein phosphatase 2 phosphatase activator	Homo sapiens	104-108
31678681-9	2020	These results corresponded with decreased inhibitory phosphorylation of the serine specific phosphatase PP2a, which is regulated by SHP-1.	cholecystokinin C-terminal flanking peptide	76-82	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	132-137
31903986-2	2020	Ulinastatin (UTI) may attenuate EGL shedding by inhibiting serine proteases and hyaluronidase.	cholecystokinin C-terminal flanking peptide	59-65	alpha-1-microglobulin/bikunin precursor	Homo sapiens	0-11
31678681-11	2020	Indeed, treatment of human B cells with IFNgamma resulted in increased STAT3 serine phosphorylation and reversed TCDD-mediated suppression of the IgM response.	cholecystokinin C-terminal flanking peptide	77-83	interferon gamma	Homo sapiens	40-48
31678681-11	2020	Indeed, treatment of human B cells with IFNgamma resulted in increased STAT3 serine phosphorylation and reversed TCDD-mediated suppression of the IgM response.	cholecystokinin C-terminal flanking peptide	77-83	signal transducer and activator of transcription 3	Homo sapiens	71-76
31573880-3	2020	Essential to the activation and amplification of the alternative pathway (AP) of complement, complement factor D (CFD) is a specific serine protease that cleaves its unique substrate, complement factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb.	cholecystokinin C-terminal flanking peptide	133-139	complement C3	Homo sapiens	271-273
31999555-6	2020	Serine/threonine-protein kinase (Pim-1) was identified as the direct target of CN-TBM with a pharmacophore model complementing well with the molecular features of CN-TBM.	cholecystokinin C-terminal flanking peptide	0-6	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	33-38
32029829-5	2020	Using pharmacologic and molecular manipulations, we further demonstrate that the NMDA-induced downregulation of PSD-95 depends on the activation of CaMKII and CaMKII-driven phosphorylation of PSD-95 serine 73.	cholecystokinin C-terminal flanking peptide	199-205	discs large MAGUK scaffold protein 4	Homo sapiens	112-118
32029829-5	2020	Using pharmacologic and molecular manipulations, we further demonstrate that the NMDA-induced downregulation of PSD-95 depends on the activation of CaMKII and CaMKII-driven phosphorylation of PSD-95 serine 73.	cholecystokinin C-terminal flanking peptide	199-205	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	159-165
31573880-3	2020	Essential to the activation and amplification of the alternative pathway (AP) of complement, complement factor D (CFD) is a specific serine protease that cleaves its unique substrate, complement factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb.	cholecystokinin C-terminal flanking peptide	133-139	complement factor D	Homo sapiens	93-112
31935717-2	2020	The serine incorporator proteins SERINC3 and SERINC5 potently reduce the infectivity of HIV-1 particles when overexpressed, and RNA interference or knockout approaches in T cells have indicated antiviral activity also of the endogenous proteins.	cholecystokinin C-terminal flanking peptide	4-10	serine incorporator 3	Homo sapiens	33-40
31573880-3	2020	Essential to the activation and amplification of the alternative pathway (AP) of complement, complement factor D (CFD) is a specific serine protease that cleaves its unique substrate, complement factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb.	cholecystokinin C-terminal flanking peptide	133-139	complement factor D	Homo sapiens	114-117
31573880-3	2020	Essential to the activation and amplification of the alternative pathway (AP) of complement, complement factor D (CFD) is a specific serine protease that cleaves its unique substrate, complement factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb.	cholecystokinin C-terminal flanking peptide	133-139	complement factor B	Homo sapiens	184-203
31573880-3	2020	Essential to the activation and amplification of the alternative pathway (AP) of complement, complement factor D (CFD) is a specific serine protease that cleaves its unique substrate, complement factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb.	cholecystokinin C-terminal flanking peptide	133-139	complement factor B	Homo sapiens	205-208
31688093-5	2020	Serine metabolism may reduce NADP+ to NADPH and permit the use of NADPH in reductive reactions.	cholecystokinin C-terminal flanking peptide	0-6	2,4-dienoyl CoA reductase 1, mitochondrial	Mus musculus	38-43
31688093-5	2020	Serine metabolism may reduce NADP+ to NADPH and permit the use of NADPH in reductive reactions.	cholecystokinin C-terminal flanking peptide	0-6	2,4-dienoyl CoA reductase 1, mitochondrial	Mus musculus	66-71
32003693-1	2020	OBJECTIVE: Neuroserpin is a serine protease inhibitor predominantly expressed in the nervous system functioning mainly in neuronal migration and axonal growth.	cholecystokinin C-terminal flanking peptide	28-34	serpin family I member 1	Homo sapiens	11-22
31732257-1	2020	Over the past decade, many drug discovery endeavors have been invested in targeting the serine proteases prolyl oligopeptidase (POP) for the treatment of Alzheimer"s and Parkinson"s disease and, more recently, epithelial cancers.	cholecystokinin C-terminal flanking peptide	88-94	prolyl endopeptidase	Homo sapiens	105-126
31732257-1	2020	Over the past decade, many drug discovery endeavors have been invested in targeting the serine proteases prolyl oligopeptidase (POP) for the treatment of Alzheimer"s and Parkinson"s disease and, more recently, epithelial cancers.	cholecystokinin C-terminal flanking peptide	88-94	prolyl endopeptidase	Homo sapiens	128-131
31743741-5	2020	Moreover, PerO treatment enhanced the expression of phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) and activated the expression of glucose transporter 4 (Glut4) and phospho-AKT serine/threonine kinase (p-AS160) in the liver.	cholecystokinin C-terminal flanking peptide	186-192	thymoma viral proto-oncogene 1	Mus musculus	182-185
31897243-4	2020	In addition, we found that the combination of metformin and LW6 increased the phosphorylation of yes-associated protein 1 at serine 127 and attenuated the nuclear localization of this transcription factor.	cholecystokinin C-terminal flanking peptide	125-131	Yes1 associated transcriptional regulator	Homo sapiens	97-121
31709727-8	2020	By sequencing the coding area of BECN 1 gene of CSQT-2 and HCC-LM3 cells, we found that the predicted translational products of BECN 1 gene contained RLPS295 VP (R, arginine; L, leucine; P, proline; S, serine; V, valine), a classic 14-3-3zeta binding motif.	cholecystokinin C-terminal flanking peptide	202-208	beclin 1	Homo sapiens	33-39
31709727-8	2020	By sequencing the coding area of BECN 1 gene of CSQT-2 and HCC-LM3 cells, we found that the predicted translational products of BECN 1 gene contained RLPS295 VP (R, arginine; L, leucine; P, proline; S, serine; V, valine), a classic 14-3-3zeta binding motif.	cholecystokinin C-terminal flanking peptide	202-208	beclin 1	Homo sapiens	128-134
31757865-3	2020	Phosphorylation of AID at serine 38 was previously hypothesized to regulate BER during CSR, as the AID phosphorylation mutant, AID(S38A), cannot interact with APE1, a BER protein.	cholecystokinin C-terminal flanking peptide	26-32	activation-induced cytidine deaminase	Mus musculus	19-22
31757865-3	2020	Phosphorylation of AID at serine 38 was previously hypothesized to regulate BER during CSR, as the AID phosphorylation mutant, AID(S38A), cannot interact with APE1, a BER protein.	cholecystokinin C-terminal flanking peptide	26-32	activation-induced cytidine deaminase	Mus musculus	99-102
31757865-3	2020	Phosphorylation of AID at serine 38 was previously hypothesized to regulate BER during CSR, as the AID phosphorylation mutant, AID(S38A), cannot interact with APE1, a BER protein.	cholecystokinin C-terminal flanking peptide	26-32	activation-induced cytidine deaminase	Mus musculus	99-102
31757865-7	2020	These data identify a novel role for phosphorylation of AID at serine 38 in mismatch repair-dependent CSR and affinity maturation.	cholecystokinin C-terminal flanking peptide	63-69	activation-induced cytidine deaminase	Mus musculus	56-59
31838986-2	2020	In patients with vasculitis, two types of ANCA have been identified: ANCA directed against the neutrophil serine protease proteinase-3 (PR3) which results in a cytoplasmic immunofluorescence pattern (c-ANCA) and ANCA directed against the neutrophil enzyme myeloperoxidase (MPO), which results in a perinuclear immunofluorescence pattern (p-ANCA).	cholecystokinin C-terminal flanking peptide	106-112	proteinase 3	Homo sapiens	122-134
31838986-2	2020	In patients with vasculitis, two types of ANCA have been identified: ANCA directed against the neutrophil serine protease proteinase-3 (PR3) which results in a cytoplasmic immunofluorescence pattern (c-ANCA) and ANCA directed against the neutrophil enzyme myeloperoxidase (MPO), which results in a perinuclear immunofluorescence pattern (p-ANCA).	cholecystokinin C-terminal flanking peptide	106-112	proteinase 3	Homo sapiens	136-139
31838986-2	2020	In patients with vasculitis, two types of ANCA have been identified: ANCA directed against the neutrophil serine protease proteinase-3 (PR3) which results in a cytoplasmic immunofluorescence pattern (c-ANCA) and ANCA directed against the neutrophil enzyme myeloperoxidase (MPO), which results in a perinuclear immunofluorescence pattern (p-ANCA).	cholecystokinin C-terminal flanking peptide	106-112	myeloperoxidase	Homo sapiens	256-271
31838986-2	2020	In patients with vasculitis, two types of ANCA have been identified: ANCA directed against the neutrophil serine protease proteinase-3 (PR3) which results in a cytoplasmic immunofluorescence pattern (c-ANCA) and ANCA directed against the neutrophil enzyme myeloperoxidase (MPO), which results in a perinuclear immunofluorescence pattern (p-ANCA).	cholecystokinin C-terminal flanking peptide	106-112	myeloperoxidase	Homo sapiens	273-276
31702488-1	2020	Butyrylcholinesterase is a serine hydrolase that catalyzes the hydrolysis of esters in the body.	cholecystokinin C-terminal flanking peptide	27-33	butyrylcholinesterase	Homo sapiens	0-21
31914657-1	2020	Factor VII activating protease (FSAP) is a circulating serine protease implicated in thrombosis, atherosclerosis, stroke, and cancer.	cholecystokinin C-terminal flanking peptide	55-61	hyaluronan binding protein 2	Homo sapiens	0-30
31914657-1	2020	Factor VII activating protease (FSAP) is a circulating serine protease implicated in thrombosis, atherosclerosis, stroke, and cancer.	cholecystokinin C-terminal flanking peptide	55-61	hyaluronan binding protein 2	Homo sapiens	32-36
31914657-6	2020	Recombinant serine protease domain of wild type FSAP, but not the Marburg I isoform of FSAP, could reproduce the effects of plasma purified FSAP.	cholecystokinin C-terminal flanking peptide	12-18	hyaluronan binding protein 2	Homo sapiens	48-52
31956373-7	2020	Results: STAT3 was constitutively activated (i.e., tyrosine-phosphorylated, serine-phosphorylated and nuclear translocation), meanwhile the expression and transcriptional activity of Mcl-1 were up-regulated in lung cancer cells following treatment with nicotine.	cholecystokinin C-terminal flanking peptide	76-82	signal transducer and activator of transcription 3	Homo sapiens	9-14
31956373-7	2020	Results: STAT3 was constitutively activated (i.e., tyrosine-phosphorylated, serine-phosphorylated and nuclear translocation), meanwhile the expression and transcriptional activity of Mcl-1 were up-regulated in lung cancer cells following treatment with nicotine.	cholecystokinin C-terminal flanking peptide	76-82	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	183-188
31935717-2	2020	The serine incorporator proteins SERINC3 and SERINC5 potently reduce the infectivity of HIV-1 particles when overexpressed, and RNA interference or knockout approaches in T cells have indicated antiviral activity also of the endogenous proteins.	cholecystokinin C-terminal flanking peptide	4-10	serine incorporator 5	Homo sapiens	45-52
31541353-3	2020	We obtained in silico and mass spectrometry evidence, that was combined with siRNA strategies, to discover that insulin-induced phosphorylation of serine 418, serine 419, and serine 422 in rat SREBP-1c was most likely mediated by p70S6 kinase.	cholecystokinin C-terminal flanking peptide	147-153	sterol regulatory element binding transcription factor 1	Rattus norvegicus	193-201
32007961-0	2020	An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson"s Disease and G2019S LRRK2 Cohorts.	cholecystokinin C-terminal flanking peptide	23-29	leucine rich repeat kinase 2	Homo sapiens	17-22
31541353-3	2020	We obtained in silico and mass spectrometry evidence, that was combined with siRNA strategies, to discover that insulin-induced phosphorylation of serine 418, serine 419, and serine 422 in rat SREBP-1c was most likely mediated by p70S6 kinase.	cholecystokinin C-terminal flanking peptide	159-165	sterol regulatory element binding transcription factor 1	Rattus norvegicus	193-201
31541353-3	2020	We obtained in silico and mass spectrometry evidence, that was combined with siRNA strategies, to discover that insulin-induced phosphorylation of serine 418, serine 419, and serine 422 in rat SREBP-1c was most likely mediated by p70S6 kinase.	cholecystokinin C-terminal flanking peptide	159-165	sterol regulatory element binding transcription factor 1	Rattus norvegicus	193-201
31541353-4	2020	Here, for the first time, we show that insulin-induced phosphorylation of these 3 serine residues mainly impinged on the mechanisms of proteostasis of both full-length and mature SREBP-1c in the McArdle-RH7777 hepatoma cells.	cholecystokinin C-terminal flanking peptide	82-88	sterol regulatory element binding transcription factor 1	Rattus norvegicus	179-187
31794879-4	2020	We also examined the expression of potential binding partners for MIF, and found that the serine protease HTRA1, known to be inhibited by MIF, was also expressed at high levels by OECs and olfactory fibroblasts in vivo and in vitro.	cholecystokinin C-terminal flanking peptide	90-96	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	66-69
31680191-6	2020	Specifically, lysine 370/372/373 and 381/382/386 mutations decreased p53 stability, and lysine 305 mutation reduced p53 phosphorylation level at serine 15, while lysine 120 and 164 mutations decreased p53 acetylation level at lysine 382.	cholecystokinin C-terminal flanking peptide	145-151	tumor protein p53	Homo sapiens	116-119
31680191-6	2020	Specifically, lysine 370/372/373 and 381/382/386 mutations decreased p53 stability, and lysine 305 mutation reduced p53 phosphorylation level at serine 15, while lysine 120 and 164 mutations decreased p53 acetylation level at lysine 382.	cholecystokinin C-terminal flanking peptide	145-151	tumor protein p53	Homo sapiens	116-119
31660824-1	2020	BACKGROUND: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh), which is a significant neurotransmitter for regulation of cognition in animals.	cholecystokinin C-terminal flanking peptide	83-89	acetylcholinesterase (Cartwright blood group)	Homo sapiens	12-32
31660824-1	2020	BACKGROUND: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh), which is a significant neurotransmitter for regulation of cognition in animals.	cholecystokinin C-terminal flanking peptide	83-89	acetylcholinesterase (Cartwright blood group)	Homo sapiens	34-38
31660824-1	2020	BACKGROUND: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh), which is a significant neurotransmitter for regulation of cognition in animals.	cholecystokinin C-terminal flanking peptide	83-89	butyrylcholinesterase	Homo sapiens	44-65
31660824-1	2020	BACKGROUND: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh), which is a significant neurotransmitter for regulation of cognition in animals.	cholecystokinin C-terminal flanking peptide	83-89	butyrylcholinesterase	Homo sapiens	67-71
31794879-4	2020	We also examined the expression of potential binding partners for MIF, and found that the serine protease HTRA1, known to be inhibited by MIF, was also expressed at high levels by OECs and olfactory fibroblasts in vivo and in vitro.	cholecystokinin C-terminal flanking peptide	90-96	HtrA serine peptidase 1	Mus musculus	106-111
31794879-4	2020	We also examined the expression of potential binding partners for MIF, and found that the serine protease HTRA1, known to be inhibited by MIF, was also expressed at high levels by OECs and olfactory fibroblasts in vivo and in vitro.	cholecystokinin C-terminal flanking peptide	90-96	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	138-141
31805346-0	2020	Deficits in developmental neurogenesis and dendritic spine maturation in mice lacking the serine protease inhibitor neuroserpin.	cholecystokinin C-terminal flanking peptide	90-96	serine (or cysteine) peptidase inhibitor, clade I, member 1	Mus musculus	116-127
31707355-9	2020	We also establish that loss of serine catabolism and purine biosynthesis resulting from AGF347 treatment impacts mTOR signaling, glutathione pools and reactive oxygen species, contributing to antitumor efficacy.	cholecystokinin C-terminal flanking peptide	31-37	mechanistic target of rapamycin kinase	Homo sapiens	113-117
31805346-1	2020	Neuroserpin is a serine protease inhibitor of the nervous system required for normal synaptic plasticity and regulating cognitive, emotional and social behavior in mice.	cholecystokinin C-terminal flanking peptide	17-23	serine (or cysteine) peptidase inhibitor, clade I, member 1	Mus musculus	0-11
31969708-6	2020	Phosphorylation by protein kinase A of specific serine residues on Rad decreases its affinity for beta subunits and relieves constitutive inhibition of CaV1.2, observed as an increase in channel open probability.	cholecystokinin C-terminal flanking peptide	48-54	Ras-related associated with diabetes	Mus musculus	67-70
31969708-6	2020	Phosphorylation by protein kinase A of specific serine residues on Rad decreases its affinity for beta subunits and relieves constitutive inhibition of CaV1.2, observed as an increase in channel open probability.	cholecystokinin C-terminal flanking peptide	48-54	calcium channel, voltage-dependent, L type, alpha 1C subunit	Mus musculus	152-158
31622858-1	2020	Previous studies have shown that several d-amino acids are widely present in plants, and serine racemase (SerR), which synthesizes d-serine in vivo, has already been identified from three plant species.	cholecystokinin C-terminal flanking peptide	131-139	serine racemase	Solanum lycopersicum	89-104
31897207-5	2020	The present study used the phosphorylation of Akt1 protein at serine 473 (pAkt473) as an indicator of signaling activation.	cholecystokinin C-terminal flanking peptide	62-68	AKT serine/threonine kinase 1	Homo sapiens	46-50
31558800-1	2020	Fusion proteins involving the BRAF serine/threonine kinase occur in many cancers.	cholecystokinin C-terminal flanking peptide	35-41	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	30-34
31622858-1	2020	Previous studies have shown that several d-amino acids are widely present in plants, and serine racemase (SerR), which synthesizes d-serine in vivo, has already been identified from three plant species.	cholecystokinin C-terminal flanking peptide	131-139	serine racemase	Solanum lycopersicum	106-110
31622858-4	2020	These SerR homologs exhibited racemase activity towards serine or aspartate and were identified on the basis of their maximum activity as SerR or aspartate racemase (AspR).	cholecystokinin C-terminal flanking peptide	56-62	serine racemase	Solanum lycopersicum	6-10
31759088-1	2020	Prolyl oligopeptidase (PREP) is a serine protease that has been studied particularly in the context of neurodegenerative diseases for decades but its physiological function has remained unclear.	cholecystokinin C-terminal flanking peptide	34-40	prolyl endopeptidase	Homo sapiens	0-21
31622858-4	2020	These SerR homologs exhibited racemase activity towards serine or aspartate and were identified on the basis of their maximum activity as SerR or aspartate racemase (AspR).	cholecystokinin C-terminal flanking peptide	56-62	serine racemase	Solanum lycopersicum	138-142
31759088-1	2020	Prolyl oligopeptidase (PREP) is a serine protease that has been studied particularly in the context of neurodegenerative diseases for decades but its physiological function has remained unclear.	cholecystokinin C-terminal flanking peptide	34-40	prolyl endopeptidase	Homo sapiens	23-27
31622858-7	2020	Phylogenetic tree analysis showed that SerR and AspR are widely distributed in plants and form a serine/aspartate racemase family cluster.	cholecystokinin C-terminal flanking peptide	97-103	serine racemase	Solanum lycopersicum	39-43
31622858-9	2020	The amino acid sequence alignment and comparison of the chromosomal gene arrangement have revealed that plant AspR genes independently evolved from SerR in each ancestral lineage of plant species by gene duplication and acquisition of two serine residues at position 150 to 152.	cholecystokinin C-terminal flanking peptide	239-245	serine racemase	Solanum lycopersicum	148-152
31715189-3	2020	The archetypal 47 kb Tcp plasmid, pCW3, encodes a gene, resP, whose putative product has sequence similarity to members of the serine recombinase family of site-specific recombinases.	cholecystokinin C-terminal flanking peptide	127-133	resP	Clostridium perfringens	56-60
31779918-1	2020	The first step in the Phosphorylated Pathway of serine (Ser) Biosynthesis (PPSB) is catalyzed by the enzyme Phosphoglycerate Dehydrogenase (PGDH), coded in Arabidopsis thaliana by three genes.	cholecystokinin C-terminal flanking peptide	48-54	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	108-138
31779918-7	2020	Under salt-stress conditions, PGDH1 overexpression increased Ser content only in roots, while PGDH3 overexpression increased the amino acid level in both aerial parts and roots, compared to the WT.	cholecystokinin C-terminal flanking peptide	61-64	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	30-35
31779918-8	2020	Our results indicate that the response of PGDH family genes to salt-stress depends on the specific gene studied and that increases in Ser content are not always correlated with enhanced plant salt tolerance.	cholecystokinin C-terminal flanking peptide	134-137	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	42-46
31779918-1	2020	The first step in the Phosphorylated Pathway of serine (Ser) Biosynthesis (PPSB) is catalyzed by the enzyme Phosphoglycerate Dehydrogenase (PGDH), coded in Arabidopsis thaliana by three genes.	cholecystokinin C-terminal flanking peptide	48-54	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	140-144
31779918-1	2020	The first step in the Phosphorylated Pathway of serine (Ser) Biosynthesis (PPSB) is catalyzed by the enzyme Phosphoglycerate Dehydrogenase (PGDH), coded in Arabidopsis thaliana by three genes.	cholecystokinin C-terminal flanking peptide	56-59	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	108-138
31779918-1	2020	The first step in the Phosphorylated Pathway of serine (Ser) Biosynthesis (PPSB) is catalyzed by the enzyme Phosphoglycerate Dehydrogenase (PGDH), coded in Arabidopsis thaliana by three genes.	cholecystokinin C-terminal flanking peptide	56-59	D-3-phosphoglycerate dehydrogenase	Arabidopsis thaliana	140-144
31805502-8	2020	Overall, our data reveal AMPK-triggered phosphorylation of Nrf2 at three serine residues, apparently determining the extent of transactivation of selected target genes.	cholecystokinin C-terminal flanking peptide	73-79	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	25-29
31805502-8	2020	Overall, our data reveal AMPK-triggered phosphorylation of Nrf2 at three serine residues, apparently determining the extent of transactivation of selected target genes.	cholecystokinin C-terminal flanking peptide	73-79	NFE2 like bZIP transcription factor 2	Homo sapiens	59-63
31805502-3	2020	Here, MS-based analysis of immunoprecipitated Nrf2 revealed serine 374, 408 and 433 in human Nrf2 to be hyperphosphorylated as a function of activated AMPK.	cholecystokinin C-terminal flanking peptide	60-66	NFE2 like bZIP transcription factor 2	Homo sapiens	46-50
31892216-1	2019	Humans with dilated cardiomyopathy (DCM) and heart failure (HF) develop low levels of corin, a multi-domain, cardiac-selective serine protease involved in natriuretic peptide cleavage and sodium and water regulation.	cholecystokinin C-terminal flanking peptide	127-133	corin, serine peptidase	Mus musculus	86-91
31805502-3	2020	Here, MS-based analysis of immunoprecipitated Nrf2 revealed serine 374, 408 and 433 in human Nrf2 to be hyperphosphorylated as a function of activated AMPK.	cholecystokinin C-terminal flanking peptide	60-66	NFE2 like bZIP transcription factor 2	Homo sapiens	93-97
31805502-3	2020	Here, MS-based analysis of immunoprecipitated Nrf2 revealed serine 374, 408 and 433 in human Nrf2 to be hyperphosphorylated as a function of activated AMPK.	cholecystokinin C-terminal flanking peptide	60-66	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	151-155
31903146-9	2020	At molecular level, BCL6 inhibited forkhead box O3 (FOXO3) transcription, subsequent translation and upregulation of phosphorylated/inactive FOXO3 through phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and/or epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase 1/2 (MAP2K1/2) signaling pathway(s).	cholecystokinin C-terminal flanking peptide	192-198	BCL6 transcription repressor	Homo sapiens	20-24
31893043-8	2019	The serine biosynthesis pathway partially contributed to pyruvate production during PKM1/2 knockdown: knockout of phosphoglycerate dehydrogenase in this pathway decreased pyruvate production from glucose.	cholecystokinin C-terminal flanking peptide	4-10	pyruvate kinase, muscle	Mus musculus	84-90
31647304-1	2019	In 2011 Fujita and coworkers proposed that beta-adrenergic stimulation causes decreased serine/threonine-protein kinase WNK4 transcription leading to the activation of Na-Cl cotransporter (NCC) which participates in salt sensitivity and salt hypertension development in rodents.	cholecystokinin C-terminal flanking peptide	88-94	WNK lysine deficient protein kinase 4	Rattus norvegicus	120-124
31723029-5	2019	We further observed that DYRK1A directly interacted with IRS-1 and phosphorylated IRS-1"s multiple serine residues.	cholecystokinin C-terminal flanking peptide	99-105	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	25-31
31723029-5	2019	We further observed that DYRK1A directly interacted with IRS-1 and phosphorylated IRS-1"s multiple serine residues.	cholecystokinin C-terminal flanking peptide	99-105	insulin receptor substrate 1	Homo sapiens	82-87
31873123-1	2019	The mitotic serine/threonine kinase aurora kinase-A (AURKA) has been identified as carcinogenic in hepatocellular carcinoma (HCC).	cholecystokinin C-terminal flanking peptide	12-18	aurora kinase A	Homo sapiens	53-58
31863073-7	2019	Collectively, our data unveil a novel role of the serine protease CAP2/Tmprss4 and GR on renal water handling upon dietary K+ depletion.	cholecystokinin C-terminal flanking peptide	50-56	CAP, adenylate cyclase-associated protein, 2 (yeast)	Mus musculus	66-70
31863073-7	2019	Collectively, our data unveil a novel role of the serine protease CAP2/Tmprss4 and GR on renal water handling upon dietary K+ depletion.	cholecystokinin C-terminal flanking peptide	50-56	transmembrane protease, serine 4	Mus musculus	71-78
31856878-6	2019	RESULTS: When significant mitochondrial depolarisations occurred due to glutamate-evoked massive influxes of Ca2+ into the cells, insulin induced 48% less activation of the IR (assessed by IR tyrosine phosphorylation, pY1150/1151), 72% less activation of Akt (assessed by Akt serine phosphorylation, pS473), 44% less activation of mTOR (assessed by mTOR pS2448), and 38% less inhibition of glycogen synthase kinase beta (GSK3beta) (assessed by GSK3beta pS9) compared with respective controls.	cholecystokinin C-terminal flanking peptide	276-282	insulin	Homo sapiens	130-137
31856878-6	2019	RESULTS: When significant mitochondrial depolarisations occurred due to glutamate-evoked massive influxes of Ca2+ into the cells, insulin induced 48% less activation of the IR (assessed by IR tyrosine phosphorylation, pY1150/1151), 72% less activation of Akt (assessed by Akt serine phosphorylation, pS473), 44% less activation of mTOR (assessed by mTOR pS2448), and 38% less inhibition of glycogen synthase kinase beta (GSK3beta) (assessed by GSK3beta pS9) compared with respective controls.	cholecystokinin C-terminal flanking peptide	276-282	insulin receptor	Rattus norvegicus	173-175
31861435-1	2019	Maspin is a member of the clade B serine protease inhibitor superfamily and exhibits diverse regulatory effects in various types of solid tumors.	cholecystokinin C-terminal flanking peptide	34-40	serpin family B member 5	Homo sapiens	0-6
31921198-1	2019	The mammalian target of rapamycin (mTOR) is an evolutionarily highly conserved atypical serine/threonine protein kinase, which regulates cell growth, proliferation, apoptosis, autophagy, and metabolism.	cholecystokinin C-terminal flanking peptide	88-94	mechanistic target of rapamycin kinase	Homo sapiens	4-33
31863073-0	2019	Deletion of the serine protease CAP2/Tmprss4 leads to dysregulated renal water handling upon dietary potassium depletion.	cholecystokinin C-terminal flanking peptide	16-22	CAP, adenylate cyclase-associated protein, 2 (yeast)	Mus musculus	32-36
31863073-0	2019	Deletion of the serine protease CAP2/Tmprss4 leads to dysregulated renal water handling upon dietary potassium depletion.	cholecystokinin C-terminal flanking peptide	16-22	transmembrane protease, serine 4	Mus musculus	37-44
31863073-2	2019	In this study, we demonstrate that following a K+-deficient diet in wildtype mice, the serine protease CAP2/Tmprss4 is upregulated in connecting tubule and cortical collecting duct and also localizes to the medulla and transitional epithelium of the papilla and minor calyx.	cholecystokinin C-terminal flanking peptide	87-93	CAP, adenylate cyclase-associated protein, 2 (yeast)	Mus musculus	103-107
31863073-2	2019	In this study, we demonstrate that following a K+-deficient diet in wildtype mice, the serine protease CAP2/Tmprss4 is upregulated in connecting tubule and cortical collecting duct and also localizes to the medulla and transitional epithelium of the papilla and minor calyx.	cholecystokinin C-terminal flanking peptide	87-93	transmembrane protease, serine 4	Mus musculus	108-115
31921198-1	2019	The mammalian target of rapamycin (mTOR) is an evolutionarily highly conserved atypical serine/threonine protein kinase, which regulates cell growth, proliferation, apoptosis, autophagy, and metabolism.	cholecystokinin C-terminal flanking peptide	88-94	mechanistic target of rapamycin kinase	Homo sapiens	35-39
31889992-1	2019	Background: Human carboxylesterases (hCES) are key serine hydrolases responsible for the hydrolysis of a wide range of endogenous and xenobiotic esters.	cholecystokinin C-terminal flanking peptide	51-57	cat eye syndrome chromosome region	Homo sapiens	37-41
31765881-5	2020	We also identified nine protease serine 1 (PRSS1) and three protease serine 2 (PRSS2) genes, which were interspersed within the chicken TCRbeta locus.	cholecystokinin C-terminal flanking peptide	33-39	T-cell receptor beta	Gallus gallus	136-143
31765881-5	2020	We also identified nine protease serine 1 (PRSS1) and three protease serine 2 (PRSS2) genes, which were interspersed within the chicken TCRbeta locus.	cholecystokinin C-terminal flanking peptide	69-75	protease, serine 1	Gallus gallus	79-84
31765881-5	2020	We also identified nine protease serine 1 (PRSS1) and three protease serine 2 (PRSS2) genes, which were interspersed within the chicken TCRbeta locus.	cholecystokinin C-terminal flanking peptide	69-75	T-cell receptor beta	Gallus gallus	136-143
31840043-2	2019	PINK1 is a nuclear-encoded mitochondrial-targeted kinase that phosphorylates a conserved serine at amino acid 65 (pS65) in ubiquitin as well as Parkin, another gene with loss-of-function mutations linked to recessive parkinsonism.	cholecystokinin C-terminal flanking peptide	89-95	PTEN induced kinase 1	Rattus norvegicus	0-5
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin like modifier activating enzyme 7	Homo sapiens	185-216
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin like modifier activating enzyme 7	Homo sapiens	218-222
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin conjugating enzyme E2 D2	Homo sapiens	241-247
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin conjugating enzyme E2 G2	Homo sapiens	249-255
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin conjugating enzyme E2 J1	Homo sapiens	257-263
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	ubiquitin conjugating enzyme E2 E1	Homo sapiens	269-275
31578200-4	2019	RNAi screening using an oncogenic YAP activation model identified the serine/threonine kinase MK5 as a positive regulator of YAP.	cholecystokinin C-terminal flanking peptide	70-76	Yes1 associated transcriptional regulator	Homo sapiens	34-37
31578200-4	2019	RNAi screening using an oncogenic YAP activation model identified the serine/threonine kinase MK5 as a positive regulator of YAP.	cholecystokinin C-terminal flanking peptide	70-76	MAPK activated protein kinase 5	Homo sapiens	94-97
31578200-4	2019	RNAi screening using an oncogenic YAP activation model identified the serine/threonine kinase MK5 as a positive regulator of YAP.	cholecystokinin C-terminal flanking peptide	70-76	Yes1 associated transcriptional regulator	Homo sapiens	125-128
31847126-2	2019	The serine/threonine hydroxyl-linked N-Acetylglucosamine (O-GlcNAc) transferase (OGT) has been shown to drive pulmonary arterial smooth muscle cell (PASMC) proliferation in IPAH.	cholecystokinin C-terminal flanking peptide	4-10	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	58-66
31847126-2	2019	The serine/threonine hydroxyl-linked N-Acetylglucosamine (O-GlcNAc) transferase (OGT) has been shown to drive pulmonary arterial smooth muscle cell (PASMC) proliferation in IPAH.	cholecystokinin C-terminal flanking peptide	4-10	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	81-84
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	serine and arginine rich splicing factor 2	Homo sapiens	89-94
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	serine and arginine rich splicing factor 5	Homo sapiens	96-101
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	serine and arginine rich splicing factor 7	Homo sapiens	103-108
31841638-5	2019	These upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7, and SRSF8) that are associated with messenger RNA splicing and export, and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1, and UBE2E1) that are crucial for protein ubiquitination and protein processing in endoplasmic reticulum (ER), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	35-41	serine and arginine rich splicing factor 8	Homo sapiens	114-119
31679971-2	2019	These effects appear to arise, at least in part, through moderate inhibition of the urokinase-type plasminogen activator (uPA, Ki = 2.4 microM), a pro-metastatic trypsin-like serine protease that is upregulated in many aggressive solid malignancies.	cholecystokinin C-terminal flanking peptide	175-181	plasminogen activator, urokinase	Rattus norvegicus	84-120
31825975-0	2019	Characterization of testis-specific serine/threonine kinase 1-like (TSSK1-like) gene and expression patterns in diploid and triploid Pacific abalone (Haliotis discus hannai; Gastropoda; Mollusca) males.	cholecystokinin C-terminal flanking peptide	36-42	testis specific serine kinase 1A (pseudogene)	Homo sapiens	68-73
31825975-1	2019	Testis-specific serine/threonine kinase 1-like (TSSK1-like), which plays important roles in late-phase spermatogenesis and male fertility, was characterized in Pacific abalone Haliotis discus hannai, an important commercial marine gastropod.	cholecystokinin C-terminal flanking peptide	16-22	testis specific serine kinase 1A (pseudogene)	Homo sapiens	48-53
31832001-2	2019	LB100, a serine/threonine protein phosphatase 2A (PP2A) inhibitor, is closely related to IR.	cholecystokinin C-terminal flanking peptide	9-15	protein phosphatase 2 phosphatase activator	Homo sapiens	50-54
31822768-0	2019	Pannexin 3 ER Ca2+ channel gating is regulated by phosphorylation at the Serine 68 residue in osteoblast differentiation.	cholecystokinin C-terminal flanking peptide	73-79	pannexin 3	Mus musculus	0-10
31822768-4	2019	Here, we show that the Panx3 ER Ca2+ channel is modulated by phosphorylation of the serine 68 residue (Ser68) to promote osteoblast differentiation.	cholecystokinin C-terminal flanking peptide	84-90	pannexin 3	Mus musculus	23-28
31866864-5	2019	Intrathecal administration of the P450scc inhibitor, aminoglutethimide, during the induction phase of neuropathic pain (days 0 to 3 post-surgery) significantly suppressed the CCI-induced development of mechanical allodynia and thermal hyperalgesia, the increased expression of astrocyte Srr in both the total and cytosol levels, and the increases in D-serine immunoreactivity at day 3 post-surgery.	cholecystokinin C-terminal flanking peptide	350-358	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	34-41
31866864-8	2019	Collectively, these results demonstrate that spinal P450scc increases the expression of astrocyte Srr and D-serine production, ultimately contributing to the development of mechanical allodynia induced by peripheral nerve injury.	cholecystokinin C-terminal flanking peptide	106-114	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	52-59
31804482-3	2019	Aurora-A-mediated phosphorylation of LDHB serine 162 significantly increases its activity in reducing pyruvate to lactate, which efficiently promotes NAD+ regeneration, glycolytic flux, lactate production and bio-synthesis with glycolytic intermediates.	cholecystokinin C-terminal flanking peptide	42-48	aurora kinase A	Homo sapiens	0-8
31804482-3	2019	Aurora-A-mediated phosphorylation of LDHB serine 162 significantly increases its activity in reducing pyruvate to lactate, which efficiently promotes NAD+ regeneration, glycolytic flux, lactate production and bio-synthesis with glycolytic intermediates.	cholecystokinin C-terminal flanking peptide	42-48	lactate dehydrogenase B	Homo sapiens	37-41
31804482-4	2019	Mechanistically, LDHB serine 162 phosphorylation relieves its substrate inhibition effect by pyruvate, resulting in remarkable elevation in the conversions of pyruvate and NADH to lactate and NAD+.	cholecystokinin C-terminal flanking peptide	22-28	lactate dehydrogenase B	Homo sapiens	17-21
31594641-2	2019	Cyclin-dependent kinase 9 (CDK9), a serine-threonine kinase, is widely implicated in the control of basal gene expression by phosphorylating Serine 2 (Ser2) of the heptad repeat in the RNA Polymerase II (RNA Pol II) C-terminal domain (CTD).	cholecystokinin C-terminal flanking peptide	141-147	cyclin dependent kinase 9	Homo sapiens	0-25
31805132-9	2019	Fewer associations were observed after treatment with a PPARgamma agonist, and the most notable was increased plasma serine.	cholecystokinin C-terminal flanking peptide	117-123	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	56-65
31806759-6	2019	The signaling pathway linking 5-HT2AR activation and normalization of KCC2 function was dependent on protein kinase C signaling and phosphorylation of KCC2 at serine 940 (S940), as mutation of S940 to alanine prevented restoration of chloride transport function by TCB-2.	cholecystokinin C-terminal flanking peptide	159-165	solute carrier family 12 member 5	Homo sapiens	70-74
31806759-6	2019	The signaling pathway linking 5-HT2AR activation and normalization of KCC2 function was dependent on protein kinase C signaling and phosphorylation of KCC2 at serine 940 (S940), as mutation of S940 to alanine prevented restoration of chloride transport function by TCB-2.	cholecystokinin C-terminal flanking peptide	159-165	solute carrier family 12 member 5	Homo sapiens	151-155
31594641-2	2019	Cyclin-dependent kinase 9 (CDK9), a serine-threonine kinase, is widely implicated in the control of basal gene expression by phosphorylating Serine 2 (Ser2) of the heptad repeat in the RNA Polymerase II (RNA Pol II) C-terminal domain (CTD).	cholecystokinin C-terminal flanking peptide	141-147	cyclin dependent kinase 9	Homo sapiens	27-31
31594641-2	2019	Cyclin-dependent kinase 9 (CDK9), a serine-threonine kinase, is widely implicated in the control of basal gene expression by phosphorylating Serine 2 (Ser2) of the heptad repeat in the RNA Polymerase II (RNA Pol II) C-terminal domain (CTD).	cholecystokinin C-terminal flanking peptide	141-147	polymerase (RNA) II (DNA directed) polypeptide F	Mus musculus	204-214
31810373-2	2019	We previously found that Serine protease 3 (PRSS3), as an oncogene, is significantly upregulated in PC.	cholecystokinin C-terminal flanking peptide	25-31	serine protease 3	Homo sapiens	44-49
31796853-0	2019	Loss of the serine protease HTRA1 impairs smooth muscle cells maturation.	cholecystokinin C-terminal flanking peptide	12-18	HtrA serine peptidase 1	Mus musculus	28-33
31644963-3	2019	Microtubule-associated Serine/Threonine-protein kinase 3 (MAST3) has been documented to play a critical role in regulating the immune response of IBD (Inflammatory bowel disease) and involved in the process of cytoskeleton organization, intracellular signal transduction and peptidyl-serine phosphorylation, but its role in the progression of RA remains unknown and is warranted for investigation.	cholecystokinin C-terminal flanking peptide	284-290	microtubule associated serine/threonine kinase 3	Rattus norvegicus	0-56
31563279-5	2019	Upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7 and SRSF8), and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1 and UBE2E1), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	29-35	serine and arginine rich splicing factor 2	Homo sapiens	83-88
31563279-5	2019	Upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7 and SRSF8), and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1 and UBE2E1), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients.	cholecystokinin C-terminal flanking peptide	29-35	serine and arginine rich splicing factor 5	Homo sapiens	90-95
31569999-4	2019	A synthetic biology approach using a mutant GPCR and chimeric G-protein revealed that Galpha13-regulated phosphorylation of LATS1 at serine 909 within its activation loop induced recruitment of the itchy E3 ubiquitin protein ligase to trigger LATS1 degradation.	cholecystokinin C-terminal flanking peptide	133-139	G protein subunit alpha 13	Homo sapiens	86-94
31569999-4	2019	A synthetic biology approach using a mutant GPCR and chimeric G-protein revealed that Galpha13-regulated phosphorylation of LATS1 at serine 909 within its activation loop induced recruitment of the itchy E3 ubiquitin protein ligase to trigger LATS1 degradation.	cholecystokinin C-terminal flanking peptide	133-139	large tumor suppressor kinase 1	Homo sapiens	124-129
31569999-4	2019	A synthetic biology approach using a mutant GPCR and chimeric G-protein revealed that Galpha13-regulated phosphorylation of LATS1 at serine 909 within its activation loop induced recruitment of the itchy E3 ubiquitin protein ligase to trigger LATS1 degradation.	cholecystokinin C-terminal flanking peptide	133-139	large tumor suppressor kinase 1	Homo sapiens	243-248
31570002-0	2019	Serine-47 phosphorylation of cytochrome c in the mammalian brain regulates cytochrome c oxidase and caspase-3 activity.	cholecystokinin C-terminal flanking peptide	0-6	cytochrome c, somatic	Homo sapiens	29-41
31570002-0	2019	Serine-47 phosphorylation of cytochrome c in the mammalian brain regulates cytochrome c oxidase and caspase-3 activity.	cholecystokinin C-terminal flanking peptide	0-6	cytochrome c, somatic	Homo sapiens	75-87
31570002-0	2019	Serine-47 phosphorylation of cytochrome c in the mammalian brain regulates cytochrome c oxidase and caspase-3 activity.	cholecystokinin C-terminal flanking peptide	0-6	caspase 3	Homo sapiens	100-109
31644963-3	2019	Microtubule-associated Serine/Threonine-protein kinase 3 (MAST3) has been documented to play a critical role in regulating the immune response of IBD (Inflammatory bowel disease) and involved in the process of cytoskeleton organization, intracellular signal transduction and peptidyl-serine phosphorylation, but its role in the progression of RA remains unknown and is warranted for investigation.	cholecystokinin C-terminal flanking peptide	284-290	microtubule associated serine/threonine kinase 3	Rattus norvegicus	58-63
31850012-1	2019	GCN2 (general control nonrepressed 2) is a serine/threonine-protein kinase that regulates translation in response to stressors such as amino acid and purin deprivation, cold shock, wounding, cadmium, and UV-C exposure.	cholecystokinin C-terminal flanking peptide	43-49	protein kinase family protein	Arabidopsis thaliana	0-4
31568613-5	2019	Hyperphosphorylation of beta-catenin at a stabilizing residue, serine 552, mediated by activation of Akt, appears to lead to beta-catenin accumulation in NOD DC.	cholecystokinin C-terminal flanking peptide	63-69	catenin (cadherin associated protein), beta 1	Mus musculus	24-36
31568613-5	2019	Hyperphosphorylation of beta-catenin at a stabilizing residue, serine 552, mediated by activation of Akt, appears to lead to beta-catenin accumulation in NOD DC.	cholecystokinin C-terminal flanking peptide	63-69	thymoma viral proto-oncogene 1	Mus musculus	101-104
31568613-5	2019	Hyperphosphorylation of beta-catenin at a stabilizing residue, serine 552, mediated by activation of Akt, appears to lead to beta-catenin accumulation in NOD DC.	cholecystokinin C-terminal flanking peptide	63-69	catenin (cadherin associated protein), beta 1	Mus musculus	125-137
31644361-7	2019	Inhibition occurs when Cdr1 phosphorylates a cluster of serine residues linking alpha-helices G and H of the Wee1 kinase domain.	cholecystokinin C-terminal flanking peptide	56-62	cerebellar degeneration related protein 1	Homo sapiens	23-27
31644361-7	2019	Inhibition occurs when Cdr1 phosphorylates a cluster of serine residues linking alpha-helices G and H of the Wee1 kinase domain.	cholecystokinin C-terminal flanking peptide	56-62	WEE1 G2 checkpoint kinase	Homo sapiens	109-113
31645435-3	2019	Pah1 phosphorylation on multiple serine/threonine residues is complex and catalyzed by diverse protein kinases.	cholecystokinin C-terminal flanking peptide	33-39	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	0-4
31645435-5	2019	Phosphoamino acid analysis coupled with phosphopeptide mapping of the CKI-phosphorylated Pah1 indicated that it is phosphorylated mainly on multiple serine residues.	cholecystokinin C-terminal flanking peptide	149-155	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	89-93
31645435-6	2019	Using site-directed mutagenesis and phosphorylation analysis of Pah1, we identified eight serine residues (i.e., Ser-114, Ser-475, Ser-511, Ser-602, Ser-677, Ser-705, Ser-748, and Ser-774) as the target sites of CKI.	cholecystokinin C-terminal flanking peptide	90-96	phosphatidate phosphatase PAH1	Saccharomyces cerevisiae S288C	64-68
31551253-2	2019	M3814 is a novel, selective pharmacological inhibitor of the serine/threonine kinase DNA-dependent protein kinase (DNA-PK), a key driver of non-homologous end-joining, one of the main DSB repair pathways, currently under clinical investigation.	cholecystokinin C-terminal flanking peptide	61-67	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	85-113
31551253-2	2019	M3814 is a novel, selective pharmacological inhibitor of the serine/threonine kinase DNA-dependent protein kinase (DNA-PK), a key driver of non-homologous end-joining, one of the main DSB repair pathways, currently under clinical investigation.	cholecystokinin C-terminal flanking peptide	61-67	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	115-121
31850012-1	2019	GCN2 (general control nonrepressed 2) is a serine/threonine-protein kinase that regulates translation in response to stressors such as amino acid and purin deprivation, cold shock, wounding, cadmium, and UV-C exposure.	cholecystokinin C-terminal flanking peptide	43-49	protein kinase family protein	Arabidopsis thaliana	6-36
31617572-9	2019	However, the one kinase inferred to be activated in both mouse models was mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2), a serine/threonine kinase that functions downstream of p38 stress-activated mitogen-activated protein kinase.	cholecystokinin C-terminal flanking peptide	155-161	MAP kinase-activated protein kinase 2	Mus musculus	135-143
31819689-9	2019	Among the differentially expressed proteins, we identified that serine-protein kinase ataxia telangiectasia mutated (ATM) and its downstream target, cellular inhibitor of apoptosis protein 1 (c-IAP1), were up-regulated by E2.	cholecystokinin C-terminal flanking peptide	64-70	baculoviral IAP repeat containing 2	Homo sapiens	149-190
31819689-9	2019	Among the differentially expressed proteins, we identified that serine-protein kinase ataxia telangiectasia mutated (ATM) and its downstream target, cellular inhibitor of apoptosis protein 1 (c-IAP1), were up-regulated by E2.	cholecystokinin C-terminal flanking peptide	64-70	baculoviral IAP repeat containing 2	Homo sapiens	192-198
31725895-3	2019	Members of the PIM family of serine/threonine kinases promote cellular proliferation by regulating a variety of cellular processes, including protein synthesis and the balance of signaling that regulates apoptosis.	cholecystokinin C-terminal flanking peptide	29-35	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	15-18
31819689-9	2019	Among the differentially expressed proteins, we identified that serine-protein kinase ataxia telangiectasia mutated (ATM) and its downstream target, cellular inhibitor of apoptosis protein 1 (c-IAP1), were up-regulated by E2.	cholecystokinin C-terminal flanking peptide	64-70	ATM serine/threonine kinase	Homo sapiens	86-115
31819689-9	2019	Among the differentially expressed proteins, we identified that serine-protein kinase ataxia telangiectasia mutated (ATM) and its downstream target, cellular inhibitor of apoptosis protein 1 (c-IAP1), were up-regulated by E2.	cholecystokinin C-terminal flanking peptide	64-70	ATM serine/threonine kinase	Homo sapiens	117-120
31617572-9	2019	However, the one kinase inferred to be activated in both mouse models was mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2), a serine/threonine kinase that functions downstream of p38 stress-activated mitogen-activated protein kinase.	cholecystokinin C-terminal flanking peptide	155-161	MAP kinase-activated protein kinase 2	Mus musculus	147-150
31617572-9	2019	However, the one kinase inferred to be activated in both mouse models was mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2), a serine/threonine kinase that functions downstream of p38 stress-activated mitogen-activated protein kinase.	cholecystokinin C-terminal flanking peptide	155-161	mitogen-activated protein kinase 14	Mus musculus	208-211
31766490-9	2019	AST inhibited serine/threonine protein kinase B (Akt)/cAMP-responsive element-binding protein (CREB) signaling pathways in mitochondria, which led to the prevention of mPTP opening.	cholecystokinin C-terminal flanking peptide	14-20	AKT serine/threonine kinase 1	Rattus norvegicus	49-52
31824497-12	2019	In contrast, peptides deriving from microtubule-associated protein tau, presenilin 2 and serine/threonine-protein kinase TBK1 were exclusively reported to bind MHC molecules encoded by the HLA-DRB1 1501 allele, a recently-identified susceptibility gene for late onset Alzheimer"s disease.	cholecystokinin C-terminal flanking peptide	89-95	microtubule associated protein tau	Homo sapiens	36-70
31824497-12	2019	In contrast, peptides deriving from microtubule-associated protein tau, presenilin 2 and serine/threonine-protein kinase TBK1 were exclusively reported to bind MHC molecules encoded by the HLA-DRB1 1501 allele, a recently-identified susceptibility gene for late onset Alzheimer"s disease.	cholecystokinin C-terminal flanking peptide	89-95	TANK binding kinase 1	Homo sapiens	121-125
31824497-12	2019	In contrast, peptides deriving from microtubule-associated protein tau, presenilin 2 and serine/threonine-protein kinase TBK1 were exclusively reported to bind MHC molecules encoded by the HLA-DRB1 1501 allele, a recently-identified susceptibility gene for late onset Alzheimer"s disease.	cholecystokinin C-terminal flanking peptide	89-95	major histocompatibility complex, class II, DR beta 1	Homo sapiens	189-197
31766501-2	2019	Recent studies of an overall cohort of 381 patients have suggested that the genotype may be the main determinant of the development of OPG, with the risk being higher in patients harbouring NF1 mutations in the 5" tertile and the cysteine/serine-rich domain.	cholecystokinin C-terminal flanking peptide	239-245	basic transcription factor 3 pseudogene 11	Homo sapiens	135-138
31766490-9	2019	AST inhibited serine/threonine protein kinase B (Akt)/cAMP-responsive element-binding protein (CREB) signaling pathways in mitochondria, which led to the prevention of mPTP opening.	cholecystokinin C-terminal flanking peptide	14-20	cAMP responsive element binding protein 1	Rattus norvegicus	95-99
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	fms related receptor tyrosine kinase 3	Homo sapiens	74-78
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	ribosomal protein S6 kinase A1	Homo sapiens	136-142
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	mitogen-activated protein kinase kinase 7	Homo sapiens	169-172
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	EPH receptor B2	Homo sapiens	173-176
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	pyruvate dehydrogenase kinase 1	Homo sapiens	189-193
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	fms related receptor tyrosine kinase 3	Homo sapiens	228-232
31756944-3	2019	Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-dependent, but not BCR/ABL-dependent, proliferation and survival of various cells, including MV4-11.	cholecystokinin C-terminal flanking peptide	111-117	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	256-263
31652301-5	2019	This change in activity is governed by the ATM kinase via phosphorylation on serine 395 and is mimicked by the S395D phosphomimetic mutant.	cholecystokinin C-terminal flanking peptide	77-83	ATM serine/threonine kinase	Homo sapiens	43-46
31752390-5	2019	Our results revealed that vascular endothelial growth factor (VEGF), a critical activator of angiogenesis, upregulated the expression of CDK7 and RNAPII, and the phosphorylation of RNAPII at serine 5 and 7 in human umbilical vein endothelial cells (HUVECs), indicating the transcriptional activity of CDK7 may be involved in VEGF-activated angiogenic activity of endothelium.	cholecystokinin C-terminal flanking peptide	191-197	vascular endothelial growth factor A	Homo sapiens	26-60
31752390-5	2019	Our results revealed that vascular endothelial growth factor (VEGF), a critical activator of angiogenesis, upregulated the expression of CDK7 and RNAPII, and the phosphorylation of RNAPII at serine 5 and 7 in human umbilical vein endothelial cells (HUVECs), indicating the transcriptional activity of CDK7 may be involved in VEGF-activated angiogenic activity of endothelium.	cholecystokinin C-terminal flanking peptide	191-197	vascular endothelial growth factor A	Homo sapiens	62-66
31824851-3	2019	Polo-Like Kinase-1 (PLK1) is a serine/threonine kinase that phosphorylates a wide range of target substrates and alters their activity.	cholecystokinin C-terminal flanking peptide	31-37	polo like kinase 1	Homo sapiens	0-18
31824851-3	2019	Polo-Like Kinase-1 (PLK1) is a serine/threonine kinase that phosphorylates a wide range of target substrates and alters their activity.	cholecystokinin C-terminal flanking peptide	31-37	polo like kinase 1	Homo sapiens	20-24
31747582-4	2019	In contrast to in vitro-activated T cells, which display hallmarks of Warburg metabolism, physiologically activated CD8+ T cells displayed greater rates of oxidative metabolism, higher bioenergetic capacity, differential use of pyruvate, and prominent flow of 13C-glucose carbon to anabolic pathways, including nucleotide and serine biosynthesis.	cholecystokinin C-terminal flanking peptide	326-332	CD8a molecule	Homo sapiens	116-119
31747582-5	2019	Glucose-dependent serine biosynthesis mediated by the enzyme Phgdh was essential for CD8+ T cell expansion in vivo.	cholecystokinin C-terminal flanking peptide	18-24	phosphoglycerate dehydrogenase	Homo sapiens	61-66
31747582-5	2019	Glucose-dependent serine biosynthesis mediated by the enzyme Phgdh was essential for CD8+ T cell expansion in vivo.	cholecystokinin C-terminal flanking peptide	18-24	CD8a molecule	Homo sapiens	85-88
31738765-8	2019	While a missense leucine-to-serine variant at position 63 in the transcription factor Oaf1 (L63S) was almost exclusively present in the reference laboratory strain, the two other variants were frequent among S. cerevisiae isolates.	cholecystokinin C-terminal flanking peptide	28-34	oleate-activated transcription factor OAF1	Saccharomyces cerevisiae S288C	86-90
31738805-1	2019	P21-activated kinases (PAKs) are serine/threonine protein kinases that are subdivided into two groups on the basis of their domain architecture: group-I (PAK1-3) and group-II (PAK4-6).	cholecystokinin C-terminal flanking peptide	33-39	H3 histone pseudogene 16	Homo sapiens	0-3
31622584-1	2019	The Staphylococcus aureusExtracellular Adherence Protein (Eap) and its homologs, EapH1 and EapH2, are a family of secreted proteins that potently inhibit the neutrophil serine proteases Neutrophil Elastase (hNE), Cathepsin G, and Proteinase 3.	cholecystokinin C-terminal flanking peptide	169-175	elastase, neutrophil expressed	Homo sapiens	186-205
31622584-1	2019	The Staphylococcus aureusExtracellular Adherence Protein (Eap) and its homologs, EapH1 and EapH2, are a family of secreted proteins that potently inhibit the neutrophil serine proteases Neutrophil Elastase (hNE), Cathepsin G, and Proteinase 3.	cholecystokinin C-terminal flanking peptide	169-175	elastase, neutrophil expressed	Homo sapiens	207-210
31622584-4	2019	A phenylalanine in EapH2 replaces the leucine in EapH1 that sits over the hNE catalytic serine and creates a potential steric clash.	cholecystokinin C-terminal flanking peptide	88-94	elastase, neutrophil expressed	Homo sapiens	74-77
31803740-2	2019	Here, we identify that the canonical Wnt is presumably acylated by palmitic acid, a saturated 16-carbon fatty acid, at a conserved serine residue.	cholecystokinin C-terminal flanking peptide	131-137	wingless-type MMTV integration site family, member 3	Danio rerio	37-40
31803133-2	2019	Serpina3k, a serine protease inhibitor, has been shown to inhibit apoptosis in injury models.	cholecystokinin C-terminal flanking peptide	13-19	serine (or cysteine) peptidase inhibitor, clade A, member 3K	Mus musculus	0-9
31729420-1	2019	Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that mediates phosphoinositide-3-kinase (PI3K)/AKT signalling.	cholecystokinin C-terminal flanking peptide	44-50	mechanistic target of rapamycin kinase	Mus musculus	0-31
31729420-1	2019	Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that mediates phosphoinositide-3-kinase (PI3K)/AKT signalling.	cholecystokinin C-terminal flanking peptide	44-50	mechanistic target of rapamycin kinase	Mus musculus	33-37
31562136-4	2019	In the present study we demonstrate that the lymphangiogenic factors VEGFC and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing.	cholecystokinin C-terminal flanking peptide	122-128	vascular endothelial growth factor C	Mus musculus	69-74
31729420-1	2019	Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that mediates phosphoinositide-3-kinase (PI3K)/AKT signalling.	cholecystokinin C-terminal flanking peptide	44-50	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	90-115
31562136-4	2019	In the present study we demonstrate that the lymphangiogenic factors VEGFC and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing.	cholecystokinin C-terminal flanking peptide	122-128	vascular endothelial growth factor D	Mus musculus	79-84
31729420-1	2019	Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that mediates phosphoinositide-3-kinase (PI3K)/AKT signalling.	cholecystokinin C-terminal flanking peptide	44-50	thymoma viral proto-oncogene 1	Mus musculus	123-126
31562136-4	2019	In the present study we demonstrate that the lymphangiogenic factors VEGFC and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing.	cholecystokinin C-terminal flanking peptide	122-128	coagulation factor II	Mus musculus	100-108
31729431-3	2019	Here we show that autophagy is crucial for this unconventional secretion pathway and that phosphorylation at serine 59 residue regulates CRYAB secretion by inhibiting its recruitment to the autophagosomes.	cholecystokinin C-terminal flanking peptide	109-115	crystallin alpha B	Homo sapiens	137-142
31723224-1	2019	A non-synonymous single nucleotide polymorphism of the human serotonin 5-HT2C receptor (5-HT2CR) gene that converts a cysteine to a serine at amino acid codon 23 (Cys23Ser) appears to impact 5-HT2CR pharmacology at a cellular and systems level.	cholecystokinin C-terminal flanking peptide	132-138	5-hydroxytryptamine receptor 2C	Homo sapiens	61-86
31915535-2	2019	The initial step of LCB biosynthesis stems from serine:palmitoyl-CoA transferase enzyme, producing 3-ketodihydrosphingosine with multiple regulatory proteins including small subunit SPT a/b and orosomucoid-like protein1-3.	cholecystokinin C-terminal flanking peptide	48-54	clathrin light chain B	Homo sapiens	20-23
31548312-0	2019	Serine 474 phosphorylation is essential for maximal Akt2 kinase activity in adipocytes.	cholecystokinin C-terminal flanking peptide	0-6	AKT serine/threonine kinase 2	Homo sapiens	52-56
31722221-5	2019	Our time-resolved phosphoproteome resource reveals how Cdc14 instructs the sequential pattern of phosphorylation changes, in part through preferential recognition of serine-based cyclin-dependent kinase (Cdk) substrates.	cholecystokinin C-terminal flanking peptide	166-172	phosphoprotein phosphatase CDC14	Saccharomyces cerevisiae S288C	55-60
31723194-0	2019	Serum D-serine accumulation after proximal renal tubular damage involves neutral amino acid transporter Asc-1.	cholecystokinin C-terminal flanking peptide	6-14	anterior suture cataract 1	Mus musculus	104-109
31723194-7	2019	Screening transcriptions of neutral amino acid transporters revealed that Asc-1, found in renal tubules and collecting ducts, was significantly increased after cisplatin-treatment, which correlates with serum D-serine increase.	cholecystokinin C-terminal flanking peptide	209-217	anterior suture cataract 1	Mus musculus	74-79
31723194-8	2019	In vitro study using a kidney cell line showed that Asc-1 is induced by cisplatin and mediated influx of D-serine preferably to L-serine.	cholecystokinin C-terminal flanking peptide	105-113	anterior suture cataract 1	Mus musculus	52-57
31723194-8	2019	In vitro study using a kidney cell line showed that Asc-1 is induced by cisplatin and mediated influx of D-serine preferably to L-serine.	cholecystokinin C-terminal flanking peptide	128-136	anterior suture cataract 1	Mus musculus	52-57
31726756-5	2019	The delivery of siRNAs targeting the anti-apoptotic oncogene survivin or the serine/threonine-protein kinase PLK1 (polo-like kinase 1; PLK-1) oncogene reveals strong inhibitory effects in vitro.	cholecystokinin C-terminal flanking peptide	77-83	polo like kinase 1	Mus musculus	109-113
31726756-5	2019	The delivery of siRNAs targeting the anti-apoptotic oncogene survivin or the serine/threonine-protein kinase PLK1 (polo-like kinase 1; PLK-1) oncogene reveals strong inhibitory effects in vitro.	cholecystokinin C-terminal flanking peptide	77-83	polo like kinase 1	Mus musculus	115-133
31726756-5	2019	The delivery of siRNAs targeting the anti-apoptotic oncogene survivin or the serine/threonine-protein kinase PLK1 (polo-like kinase 1; PLK-1) oncogene reveals strong inhibitory effects in vitro.	cholecystokinin C-terminal flanking peptide	77-83	polo like kinase 1	Mus musculus	135-140
31717402-2	2019	Mitogen-Activated Protein (MAP) kinase is a notoriously oncogenic signaling pathway in human malignancies, where the extracellular signal-regulated kinases (ERK1/2) are focal serine/threonine kinases in the MAP kinase module with numerous cytosolic and nuclear mitogenic effector proteins.	cholecystokinin C-terminal flanking peptide	175-181	mitogen-activated protein kinase 3	Homo sapiens	157-163
31704997-2	2019	These serine proteases specifically cleave desmoglein 1 (Dsg1) in mammals and are key elements in staphylococcal skin infections.	cholecystokinin C-terminal flanking peptide	6-12	desmoglein 1 alpha	Mus musculus	43-55
31704997-2	2019	These serine proteases specifically cleave desmoglein 1 (Dsg1) in mammals and are key elements in staphylococcal skin infections.	cholecystokinin C-terminal flanking peptide	6-12	desmoglein 1 alpha	Mus musculus	57-61
31799256-1	2019	The peroxisomal enzyme human D-amino acid oxidase (hDAAO) is attracting attention owing to its role in degrading D-serine, the main co-agonist of N-methyl D-aspartate receptors in brain, and its involvement in brain functions and diseases.	cholecystokinin C-terminal flanking peptide	113-121	D-amino acid oxidase	Homo sapiens	29-49
31799256-1	2019	The peroxisomal enzyme human D-amino acid oxidase (hDAAO) is attracting attention owing to its role in degrading D-serine, the main co-agonist of N-methyl D-aspartate receptors in brain, and its involvement in brain functions and diseases.	cholecystokinin C-terminal flanking peptide	113-121	D-amino acid oxidase	Homo sapiens	51-56
31718065-6	2019	MDS identified stable H-bonds between residues S152, S203, S205, Q230/R703, and UPF2/AMPPNP, and suggest that phosphorylation of Serine residues may control UPF1-UPF2 binding.	cholecystokinin C-terminal flanking peptide	129-135	UPF2 regulator of nonsense mediated mRNA decay	Homo sapiens	80-84
31718065-6	2019	MDS identified stable H-bonds between residues S152, S203, S205, Q230/R703, and UPF2/AMPPNP, and suggest that phosphorylation of Serine residues may control UPF1-UPF2 binding.	cholecystokinin C-terminal flanking peptide	129-135	UPF1 RNA helicase and ATPase	Homo sapiens	157-161
31718065-6	2019	MDS identified stable H-bonds between residues S152, S203, S205, Q230/R703, and UPF2/AMPPNP, and suggest that phosphorylation of Serine residues may control UPF1-UPF2 binding.	cholecystokinin C-terminal flanking peptide	129-135	UPF2 regulator of nonsense mediated mRNA decay	Homo sapiens	162-166
31687929-6	2019	CDK5 phosphorylated PER2 at serine residue 394 (S394) in a diurnal fashion.	cholecystokinin C-terminal flanking peptide	28-34	cyclin dependent kinase 5	Homo sapiens	0-4
31558619-7	2019	We further revealed that CaMKII-dependent phosphorylation of the scaffolding protein gephyrin at serine 325 promoted the synaptic accumulation of GlyR on Mauthner neurons through the enhancement of the gephyrin-GlyR binding, which was indispensable for and could induce desensitization of the ASR.	cholecystokinin C-terminal flanking peptide	97-103	gephyrin a	Danio rerio	85-93
31558619-7	2019	We further revealed that CaMKII-dependent phosphorylation of the scaffolding protein gephyrin at serine 325 promoted the synaptic accumulation of GlyR on Mauthner neurons through the enhancement of the gephyrin-GlyR binding, which was indispensable for and could induce desensitization of the ASR.	cholecystokinin C-terminal flanking peptide	97-103	gephyrin a	Danio rerio	202-210
31699096-10	2019	Increased inflammatory cytokine expression resulted in serine phosphorylation of IRS1, which induced insulin resistance (IR).	cholecystokinin C-terminal flanking peptide	55-61	insulin receptor substrate 1	Mus musculus	81-85
31699096-11	2019	Furthermore these inflammatory cytokines activated the MAPK pathway, which further promoted the serine phosphorylation of IRS1.	cholecystokinin C-terminal flanking peptide	96-102	insulin receptor substrate 1	Mus musculus	122-126
31687929-6	2019	CDK5 phosphorylated PER2 at serine residue 394 (S394) in a diurnal fashion.	cholecystokinin C-terminal flanking peptide	28-34	period circadian regulator 2	Homo sapiens	20-24
31693898-4	2019	While mutating specific serines on hnRNP M had little effect on its ability to control pre-mRNA splicing or transcript levels of housekeeping genes in resting macrophages, it greatly impacted the protein"s ability to dampen induction of specific innate immune transcripts following pathogen sensing.	cholecystokinin C-terminal flanking peptide	24-31	heterogeneous nuclear ribonucleoprotein M	Homo sapiens	35-42
31594806-3	2019	We show that yeast cells lacking seipin displayed altered sensitivity to sphingolipid inhibitors, accumulated sphingoid precursors and intermediates, and increased serine palmitoyltransferase (SPT) and fatty acid (FA) elongase activities.	cholecystokinin C-terminal flanking peptide	164-170	seipin	Saccharomyces cerevisiae S288C	33-39
31742248-3	2019	ABHD5 acts in vivo and in vitro as a serine protease cleaving HDAC4.	cholecystokinin C-terminal flanking peptide	37-43	abhydrolase domain containing 5	Mus musculus	0-5
31566433-3	2019	It has also been reported that both O-GlcNAcylation and phosphorylation occur on serine199 of beta-actin.	cholecystokinin C-terminal flanking peptide	81-87	actin, beta	Rattus norvegicus	94-104
31695192-0	2019	Author Correction: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.	cholecystokinin C-terminal flanking peptide	35-41	serine/threonine kinase 11	Homo sapiens	19-23
31614149-10	2019	Last, NFIA induced phosphorylation of NF-kB p65 at serine 536, thus inducing TMZ resistance in GBM cells.	cholecystokinin C-terminal flanking peptide	51-57	nuclear factor I A	Homo sapiens	6-10
31614149-10	2019	Last, NFIA induced phosphorylation of NF-kB p65 at serine 536, thus inducing TMZ resistance in GBM cells.	cholecystokinin C-terminal flanking peptide	51-57	RELA proto-oncogene, NF-kB subunit	Homo sapiens	44-47
31742248-3	2019	ABHD5 acts in vivo and in vitro as a serine protease cleaving HDAC4.	cholecystokinin C-terminal flanking peptide	37-43	histone deacetylase 4	Mus musculus	62-67
31611952-8	2019	A PPI network, composed of 44 nodes and 886 edges, was constructed, and its significant module had 16 hub genes in the whole network: Opa interacting protein 5, exonuclease 1, PCNA clamp-associated factor, checkpoint kinase 1, hyaluronan-mediated motility receptor, maternal embryonic leucine zipper kinase, non-SMC condensin I complex subunit G, centromere protein F, BUB1 mitotic checkpoint serine/threonine kinase, cyclin A2, thyroid hormone receptor interactor 13, TPX2 microtubule nucleation factor, nucleolar and spindle associated protein 1, kinesin family member 20A, aurora kinase A and centrosomal protein 55.	cholecystokinin C-terminal flanking peptide	393-399	Opa interacting protein 5	Homo sapiens	134-159
31672640-10	2019	The reduction of the gephyrin puncta density was independent of the entire extracellular part of TM-agrin but required a highly conserved serine residue in the intracellular domain of TM-agrin.	cholecystokinin C-terminal flanking peptide	138-144	agrin	Homo sapiens	187-192
31683713-1	2019	The serine protease high-temperature-required protein A2 (HtrA2) has been identified as a key intracellular molecule promoting apoptosis in cells during ischemia reperfusion (IR) injury.	cholecystokinin C-terminal flanking peptide	4-10	HtrA serine peptidase 2	Homo sapiens	58-63
31548268-0	2019	Structural modeling and role of HAX-1 as a positive allosteric modulator of human serine protease HtrA2.	cholecystokinin C-terminal flanking peptide	82-88	HCLS1 associated protein X-1	Homo sapiens	32-37
31548268-0	2019	Structural modeling and role of HAX-1 as a positive allosteric modulator of human serine protease HtrA2.	cholecystokinin C-terminal flanking peptide	82-88	HtrA serine peptidase 2	Homo sapiens	98-103
31655619-19	2019	Consistent with this hypothesis, artemisinin increased the phosphorylation of Erk1/2 upstream kinases proto-oncogene c-RAF serine/threonine-protein kinase (c-Raf) and of Erk1/2 downstream targets p90 ribosomal s6 kinase (p90rsk) and cAMP response element binding protein (CREB).	cholecystokinin C-terminal flanking peptide	123-129	mitogen activated protein kinase 3	Rattus norvegicus	78-84
31655619-19	2019	Consistent with this hypothesis, artemisinin increased the phosphorylation of Erk1/2 upstream kinases proto-oncogene c-RAF serine/threonine-protein kinase (c-Raf) and of Erk1/2 downstream targets p90 ribosomal s6 kinase (p90rsk) and cAMP response element binding protein (CREB).	cholecystokinin C-terminal flanking peptide	123-129	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	117-122
31652779-8	2019	In MDA-MB-231 cells, we found that AC8 overexpression reduces the Orai1 phosphoserine content, thus suggesting that AC8 interferes with Orai1 serine phosphorylation, which takes place at residues located in the AC8-binding site.	cholecystokinin C-terminal flanking peptide	79-85	adenylate cyclase 8	Homo sapiens	35-38
31652779-8	2019	In MDA-MB-231 cells, we found that AC8 overexpression reduces the Orai1 phosphoserine content, thus suggesting that AC8 interferes with Orai1 serine phosphorylation, which takes place at residues located in the AC8-binding site.	cholecystokinin C-terminal flanking peptide	79-85	ORAI calcium release-activated calcium modulator 1	Homo sapiens	66-71
31652779-8	2019	In MDA-MB-231 cells, we found that AC8 overexpression reduces the Orai1 phosphoserine content, thus suggesting that AC8 interferes with Orai1 serine phosphorylation, which takes place at residues located in the AC8-binding site.	cholecystokinin C-terminal flanking peptide	79-85	adenylate cyclase 8	Homo sapiens	116-119
31652779-8	2019	In MDA-MB-231 cells, we found that AC8 overexpression reduces the Orai1 phosphoserine content, thus suggesting that AC8 interferes with Orai1 serine phosphorylation, which takes place at residues located in the AC8-binding site.	cholecystokinin C-terminal flanking peptide	79-85	ORAI calcium release-activated calcium modulator 1	Homo sapiens	136-141
31652779-8	2019	In MDA-MB-231 cells, we found that AC8 overexpression reduces the Orai1 phosphoserine content, thus suggesting that AC8 interferes with Orai1 serine phosphorylation, which takes place at residues located in the AC8-binding site.	cholecystokinin C-terminal flanking peptide	79-85	adenylate cyclase 8	Homo sapiens	116-119
31709262-1	2019	The human SLC1A5 commonly known as ASCT2 is a sodium-dependent neutral amino acid antiporter involved in transmembrane traffic of glutamine that is exchanged through the cell membrane with smaller amino acids such as serine or threonine.	cholecystokinin C-terminal flanking peptide	217-223	solute carrier family 1 member 5	Homo sapiens	10-16
31709262-1	2019	The human SLC1A5 commonly known as ASCT2 is a sodium-dependent neutral amino acid antiporter involved in transmembrane traffic of glutamine that is exchanged through the cell membrane with smaller amino acids such as serine or threonine.	cholecystokinin C-terminal flanking peptide	217-223	solute carrier family 1 member 5	Homo sapiens	35-40
31737186-7	2019	LINC00460 increased the expression of serine/threonine kinase AKT2 via sponging miR-612.	cholecystokinin C-terminal flanking peptide	38-44	long intergenic non-protein coding RNA 460	Homo sapiens	0-9
31737186-7	2019	LINC00460 increased the expression of serine/threonine kinase AKT2 via sponging miR-612.	cholecystokinin C-terminal flanking peptide	38-44	AKT serine/threonine kinase 2	Homo sapiens	62-66
31737186-7	2019	LINC00460 increased the expression of serine/threonine kinase AKT2 via sponging miR-612.	cholecystokinin C-terminal flanking peptide	38-44	microRNA 612	Homo sapiens	80-87
31578252-8	2019	We show that, by replacing Cys181 of recombinant AtMAPK4 by a redox-insensitive serine residue, the kinase activity decreased, indicating the importance of this noncatalytic cysteine for the kinase mechanism.	cholecystokinin C-terminal flanking peptide	80-86	MAP kinase 4	Arabidopsis thaliana	49-56
31614447-4	2019	Ceramide elevation by serine palmitoyltransferse (SPT) activation was the primary source of the sphingosine elevation as myriocin, an inhibitor of SPT, prevented sphingosine elevation and protected oligodendrocytes.	cholecystokinin C-terminal flanking peptide	22-28	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	50-53
31681359-8	2019	Residues Tyr35" and Arg36", entering the active site from the other subunits in the dimer, mediate interactions between AGT and l-serine when used as a substrate.	cholecystokinin C-terminal flanking peptide	128-136	alanine:glyoxylate aminotransferase	Arabidopsis thaliana	120-123
31681359-9	2019	In comparison, AGT1 from humans and AGT1 from Anabaena lack these two residues and instead position a tyrosine ring into the binding site, which accounts for their preference for l-alanine instead of l-serine.	cholecystokinin C-terminal flanking peptide	200-208	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	15-19
31681359-9	2019	In comparison, AGT1 from humans and AGT1 from Anabaena lack these two residues and instead position a tyrosine ring into the binding site, which accounts for their preference for l-alanine instead of l-serine.	cholecystokinin C-terminal flanking peptide	200-208	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	36-40
31832571-2	2019	Transcriptional activity is dependent on serine phosphorylation of IRF3, while transcription-independent IRF3-mediated apoptosis requires ubiquitination.	cholecystokinin C-terminal flanking peptide	41-47	interferon regulatory factor 3	Mus musculus	67-71
31649622-1	2019	Mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase of the phosphatidylinositol kinase-related kinase family that regulates cell growth, metabolism, and autophagy.	cholecystokinin C-terminal flanking peptide	52-58	mechanistic target of rapamycin kinase	Homo sapiens	0-29
31649622-1	2019	Mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase of the phosphatidylinositol kinase-related kinase family that regulates cell growth, metabolism, and autophagy.	cholecystokinin C-terminal flanking peptide	52-58	mechanistic target of rapamycin kinase	Homo sapiens	31-35
31548394-1	2019	The Pim and AKT serine/threonine protein kinases are implicated as drivers of cancer.	cholecystokinin C-terminal flanking peptide	16-22	AKT serine/threonine kinase 1	Homo sapiens	12-15
31548413-0	2019	The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle.	cholecystokinin C-terminal flanking peptide	32-40	3-phosphoglycerate dehydrogenase	Mus musculus	84-89
31548413-0	2019	The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle.	cholecystokinin C-terminal flanking peptide	34-40	3-phosphoglycerate dehydrogenase	Mus musculus	84-89
31548413-1	2019	Astrocytes express the 3-phosphoglycerate dehydrogenase (Phgdh) enzyme required for the synthesis of l-serine from glucose.	cholecystokinin C-terminal flanking peptide	101-109	3-phosphoglycerate dehydrogenase	Mus musculus	23-55
31548413-1	2019	Astrocytes express the 3-phosphoglycerate dehydrogenase (Phgdh) enzyme required for the synthesis of l-serine from glucose.	cholecystokinin C-terminal flanking peptide	101-109	3-phosphoglycerate dehydrogenase	Mus musculus	57-62
31548413-2	2019	Astrocytic l-serine was proposed to regulate NMDAR activity by shuttling to neurons to sustain d-serine production, but this hypothesis remains untested.	cholecystokinin C-terminal flanking peptide	11-19	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	45-50
31673674-3	2019	Genetic testing has revealed the presence of genetic mutations (c.A479G, p.N160S) of ACE, which causes the 160th codon of the ACE protein to change from aspartic acid to serine, and at the same time genotype of apolipoprotein E (APOE) is e3/e4.	cholecystokinin C-terminal flanking peptide	170-176	angiotensin I converting enzyme	Homo sapiens	85-88
31673674-3	2019	Genetic testing has revealed the presence of genetic mutations (c.A479G, p.N160S) of ACE, which causes the 160th codon of the ACE protein to change from aspartic acid to serine, and at the same time genotype of apolipoprotein E (APOE) is e3/e4.	cholecystokinin C-terminal flanking peptide	170-176	angiotensin I converting enzyme	Homo sapiens	126-129
31673674-3	2019	Genetic testing has revealed the presence of genetic mutations (c.A479G, p.N160S) of ACE, which causes the 160th codon of the ACE protein to change from aspartic acid to serine, and at the same time genotype of apolipoprotein E (APOE) is e3/e4.	cholecystokinin C-terminal flanking peptide	170-176	apolipoprotein E	Homo sapiens	211-227
31673674-3	2019	Genetic testing has revealed the presence of genetic mutations (c.A479G, p.N160S) of ACE, which causes the 160th codon of the ACE protein to change from aspartic acid to serine, and at the same time genotype of apolipoprotein E (APOE) is e3/e4.	cholecystokinin C-terminal flanking peptide	170-176	apolipoprotein E	Homo sapiens	229-233
31594963-1	2019	p21-activated kinases (PAKs) are serine/threonine kinases functioning as downstream effectors of the small GTPases Rac1 and Cdc42.	cholecystokinin C-terminal flanking peptide	33-39	Rac family small GTPase 1	Homo sapiens	115-119
31594963-1	2019	p21-activated kinases (PAKs) are serine/threonine kinases functioning as downstream effectors of the small GTPases Rac1 and Cdc42.	cholecystokinin C-terminal flanking peptide	33-39	cell division cycle 42	Homo sapiens	124-129
31632276-8	2019	Phosphorylated NF-kappaB p65 at serine 276, a marker of NF-kappaB activation, was markedly induced by MWCNTs in the nucleus of fibroblastic cells.	cholecystokinin C-terminal flanking peptide	32-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	15-24
31632276-8	2019	Phosphorylated NF-kappaB p65 at serine 276, a marker of NF-kappaB activation, was markedly induced by MWCNTs in the nucleus of fibroblastic cells.	cholecystokinin C-terminal flanking peptide	32-38	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	25-28
31632276-8	2019	Phosphorylated NF-kappaB p65 at serine 276, a marker of NF-kappaB activation, was markedly induced by MWCNTs in the nucleus of fibroblastic cells.	cholecystokinin C-terminal flanking peptide	32-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-65
31612048-10	2019	Additionally, it was demonstrated that the tumor cells with higher levels of PD-L1 expression suppressed signaling pathways involved in T-cell activation, such as the T-cell receptor- zeta chain of T cell receptor associated protein kinase ZAP70-RAS-GTPase-extracellular-signal-regulated kinases and CD28-PI3K-Akt serine/threonine kinases pathways.	cholecystokinin C-terminal flanking peptide	314-320	CD274 molecule	Homo sapiens	77-82
31612048-10	2019	Additionally, it was demonstrated that the tumor cells with higher levels of PD-L1 expression suppressed signaling pathways involved in T-cell activation, such as the T-cell receptor- zeta chain of T cell receptor associated protein kinase ZAP70-RAS-GTPase-extracellular-signal-regulated kinases and CD28-PI3K-Akt serine/threonine kinases pathways.	cholecystokinin C-terminal flanking peptide	314-320	CD247 molecule	Homo sapiens	167-194
31612048-10	2019	Additionally, it was demonstrated that the tumor cells with higher levels of PD-L1 expression suppressed signaling pathways involved in T-cell activation, such as the T-cell receptor- zeta chain of T cell receptor associated protein kinase ZAP70-RAS-GTPase-extracellular-signal-regulated kinases and CD28-PI3K-Akt serine/threonine kinases pathways.	cholecystokinin C-terminal flanking peptide	314-320	zeta chain of T cell receptor associated protein kinase 70	Homo sapiens	240-245
31706823-1	2021	BACKGROUND/PURPOSE: SraP is a serine-rich repeat protein (SRRP) from Staphylococcus aureus that binds to sialylated receptors to promote bacterial adhesion to and invasion into host epithelial cells, mediated by the l-lectin module of its ligand-binding region.	cholecystokinin C-terminal flanking peptide	30-36	steroid receptor RNA activator 1	Mus musculus	20-24
31653237-3	2019	Clinical studies suggested that NMDAR modulators (glycine, D-serine, D-cycloserine and glycine transporter inhibitors) may be beneficial in treating schizophrenia patients.	cholecystokinin C-terminal flanking peptide	59-67	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	32-37
31709256-8	2019	Accordingly, we demonstrated that NLRP2 interacts with IKKa and positively regulates the DNA-binding activity of p50 and p65 NF-kappaB, by modulating the p65 NF-kappaB phosphorylation status in Serine 536.	cholecystokinin C-terminal flanking peptide	194-200	NLR family pyrin domain containing 2	Homo sapiens	34-39
31709256-8	2019	Accordingly, we demonstrated that NLRP2 interacts with IKKa and positively regulates the DNA-binding activity of p50 and p65 NF-kappaB, by modulating the p65 NF-kappaB phosphorylation status in Serine 536.	cholecystokinin C-terminal flanking peptide	194-200	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	55-59
31709256-8	2019	Accordingly, we demonstrated that NLRP2 interacts with IKKa and positively regulates the DNA-binding activity of p50 and p65 NF-kappaB, by modulating the p65 NF-kappaB phosphorylation status in Serine 536.	cholecystokinin C-terminal flanking peptide	194-200	nuclear factor kappa B subunit 1	Homo sapiens	113-116
31709256-8	2019	Accordingly, we demonstrated that NLRP2 interacts with IKKa and positively regulates the DNA-binding activity of p50 and p65 NF-kappaB, by modulating the p65 NF-kappaB phosphorylation status in Serine 536.	cholecystokinin C-terminal flanking peptide	194-200	RELA proto-oncogene, NF-kB subunit	Homo sapiens	121-124
31709256-8	2019	Accordingly, we demonstrated that NLRP2 interacts with IKKa and positively regulates the DNA-binding activity of p50 and p65 NF-kappaB, by modulating the p65 NF-kappaB phosphorylation status in Serine 536.	cholecystokinin C-terminal flanking peptide	194-200	RELA proto-oncogene, NF-kB subunit	Homo sapiens	154-157
31644910-2	2019	Using unbiased mass spectrometry, we discover multiple serine phosphorylation sites in the MALT1 C terminus after T cell activation.	cholecystokinin C-terminal flanking peptide	55-61	MALT1 paracaspase	Homo sapiens	91-96
31708778-2	2019	T-LAK cell-originated protein kinase (TOPK) belongs to serine/threonine protein kinase and is highly expressed in several cancer cells and tissues, such as colon cancer, lung cancer, esophagus cancer, and so on.	cholecystokinin C-terminal flanking peptide	55-61	PDZ binding kinase	Homo sapiens	0-36
31708778-2	2019	T-LAK cell-originated protein kinase (TOPK) belongs to serine/threonine protein kinase and is highly expressed in several cancer cells and tissues, such as colon cancer, lung cancer, esophagus cancer, and so on.	cholecystokinin C-terminal flanking peptide	55-61	PDZ binding kinase	Homo sapiens	38-42
31623211-8	2019	Interestingly, replacing the critical serine (Ser) at position 13 with an alanine (Ala) residue resulted in a 2-fold increase in potency at the alpha1beta1deltaepsilon nAChR, and showed loss of activity on alpha3beta2 and alpha3beta4 nAChRs.	cholecystokinin C-terminal flanking peptide	38-44	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	168-173
31623211-8	2019	Interestingly, replacing the critical serine (Ser) at position 13 with an alanine (Ala) residue resulted in a 2-fold increase in potency at the alpha1beta1deltaepsilon nAChR, and showed loss of activity on alpha3beta2 and alpha3beta4 nAChRs.	cholecystokinin C-terminal flanking peptide	46-49	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	168-173
31615983-3	2019	By using genome-wide CRISPR/Cas9 library screening, we identify phosphoglycerate dehydrogenase (PHGDH), the first committed enzyme in the serine synthesis pathway (SSP), as a critical driver for Sorafenib resistance.	cholecystokinin C-terminal flanking peptide	138-144	phosphoglycerate dehydrogenase	Homo sapiens	64-94
31615983-3	2019	By using genome-wide CRISPR/Cas9 library screening, we identify phosphoglycerate dehydrogenase (PHGDH), the first committed enzyme in the serine synthesis pathway (SSP), as a critical driver for Sorafenib resistance.	cholecystokinin C-terminal flanking peptide	138-144	phosphoglycerate dehydrogenase	Homo sapiens	96-101
31615983-5	2019	With RNAi knockdown and CRISPR/Cas9 knockout models, we show that inactivation of PHGDH paralyzes the SSP and reduce the production of alphaKG, serine, and NADPH.	cholecystokinin C-terminal flanking peptide	144-150	phosphoglycerate dehydrogenase	Homo sapiens	82-87
31618847-1	2019	Protein phosphatase 2A (PP2A), a major serine/threonine phosphatase in mammalian cells, is known to regulate the kinase-driven intracellular signaling pathways.	cholecystokinin C-terminal flanking peptide	39-45	protein phosphatase 2 phosphatase activator	Homo sapiens	24-29
31614827-0	2019	Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells.	cholecystokinin C-terminal flanking peptide	63-69	p21 (RAC1) activated kinase 1	Homo sapiens	56-60
31614827-6	2019	In this study, we aimed to determine if simultaneous inhibition of BCR-ABL1 oncogenic tyrosine kinase and PAK1/2 serine/threonine kinase exert better anti-CML effect than that of individual treatments.	cholecystokinin C-terminal flanking peptide	113-119	p21 (RAC1) activated kinase 1	Homo sapiens	106-112
31600984-3	2019	C1s, a serine protease, plays an important role in the CS and could be an attractive target since it blocks the system at an early stage of the complement cascade.	cholecystokinin C-terminal flanking peptide	7-13	complement C1s	Homo sapiens	0-3
31548413-2	2019	Astrocytic l-serine was proposed to regulate NMDAR activity by shuttling to neurons to sustain d-serine production, but this hypothesis remains untested.	cholecystokinin C-terminal flanking peptide	95-103	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	45-50
31548413-3	2019	We now report that inhibition of astrocytic Phgdh suppressed the de novo synthesis of l-and d-serine and reduced the NMDAR synaptic potentials and long-term potentiation (LTP) at the Schaffer collaterals-CA1 synapse.	cholecystokinin C-terminal flanking peptide	86-100	3-phosphoglycerate dehydrogenase	Mus musculus	44-49
31548413-3	2019	We now report that inhibition of astrocytic Phgdh suppressed the de novo synthesis of l-and d-serine and reduced the NMDAR synaptic potentials and long-term potentiation (LTP) at the Schaffer collaterals-CA1 synapse.	cholecystokinin C-terminal flanking peptide	86-100	carbonic anhydrase 1	Mus musculus	204-207
31548413-4	2019	Likewise, enzymatic removal of extracellular l-serine impaired LTP, supporting an l-serine shuttle mechanism between glia and neurons in generating the NMDAR coagonist d-serine.	cholecystokinin C-terminal flanking peptide	45-53	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	152-157
31548413-4	2019	Likewise, enzymatic removal of extracellular l-serine impaired LTP, supporting an l-serine shuttle mechanism between glia and neurons in generating the NMDAR coagonist d-serine.	cholecystokinin C-terminal flanking peptide	82-90	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	152-157
31548413-4	2019	Likewise, enzymatic removal of extracellular l-serine impaired LTP, supporting an l-serine shuttle mechanism between glia and neurons in generating the NMDAR coagonist d-serine.	cholecystokinin C-terminal flanking peptide	168-176	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	152-157
31548413-5	2019	Moreover, deletion of serine racemase (SR) in glutamatergic neurons abrogated d-serine synthesis to the same extent as Phgdh inhibition, suggesting that neurons are the predominant source of the newly synthesized d-serine.	cholecystokinin C-terminal flanking peptide	78-86	serine racemase	Mus musculus	22-37
31548413-5	2019	Moreover, deletion of serine racemase (SR) in glutamatergic neurons abrogated d-serine synthesis to the same extent as Phgdh inhibition, suggesting that neurons are the predominant source of the newly synthesized d-serine.	cholecystokinin C-terminal flanking peptide	213-221	serine racemase	Mus musculus	22-37
31548413-10	2019	Our observations suggest that glycine is a multifaceted regulator of d-serine metabolism and implicate both d-serine and glycine in mediating NMDAR synaptic activation at the mature hippocampus through a Phgdh-dependent shuttle mechanism.	cholecystokinin C-terminal flanking peptide	69-77	3-phosphoglycerate dehydrogenase	Mus musculus	204-209
31548413-10	2019	Our observations suggest that glycine is a multifaceted regulator of d-serine metabolism and implicate both d-serine and glycine in mediating NMDAR synaptic activation at the mature hippocampus through a Phgdh-dependent shuttle mechanism.	cholecystokinin C-terminal flanking peptide	108-116	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	142-147
31548413-10	2019	Our observations suggest that glycine is a multifaceted regulator of d-serine metabolism and implicate both d-serine and glycine in mediating NMDAR synaptic activation at the mature hippocampus through a Phgdh-dependent shuttle mechanism.	cholecystokinin C-terminal flanking peptide	108-116	3-phosphoglycerate dehydrogenase	Mus musculus	204-209
31637210-1	2019	Serpin family D member 1 (SERPIND1) belongs to the serine protease inhibitor family.	cholecystokinin C-terminal flanking peptide	51-57	serpin family D member 1	Homo sapiens	0-24
31637210-1	2019	Serpin family D member 1 (SERPIND1) belongs to the serine protease inhibitor family.	cholecystokinin C-terminal flanking peptide	51-57	serpin family D member 1	Homo sapiens	26-34
31570403-1	2019	Objective: Metallo-beta-lactamase (MBL)-producing Enterobacteriaceae, particularly those that co-harbor serine beta-lactamases, are a serious emerging public health threat given their rapid dissemination and the limited number of treatment options.	cholecystokinin C-terminal flanking peptide	94-110	hypothetical protein	Klebsiella pneumoniae	11-33
31612389-10	2019	Moreover, CPA6 could activate AKT serine/threonine kinase (AKT) signaling pathway as confirmed by Western blotting.	cholecystokinin C-terminal flanking peptide	34-40	carboxypeptidase A6	Homo sapiens	10-14
31612389-10	2019	Moreover, CPA6 could activate AKT serine/threonine kinase (AKT) signaling pathway as confirmed by Western blotting.	cholecystokinin C-terminal flanking peptide	34-40	AKT serine/threonine kinase 1	Homo sapiens	30-33
31612389-10	2019	Moreover, CPA6 could activate AKT serine/threonine kinase (AKT) signaling pathway as confirmed by Western blotting.	cholecystokinin C-terminal flanking peptide	34-40	AKT serine/threonine kinase 1	Homo sapiens	59-62
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	117-123	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	93-97
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	117-123	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	142-147
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	117-123	cyclin B2	Homo sapiens	226-270
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	167-173	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	93-97
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	167-173	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	142-147
31555364-11	2019	By constructing a PPI network and screening hub gene modules, 5 upregulated genes, including BUB1 mitotic checkpoint serine/threonine kinase, BUB1B mitotic checkpoint serine/threonine kinase B, cell division cycle protein 45, cyclin B2 and pituitary tumor-transforming 1.	cholecystokinin C-terminal flanking peptide	167-173	cyclin B2	Homo sapiens	226-270
31553664-3	2019	Approach and Results: Fam20C (family with sequence similarity 20, member C) phosphorylates serines in secretory proteins containing the motif S-X-E/phospho-Ser, including the cholesterol-regulating PCSK9.	cholecystokinin C-terminal flanking peptide	91-98	FAM20C golgi associated secretory pathway kinase	Homo sapiens	22-28
31553664-3	2019	Approach and Results: Fam20C (family with sequence similarity 20, member C) phosphorylates serines in secretory proteins containing the motif S-X-E/phospho-Ser, including the cholesterol-regulating PCSK9.	cholecystokinin C-terminal flanking peptide	91-98	FAM20C golgi associated secretory pathway kinase	Homo sapiens	30-74
31553664-3	2019	Approach and Results: Fam20C (family with sequence similarity 20, member C) phosphorylates serines in secretory proteins containing the motif S-X-E/phospho-Ser, including the cholesterol-regulating PCSK9.	cholecystokinin C-terminal flanking peptide	91-98	proprotein convertase subtilisin/kexin type 9	Homo sapiens	198-203
31594908-1	2019	The Target of Rapamycin (TOR or mTOR) is a serine/threonine kinase that regulates growth, development, and behaviors by modulating protein synthesis, autophagy, and multiple other cellular processes in response to changes in nutrients and other cues.	cholecystokinin C-terminal flanking peptide	43-49	RAR related orphan receptor C	Homo sapiens	25-28
31625245-1	2019	The serine proteases, tissue- and urokinase-type plasminogen activators (PLAT and PLAU) and their inhibitors SERPINE1/2 are regulators of plasminogen to plasmin conversion.	cholecystokinin C-terminal flanking peptide	4-10	plasminogen activator, tissue type	Sus scrofa	73-77
31625245-1	2019	The serine proteases, tissue- and urokinase-type plasminogen activators (PLAT and PLAU) and their inhibitors SERPINE1/2 are regulators of plasminogen to plasmin conversion.	cholecystokinin C-terminal flanking peptide	4-10	plasminogen activator, urokinase	Sus scrofa	82-86
31625245-1	2019	The serine proteases, tissue- and urokinase-type plasminogen activators (PLAT and PLAU) and their inhibitors SERPINE1/2 are regulators of plasminogen to plasmin conversion.	cholecystokinin C-terminal flanking peptide	4-10	serpin family E member 1	Sus scrofa	109-117
31574902-1	2019	STK16, reported as a Golgi localized serine/threonine kinase, has been shown to participate in multiple cellular processes, including the TGF-beta signaling pathway, TGN protein secretion and sorting, as well as cell cycle and Golgi assembly regulation.	cholecystokinin C-terminal flanking peptide	37-43	serine/threonine kinase 16	Homo sapiens	0-5
31570403-1	2019	Objective: Metallo-beta-lactamase (MBL)-producing Enterobacteriaceae, particularly those that co-harbor serine beta-lactamases, are a serious emerging public health threat given their rapid dissemination and the limited number of treatment options.	cholecystokinin C-terminal flanking peptide	94-110	hypothetical protein	Klebsiella pneumoniae	35-38
31572066-10	2019	High levels of RUVBL2 promoted carcinogenesis through the heat shock protein 90 (HSP90)-Cell Division Cycle 37 (CDC37), AKT serine/threonine kinase (AKT) and mitogen-activated protein kinase (ERK/MAPK) pathways.	cholecystokinin C-terminal flanking peptide	124-130	RuvB like AAA ATPase 2	Homo sapiens	15-21
31552099-6	2019	There are multiple splice factors and signaling pathways that influence the Bcl-xL/Bcl-xS splicing ratio, including serine/arginine-rich (SR) proteins, heterogeneous nuclear ribonucleoproteins (hnRNPs), transcription factors, and cytokines.	cholecystokinin C-terminal flanking peptide	116-122	BCL2 like 1	Homo sapiens	76-82
31557263-7	2019	Remarkably, a Trx2 version, in which all five cysteines were replaced by serine residues, complements for the wildtype protein in conditional knock-out cells and confers parasite infectivity in the mouse model.	cholecystokinin C-terminal flanking peptide	73-79	thioredoxin 2	Mus musculus	14-18
31558706-4	2019	Mass spectrometry identified the serine residues at positions 385 and 400 in the linker and substrate-binding domains of HSP70, respectively, as sites of phosphorylation mediated by EGF signaling, and this result was further confirmed by site-directed mutagenesis.	cholecystokinin C-terminal flanking peptide	33-39	heat shock protein family A (Hsp70) member 4	Homo sapiens	121-126
31541180-5	2019	As we show by NMR spectroscopy, the serine beta-lactamases (KPC-2, SFC-1, CMY-10, OXA-23, and OXA-48) and metallo-beta-lactamases (NDM-1, VIM-1, BcII, CphA, and L1) tested all degrade carbapenems to preferentially give the Delta2 (enamine) and/or (R)-Delta1 (imine) products.	cholecystokinin C-terminal flanking peptide	36-42	UBA domain containing 1	Homo sapiens	60-65
31541180-5	2019	As we show by NMR spectroscopy, the serine beta-lactamases (KPC-2, SFC-1, CMY-10, OXA-23, and OXA-48) and metallo-beta-lactamases (NDM-1, VIM-1, BcII, CphA, and L1) tested all degrade carbapenems to preferentially give the Delta2 (enamine) and/or (R)-Delta1 (imine) products.	cholecystokinin C-terminal flanking peptide	36-42	delta like non-canonical Notch ligand 1	Homo sapiens	223-257
31572367-1	2019	Mst1 is a multifunctional serine/threonine kinase that is highly expressed in several immune organs.	cholecystokinin C-terminal flanking peptide	26-32	macrophage stimulating 1	Homo sapiens	0-4
31609304-5	2019	We detail the use of chronic flavopiridol mediated CDK9 inhibition to abrogate phosphorylation of serine 2 residue on the C-terminal repeat domain (CTD) of RNA polymerase II (RNA Pol II), suppressing the release of RNA Pol II into productive transcription elongation.	cholecystokinin C-terminal flanking peptide	98-104	cyclin-dependent kinase 9 (CDC2-related kinase)	Mus musculus	51-55
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	147-153	cathepsin C	Homo sapiens	9-20
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	147-153	cathepsin C	Homo sapiens	22-26
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	147-153	carboxypeptidase Q	Homo sapiens	67-81
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	215-221	cathepsin C	Homo sapiens	9-20
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	215-221	cathepsin C	Homo sapiens	22-26
31557781-1	2019	Cysteine cathepsin C (CatC) is a ubiquitously expressed, lysosomal aminopeptidase involved in the activation of zymogens of immune-cell-associated serine proteinases (elastase, cathepsin G, proteinase 3, neutrophil serine proteinase 4, lymphocyte granzymes, and mast cell chymases).	cholecystokinin C-terminal flanking peptide	215-221	carboxypeptidase Q	Homo sapiens	67-81
31607864-6	2019	The coagulation cascade and some of its major components, serine proteases such as thrombin, are known to participate in the acute phase of a stroke.	cholecystokinin C-terminal flanking peptide	58-64	coagulation factor II, thrombin	Homo sapiens	83-91
31552233-4	2019	The choice for this phosphorylated amino acid is due to the fact that osteopontin is a serine-rich glycol-phosphoprotein and has been associated to the early stages of bone formation, and regeneration.	cholecystokinin C-terminal flanking peptide	87-93	secreted phosphoprotein 1	Homo sapiens	70-81
31660449-7	2019	Phosphorylation of AMPK at threonine 172 and IRS1 at serine 307 and tyrosine 632 were both increased in adipose tissues from TR-SPF-fed mice.	cholecystokinin C-terminal flanking peptide	53-59	insulin receptor substrate 1	Mus musculus	45-49
31552251-6	2019	AHR activation induces the expression of resistance genes against the inhibitors of V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) in melanoma and upregulation of programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells surrounding melanoma.	cholecystokinin C-terminal flanking peptide	120-126	aryl hydrocarbon receptor	Sus scrofa	0-3
31552251-6	2019	AHR activation induces the expression of resistance genes against the inhibitors of V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) in melanoma and upregulation of programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells surrounding melanoma.	cholecystokinin C-terminal flanking peptide	120-126	B-Raf proto-oncogene, serine/threonine kinase	Sus scrofa	145-149
31660449-8	2019	Increased expression and phosphorylation of IRS1 at both serine 307 and tyrosine 632 in adipose tissues indicated that adipocytes obtained from abdominal fat in TR-SPF-fed mice were more susceptible to insulin signaling than that of the control.	cholecystokinin C-terminal flanking peptide	57-63	insulin receptor substrate 1	Mus musculus	44-48
31825015-2	2019	Glycogen synthase kinase 3 (GSK3) is a multi-functional serine/threonine kinase existing as two distinct but related isoforms (alpha and beta).	cholecystokinin C-terminal flanking peptide	56-62	glycogen synthase kinase 3 beta	Mus musculus	0-26
31598242-4	2019	Moreover, the reaction of Novichok agents with acetylcholinesterase serine was calculated to be most thermodynamically favoured for Novichok candidate A234.	cholecystokinin C-terminal flanking peptide	68-74	acetylcholinesterase (Cartwright blood group)	Homo sapiens	47-67
31825015-2	2019	Glycogen synthase kinase 3 (GSK3) is a multi-functional serine/threonine kinase existing as two distinct but related isoforms (alpha and beta).	cholecystokinin C-terminal flanking peptide	56-62	glycogen synthase kinase 3 beta	Mus musculus	28-32
31803403-0	2019	Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.	cholecystokinin C-terminal flanking peptide	54-60	HGF activator	Homo sapiens	71-75
31803403-0	2019	Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.	cholecystokinin C-terminal flanking peptide	54-60	hepsin	Homo sapiens	92-98
31803403-1	2019	Matriptase and hepsin are type II transmembrane serine proteases (TTSPs).	cholecystokinin C-terminal flanking peptide	48-54	hepsin	Homo sapiens	15-21
31803403-2	2019	Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis.	cholecystokinin C-terminal flanking peptide	35-41	HGF activator	Homo sapiens	51-55
31803403-2	2019	Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis.	cholecystokinin C-terminal flanking peptide	35-41	HGF activator	Homo sapiens	57-91
31803403-6	2019	We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin.	cholecystokinin C-terminal flanking peptide	146-152	hepsin	Homo sapiens	88-94
31803403-6	2019	We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin.	cholecystokinin C-terminal flanking peptide	146-152	coagulation factor II, thrombin	Homo sapiens	177-185
31559596-2	2019	It was established that two serine proteases-neutrophil elastase 1 (HNE1) and cathepsin G (CatG)-are the key agents in psoriasis development.	cholecystokinin C-terminal flanking peptide	28-34	elastase, neutrophil expressed	Homo sapiens	45-64
31943990-0	2019	Use of Serine/Threonine Ligation for the Total Chemical Synthesis of HMGA1a Protein with Site-Specific Lysine Acetylations.	cholecystokinin C-terminal flanking peptide	7-13	high mobility group AT-hook 1	Homo sapiens	69-75
31636950-4	2019	STK11, a serine/threonine kinase, has been reported to be downregulated in human diseases associated with ciliopathies and functions as a tumor suppressor.	cholecystokinin C-terminal flanking peptide	9-15	serine/threonine kinase 11	Homo sapiens	0-5
31559596-2	2019	It was established that two serine proteases-neutrophil elastase 1 (HNE1) and cathepsin G (CatG)-are the key agents in psoriasis development.	cholecystokinin C-terminal flanking peptide	28-34	cathepsin G	Homo sapiens	78-89
31559596-2	2019	It was established that two serine proteases-neutrophil elastase 1 (HNE1) and cathepsin G (CatG)-are the key agents in psoriasis development.	cholecystokinin C-terminal flanking peptide	28-34	cathepsin G	Homo sapiens	91-95
31624779-1	2019	Factor XII (FXII) becomes a serine protease when blood is exposed to artificial medical surfaces or when pathologic surfaces arise in disease states leading to its autoactivation.	cholecystokinin C-terminal flanking peptide	28-34	coagulation factor XII (Hageman factor)	Mus musculus	0-10
31624779-1	2019	Factor XII (FXII) becomes a serine protease when blood is exposed to artificial medical surfaces or when pathologic surfaces arise in disease states leading to its autoactivation.	cholecystokinin C-terminal flanking peptide	28-34	coagulation factor XII (Hageman factor)	Mus musculus	12-16
31933933-9	2019	Knockdown of miR-106a impeded cell migration and invasion but contributed to irradiation-induced inhibition of survival and increase of phosphorylation of histone in Serine 139 (gamma-H2AX) protein in HCC cells.	cholecystokinin C-terminal flanking peptide	166-172	microRNA 106a	Homo sapiens	13-21
31641627-13	2019	The second sample harboured a missense mutation at position 1819 (TCC--GCC), wherein the codon 607 (TCC) coding for serine was substituted by alanine (GCC) which is a variant of unknown significance.	cholecystokinin C-terminal flanking peptide	116-122	guanylate cyclase 2C	Homo sapiens	71-74
31641627-13	2019	The second sample harboured a missense mutation at position 1819 (TCC--GCC), wherein the codon 607 (TCC) coding for serine was substituted by alanine (GCC) which is a variant of unknown significance.	cholecystokinin C-terminal flanking peptide	116-122	guanylate cyclase 2C	Homo sapiens	151-154
31902362-6	2019	Serine/threonine phosphatase assay was applied to detect the activity of protein phosphatase 2A (PP2A).	cholecystokinin C-terminal flanking peptide	0-6	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	97-101
31807622-6	2019	Despite being rich in cysteine, the caprine KAP15-1 protein possesses a high content of serine and moderate content of glycine and phenylalanine.	cholecystokinin C-terminal flanking peptide	88-94	keratin-associated protein 15-1	Capra hircus	44-51
31589099-6	2019	Metabolite analysis suggests that activation of glycine-to-serine conversion catalyzed through glycine decarboxylase in conjunction with serine hydroxymethyltransferase in trxo1 is slowed down at onset of illumination.	cholecystokinin C-terminal flanking peptide	59-65	glycine decarboxylase	Homo sapiens	95-116
31933723-4	2019	The alpha-syn oligomers formed in PBS are not phosphorylated and are different from the alpha-syn oligomers formed in the plasma of NC and PD that are moderately and highly phosphorylated at serine 129, which is a key phosphorylation site of the alpha-syn molecule in PD patients.	cholecystokinin C-terminal flanking peptide	191-197	synuclein alpha	Homo sapiens	4-13
31933723-4	2019	The alpha-syn oligomers formed in PBS are not phosphorylated and are different from the alpha-syn oligomers formed in the plasma of NC and PD that are moderately and highly phosphorylated at serine 129, which is a key phosphorylation site of the alpha-syn molecule in PD patients.	cholecystokinin C-terminal flanking peptide	191-197	synuclein alpha	Homo sapiens	88-97
31933723-4	2019	The alpha-syn oligomers formed in PBS are not phosphorylated and are different from the alpha-syn oligomers formed in the plasma of NC and PD that are moderately and highly phosphorylated at serine 129, which is a key phosphorylation site of the alpha-syn molecule in PD patients.	cholecystokinin C-terminal flanking peptide	191-197	synuclein alpha	Homo sapiens	88-97
31589099-6	2019	Metabolite analysis suggests that activation of glycine-to-serine conversion catalyzed through glycine decarboxylase in conjunction with serine hydroxymethyltransferase in trxo1 is slowed down at onset of illumination.	cholecystokinin C-terminal flanking peptide	137-143	glycine decarboxylase	Homo sapiens	95-116
31620609-9	2019	Telmisartan dose-dependently increased p-PKCzeta-Thr410 which is known to reduce insulin action by inducing IRS-1 serine phosphorylation.	cholecystokinin C-terminal flanking peptide	114-120	protein kinase C, zeta	Mus musculus	41-48
31620609-9	2019	Telmisartan dose-dependently increased p-PKCzeta-Thr410 which is known to reduce insulin action by inducing IRS-1 serine phosphorylation.	cholecystokinin C-terminal flanking peptide	114-120	insulin receptor substrate 1	Mus musculus	108-113
31938312-1	2018	LATS1 is a serine/threonine kinase of the Hippo signaling pathway that phosphorylates and inactivates transcriptional co-activators YAP1 and WWTR1.	cholecystokinin C-terminal flanking peptide	11-17	large tumor suppressor kinase 1	Homo sapiens	0-5
31938428-2	2018	p21-activated kinase 4 (PAK4) is a member of serine/threonine protein kinases but the role of PAK4 in renal fibrosis remains unknown.	cholecystokinin C-terminal flanking peptide	45-51	p21 (RAC1) activated kinase 4	Homo sapiens	0-22
31938428-2	2018	p21-activated kinase 4 (PAK4) is a member of serine/threonine protein kinases but the role of PAK4 in renal fibrosis remains unknown.	cholecystokinin C-terminal flanking peptide	45-51	p21 (RAC1) activated kinase 4	Homo sapiens	24-28
31938312-1	2018	LATS1 is a serine/threonine kinase of the Hippo signaling pathway that phosphorylates and inactivates transcriptional co-activators YAP1 and WWTR1.	cholecystokinin C-terminal flanking peptide	11-17	Yes1 associated transcriptional regulator	Homo sapiens	132-136
31938312-1	2018	LATS1 is a serine/threonine kinase of the Hippo signaling pathway that phosphorylates and inactivates transcriptional co-activators YAP1 and WWTR1.	cholecystokinin C-terminal flanking peptide	11-17	WW domain containing transcription regulator 1	Homo sapiens	141-146
31966548-1	2017	SERPINE2, also known as protease nexin-1 (PN-1), is a serine protease inhibitor produced by many cell types and has pleiotropic biological functions.	cholecystokinin C-terminal flanking peptide	54-60	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	0-8
31966548-1	2017	SERPINE2, also known as protease nexin-1 (PN-1), is a serine protease inhibitor produced by many cell types and has pleiotropic biological functions.	cholecystokinin C-terminal flanking peptide	54-60	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	24-40
31966548-1	2017	SERPINE2, also known as protease nexin-1 (PN-1), is a serine protease inhibitor produced by many cell types and has pleiotropic biological functions.	cholecystokinin C-terminal flanking peptide	54-60	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	42-46